Table of Contents

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 10-Q

 

( Mark One )

 

x   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2014

 

OR

 

o   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from              to             

 

Commission file number 001-10865

 

AMAG Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware

 

04-2742593

(State or Other Jurisdiction of

 

(I.R.S. Employer

Incorporation or Organization)

 

Identification No.)

 

 

 

1100 Winter Street

 

 

Waltham, Massachusetts

 

02451

(Address of Principal Executive Offices)

 

(Zip Code)

 

(617) 498-3300

(Registrant’s Telephone Number, Including Area Code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes x No o

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes x No o

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of “accelerated filer,” “large accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer o

 

Accelerated filer x

 

 

 

Non-accelerated filer o

 

Smaller Reporting Company o

(Do not check if a smaller reporting company)

 

 

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).  Yes o No x

 

As of April 29, 2014, there were 21,915,093 shares of the registrant’s common stock, par value $0.01 per share, outstanding.

 

 

 



Table of Contents

 

AMAG PHARMACEUTICALS, INC.
FORM 10-Q
TABLE OF CONTEN TS

 

PART I.

FINANCIAL INFORMATION (Unaudited)

 

Item 1.

Financial Statements

 

 

Condensed Consolidated Balance Sheets as of March 31, 2014 and December 31, 2013

4

 

Condensed Consolidated Statements of Operations for the three months ended March 31, 2014 and 2013

5

 

Condensed Consolidated Statements of Comprehensive Loss for the three months ended March 31, 2014 and 2013

6

 

Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2014 and 2013

7

 

Notes to Condensed Consolidated Financial Statements

8

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

28

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

44

Item 4.

Controls and Procedures

44

 

 

 

PART II.

OTHER INFORMATION

 

Item 1.

Legal Proceedings

44

Item 1A.

Risk Factors

45

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

81

Item 6.

Exhibits

82

 

 

 

SIGNATURES

85

 

 

CERTIFICATIONS

 

 

2



Table of Contents

 

PART I.         FINANCIAL INFORMATION

 

Item 1.  Financial Statements

 

3



Table of Contents

 

AMAG PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)

(Unaudited)

 

 

 

March 31, 2014

 

December 31, 2013

 

ASSETS

 

 

 

 

 

Current assets:

 

 

 

 

 

Cash and cash equivalents

 

$

200,916

 

$

26,986

 

Investments

 

184,557

 

186,803

 

Accounts receivable, net

 

10,115

 

6,842

 

Inventories

 

20,804

 

17,217

 

Receivable from collaboration

 

202

 

278

 

Prepaid and other current assets

 

4,410

 

3,396

 

Restricted cash

 

 

2,883

 

Total current assets

 

421,004

 

244,405

 

Property and equipment, net

 

1,837

 

1,846

 

Intangible assets, net

 

16,815

 

16,844

 

Restricted cash

 

400

 

400

 

Other long-term assets

 

6,407

 

1,964

 

Total assets

 

$

446,463

 

$

265,459

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

Current liabilities:

 

 

 

 

 

Accounts payable

 

$

5,125

 

$

2,629

 

Accrued expenses

 

21,851

 

22,266

 

Deferred revenues

 

9,118

 

8,226

 

Total current liabilities

 

36,094

 

33,121

 

Long-term liabilities:

 

 

 

 

 

Convertible 2.5% senior notes, net

 

162,561

 

 

Deferred revenues

 

40,567

 

44,534

 

Acquisition-related contingent consideration

 

14,040

 

13,609

 

Other long-term liabilities

 

2,105

 

1,787

 

Total liabilities

 

255,367

 

93,051

 

Commitments and contingencies

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

Preferred stock, par value $0.01 per share, 2,000,000 shares authorized; none issued

 

 

 

Common stock, par value $0.01 per share, 58,750,000 shares authorized; 21,877,192 and 21,772,571 shares issued and outstanding at March 31, 2014 and December 31, 2013, respectively

 

219

 

218

 

Additional paid-in capital

 

667,653

 

641,941

 

Accumulated other comprehensive loss

 

(3,414

)

(3,491

)

Accumulated deficit

 

(473,362

)

(466,260

)

Total stockholders’ equity

 

191,096

 

172,408

 

Total liabilities and stockholders’ equity

 

$

446,463

 

$

265,459

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

4



Table of Contents

 

AMAG PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(IN THOUSANDS, EXCEPT PER SHARE DATA)

(Unaudited)

 

 

 

Three Months Ended March 31,

 

 

 

2014

 

2013

 

Revenues:

 

 

 

 

 

U.S. Feraheme product sales, net

 

$

17,375

 

$

15,578

 

License fee and other collaboration revenues

 

3,120

 

2,003

 

Other product sales and royalties

 

340

 

299

 

Total revenues

 

20,835

 

17,880

 

Costs and expenses:

 

 

 

 

 

Cost of product sales

 

2,837

 

2,942

 

Research and development expenses

 

6,498

 

5,404

 

Selling, general and administrative expenses

 

17,491

 

14,005

 

Total costs and expenses

 

26,826

 

22,351

 

Other income (expense):

 

 

 

 

 

Interest expense

 

(1,476

)

 

Interest and dividend income, net

 

265

 

271

 

Gains on sale of assets

 

100

 

299

 

Gains on investments, net

 

 

6

 

Total other income (expense)

 

(1,111

)

576

 

Net loss

 

$

(7,102

)

$

(3,895

)

 

 

 

 

 

 

Net loss per share:

 

 

 

 

 

Basic and diluted

 

$

(0.33

)

$

(0.18

)

 

 

 

 

 

 

Weighted average shares outstanding used to compute net loss per share:

 

 

 

 

 

Basic and diluted

 

21,824

 

21,544

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

5



Table of Contents

 

AMAG PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(IN THOUSANDS)

(Unaudited)

 

 

 

Three Months Ended March 31,

 

 

 

2014

 

2013

 

 

 

 

 

 

 

Net loss

 

$

(7,102

)

$

(3,895

)

Other comprehensive income (loss):

 

 

 

 

 

Unrealized gains (losses) on securities:

 

 

 

 

 

Holding gains (losses) arising during period, net of tax

 

77

 

(87

)

Reclassification adjustment for (gains) losses included in net loss

 

 

(6

)

Net unrealized gains (losses) on securities

 

77

 

(93

)

Total comprehensive loss

 

$

(7,025

)

$

(3,988

)

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

6



Table of Contents

 

AMAG PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(IN THOUSANDS)

(Unaudited)

 

 

 

Three Months Ended March 31,

 

 

 

2014

 

2013

 

Cash flows from operating activities:

 

 

 

 

 

Net loss

 

$

(7,102

)

$

(3,895

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

Depreciation and amortization

 

162

 

650

 

Amortization of premium/discount on purchased securities

 

664

 

681

 

Write-down of inventory to net realizable value

 

1,437

 

 

Non-cash equity-based compensation expense

 

1,930

 

2,283

 

Amortization of debt discount and debt issuance costs

 

851

 

 

Gains on sale of assets

 

(100

)

(299

)

Gains on investments, net

 

 

(6

)

Change in fair value of contingent consideration

 

789

 

 

Changes in operating assets and liabilities:

 

 

 

 

 

Accounts receivable, net

 

(3,273

)

(2,109

)

Inventories

 

(2,521

)

1,834

 

Receivable from collaboration

 

76

 

155

 

Prepaid and other current assets

 

(1,014

)

(6

)

Other long-term assets

 

885

 

 

Accounts payable and accrued expenses

 

(1,101

)

(7,074

)

Deferred revenues

 

(3,075

)

(1,816

)

Other long-term liabilities

 

318

 

(111

)

Total adjustments

 

(3,972

)

(5,818

)

Net cash used in operating activities

 

(11,074

)

(9,713

)

 

 

 

 

 

 

Cash flows from investing activities:

 

 

 

 

 

Proceeds from sales or maturities of investments

 

26,706

 

30,663

 

Purchase of investments

 

(25,046

)

(33,906

)

Proceeds from sale of assets

 

100

 

368

 

Capital expenditures

 

(124

)

(23

)

Change in restricted cash

 

2,883

 

 

Net cash provided by (used in) investing activities

 

4,519

 

(2,898

)

 

 

 

 

 

 

Cash flows from financing activities:

 

 

 

 

 

Payment of contingent consideration

 

(31

)

 

Proceeds from issuance of convertible debt

 

200,000

 

 

Payment of debt issuance costs

 

(6,361

)

 

Proceeds from issuance of warrants

 

25,620

 

 

Purchase of convertible bond hedges

 

(39,760

)

 

Proceeds from the exercise of stock options

 

1,017

 

163

 

Net cash provided by financing activities

 

180,485

 

163

 

 

 

 

 

 

 

Net increase (decrease) in cash and cash equivalents

 

173,930

 

(12,448

)

Cash and cash equivalents at beginning of the period

 

26,986

 

46,293

 

Cash and cash equivalents at end of the period

 

$

200,916

 

$

33,845

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

7



Table of Contents

 

AMAG PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2014

(Unaudited)

 

A.                Description of Business

 

AMAG Pharmaceuticals, Inc., a Delaware corporation, was founded in 1981. We are a specialty pharmaceutical company that markets Feraheme ® (ferumoxytol) Injection for Intravenous, or IV, use to treat iron deficiency anemia, or IDA, and MuGard ® Mucoadhesive Oral Wound Rinse for the management of oral mucositis .

 

Currently, our principal source of revenue is from the sale of Feraheme , which was approved for marketing in the U.S. in June 2009 by the U.S. Food and Drug Administration, or the FDA, for use as an IV iron replacement therapy for the treatment of IDA in adult patients with chronic kidney disease, or CKD. We began selling Feraheme in the U.S. in July 2009 through our own commercial organization, including a specialty sales force. We sell Feraheme to authorized wholesalers and specialty distributors, who in turn, sell Feraheme to healthcare providers who administer Feraheme primarily within hospitals, hematology and oncology centers, and nephrology clinics.

 

Outside of the U.S., ferumoxytol has been granted marketing approval in Canada, Switzerland and the European Union, or EU, for use as an IV iron replacement therapy for the treatment of IDA in adult patients with CKD. The European marketing authorization for Rienso in the EU is valid in the 28 EU Member States as well as in Iceland, Liechtenstein and Norway. Under our amended agreement with Takeda Pharmaceutical Company Limited, or Takeda, Takeda has an exclusive license to market and sell ferumoxytol in Canada, the EU and Switzerland, as well as certain other geographic territories. In Canada, Takeda promotes ferumoxytol under the trade name Feraheme and in the EU and Switzerland, Takeda promotes ferumoxytol under the trade name Rienso ®  30mg/ml solution for Injection.

 

On June 6, 2013, or the Acquisition Date, we entered into a License Agreement with Access Pharmaceuticals, Inc., or Access, under which we acquired the U.S. commercial rights to MuGard , or the Access License Agreement. MuGard was launched in the U.S. by Access in 2010 after receiving 510(k) clearance from the FDA and is indicated for the management of oral mucositis/stomatitis (that may be caused by radiotherapy and/or chemotherapy) and all types of oral wounds (mouth sores and injuries), including aphthous ulcers/canker sores and traumatic ulcers, such as those caused by oral surgery or ill-fitting dentures or braces. Under the Access License Agreement, we obtained an exclusive, royalty-bearing license, with the right to grant sublicenses, to certain intellectual property rights, including know-how, patents and trademarks, to use, import, offer for sale, sell, manufacture and commercialize MuGard in the U.S. and its territories, or the U.S. Territory, for the management of all diseases or conditions of the oropharyngeal cavity, including mucositis, or the MuGard Rights. Additional details regarding the Access License Agreement and the MuGard Rights can be found in Note H, “ Business Combination.

 

Throughout this Quarterly Report on Form 10-Q, AMAG Pharmaceuticals, Inc. and our consolidated subsidiaries are collectively referred to as “the Company,” “we,” “us,” or “our.”

 

B.                Basis of Presentation and Summary of Significant Accounting Policies

 

Basis of Presentation

 

These condensed consolidated financial statements are unaudited and, in the opinion of management, include all adjustments necessary for a fair statement of the financial position and results of operations of the Company for the interim periods presented. Such adjustments consisted only of normal recurring items. The

 

8



Table of Contents

 

year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America.

 

In accordance with accounting principles generally accepted in the United States of America for interim financial reports and the instructions for Form 10-Q and the rules of the Securities and Exchange Commission, certain information and footnote disclosures normally included in annual financial statements have been condensed or omitted. Our accounting policies are described in the Notes to the Financial Statements in our Annual Report on Form 10-K for the year ended December 31, 2013. Interim results are not necessarily indicative of the results of operations for the full year. These interim financial statements should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2013.

 

Use of Estimates and Assumptions

 

The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the related disclosure of contingent assets and liabilities. The most significant estimates and assumptions are used in, but are not limited to, revenue recognition related to product sales and collaboration agreements, product sales allowances and accruals, assessing investments for potential other-than-temporary impairment, determining the fair values of our investments, assets acquired in a business combination, our debt obligations, and contingent consideration, the impairment of long-lived assets, including intangible assets, accrued expenses, and equity-based compensation expense. Actual results could differ materially from those estimates.

 

Cash and Cash Equivalents

 

Cash and cash equivalents consists principally of cash held in commercial bank accounts, money market funds and U.S. Treasury securities having an original maturity of less than three months. We consider all highly liquid investments with a maturity of three months or less at acquisition date to be cash equivalents. At March 31, 2014, substantially all of our cash and cash equivalents were held in either commercial bank accounts or money market funds.

 

Principles of Consolidation

 

The accompanying condensed consolidated financial statements include our accounts and the accounts of our wholly-owned subsidiaries, AMAG Europe Limited, AMAG Securities Corporation and Snowbird, Inc. AMAG Europe Limited was incorporated in October 2009 in London, England. AMAG Securities Corporation is a Massachusetts corporation which was incorporated in August 2007. Snowbird, Inc. is a Delaware corporation which was incorporated in December 2013. All intercompany account balances and transactions between the companies have been eliminated.

 

Fair Value Measurements

 

Under current accounting standards, fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.

 

9



Table of Contents

 

Current accounting guidance establishes a hierarchy used to categorize how fair value is measured and which is based on three levels of inputs, of which the first two are considered observable and the third unobservable, as follows:

 

Level 1 - Quoted prices in active markets for identical assets or liabilities.

 

Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

 

Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

 

We hold certain assets and liabilities that are required to be measured at fair value on a recurring basis, including our cash equivalents, investments, and contingent consideration.

 

Revenue Recognition and Related Sales Allowances and Accruals

 

An analysis of our U.S. Ferahem e product sales allowances and accruals for the three months ended March 31, 2014 and 2013 is as follows (in thousands):

 

 

 

Three Months Ended March 31,

 

 

 

2014

 

2013

 

Provision for U.S. Feraheme product sales allowances and accruals

 

 

 

 

 

Discounts and chargebacks

 

$

10,533

 

$

7,493

 

Government and other rebates

 

3,187

 

2,387

 

Returns

 

226

 

193

 

Total provision for U.S. Feraheme product sales allowances and accruals

 

$

13,946

 

$

10,073

 

 

 

 

 

 

 

Total gross U.S. Feraheme product sales

 

$

31,321

 

$

25,651

 

 

 

 

 

 

 

Total provision for U.S. Feraheme product sales allowances and  accruals as a percent of total gross U.S. Feraheme product sales

 

45

%

39

%

 

Consistent with industry practice, we generally offer our wholesalers, specialty distributors and other customers a limited right to return Feraheme based on the product’s expiration date which, once packaged, is currently five years in the U.S. We estimate product returns based on the historical return patterns and known or expected changes in the marketplace. We currently have limited actual returns data, and therefore are not able to solely rely on our actual returns experience. We track actual returns by individual production lots. Returns on lots eligible for credits under our returned goods policy are monitored and compared with historical return trends and rates.

 

We consider several additional factors in our product return estimation process, including our internal sales forecasts and inventory levels in the distribution channel. We expect that wholesalers and healthcare providers will not stock significant inventory due to the cost and expense to store Feraheme . Based on these factors, we determine whether an adjustment to the sales return reserve is appropriate.

 

We record an estimate of returns at the time of sale. If necessary, our estimated rate of returns may be adjusted for actual return experience as it becomes available and for known or expected changes in the marketplace. We did not significantly adjust our reserve for product returns during the three months

 

10



Table of Contents

 

ended March 31, 2014 or 2013. To date, returns of Feraheme have been relatively limited and returns experience may change over time. A future adjustment to our product returns estimate would result in a corresponding change to our net product sales in the period of adjustment and could be significant.

 

In addition, as part of our sales allowances and accruals, we reserve for estimated Medicaid rebates associated with instances where Medicaid will act as the insurer and for which we are required to pay a statutory rebate to Medicaid. We regularly assess our Medicaid reserve balance and the rate at which we accrue for claims against product sales. We did not adjust our Medicaid reserve balance during the three months ended March 31, 2014 or 2013. If we determine in future periods that our actual rebate experience is not indicative of expected claims, if our actual claims experience changes, or if other factors affect estimated claims rates, we may be required to adjust our current Medicaid accumulated reserve estimate, which would affect our net product sales in the period of the adjustment and could be significant.

 

Concentrations and Significant Customer Information

 

Financial instruments which potentially subject us to concentrations of credit risk consist principally of cash, investments, and accounts receivable. As of March 31, 2014, our cash, cash equivalents and investments amounted to approximately $385.5 million. We currently invest our excess cash primarily in U.S. government and agency money market funds, and investments in corporate debt securities, U.S. treasury and government agency securities, and commercial paper. As of March 31, 2014, we had approximately $196.3 million of our total $200.9 million cash and cash equivalents balance invested in institutional money market funds, of which $179.9 million was invested in a single fund.

 

Our operations are located solely within the U.S. We are focused principally on developing, manufacturing, and commercializing Feraheme/Rienso and commercializing MuGard . We perform ongoing credit evaluations of our customers and generally do not require collateral. The following table sets forth customers who represented 10% or more of our total revenues for the three months ended March 31, 2014 and 2013:

 

 

 

Three Months Ended March 31,

 

 

 

2014

 

2013

 

AmerisourceBergen Drug Corporation

 

39

%

43

%

McKesson Corporation

 

22

%

22

%

Cardinal Health, Inc.

 

15

%

15

%

Takeda Pharmaceuticals Company Limited

 

11

%

12

%

 

In addition, approximately 28% and 30% of our end-user demand during the three months ended March 31, 2014 and 2013, respectively, was generated by members of a single group purchasing organization, or GPO, with which we have contracted. Revenues from customers outside of the U.S. amounted to approximately 16% and 12% of our total revenues for the three months ended March 31, 2014 and 2013, respectively, and were principally related to collaboration revenue recognized in connection with our collaboration agreement with Takeda, which is headquartered in Japan.

 

We are currently solely dependent on a single supply chain for our Feraheme/Rienso drug substance and finished drug product. We are exposed to a significant loss of revenue from the sale of Feraheme/Rienso if our suppliers and/or manufacturers cannot fulfill demand for any reason.

 

11



Table of Contents

 

C.            Investments

 

As of March 31, 2014 and December 31, 2013, our investments equaled $184.6 million and $186.8 million, respectively, and consisted of securities classified as available-for-sale in accordance with accounting standards which provide guidance related to accounting and classification of certain investments in debt and equity securities.

 

The following is a summary of our investments as of March 31, 2014 and December 31, 2013 (in thousands):

 

 

 

March 31, 2014

 

 

 

 

 

Gross

 

Gross

 

Estimated

 

 

 

Amortized

 

Unrealized

 

Unrealized

 

Fair

 

 

 

Cost

 

Gains

 

Losses

 

Value

 

Corporate debt securities

 

 

 

 

 

 

 

 

 

Due in one year or less

 

$

23,492

 

$

46

 

$

(2

)

$

23,536

 

Due in one to three years

 

108,536

 

159

 

(47

)

108,648

 

U.S. treasury and government agency securities

 

 

 

 

 

 

 

 

 

Due in one year or less

 

21,079

 

35

 

 

21,114

 

Due in one to three years

 

29,772

 

17

 

(28

)

29,761

 

Commercial paper

 

 

 

 

 

 

 

 

 

Due in one year or less

 

1,499

 

 

(1

)

1,498

 

Total investments

 

$

184,378

 

$

257

 

$

(78

)

$

184,557

 

 

 

 

December 31, 2013

 

 

 

 

 

Gross

 

Gross

 

Estimated

 

 

 

Amortized

 

Unrealized

 

Unrealized

 

Fair

 

 

 

Cost

 

Gains

 

Losses

 

Value

 

Corporate debt securities

 

 

 

 

 

 

 

 

 

Due in one year or less

 

$

42,609

 

$

44

 

$

(4

)

$

42,649

 

Due in one to three years

 

91,443

 

137

 

(106

)

91,474

 

U.S. treasury and government agency securities

 

 

 

 

 

 

 

 

 

Due in one year or less

 

18,526

 

19

 

 

18,545

 

Due in one to three years

 

34,123

 

37

 

(25

)

34,135

 

Total investments

 

$

186,701

 

$

237

 

$

(135

)

$

186,803

 

 

Impairments and Unrealized Gains and Losses on Investments

 

We did not recognize any other-than-temporary impairment losses in our condensed consolidated statements of operations related to our securities during the three months ended March 31, 2014 and 2013. We considered various factors, including the length of time that each security was in an unrealized loss position and our ability and intent to hold these securities until the recovery of their amortized cost basis occurs. As of March 31, 2014, an insignificant portion of our investments has been in an unrealized loss position for more than one year. Future events may occur, or additional information may become available, which may cause us to identify credit losses where we do not expect to receive cash flows sufficient to recover the entire amortized cost basis of a security and which may necessitate the recording of future realized losses on securities in our portfolio. Significant losses in the estimated fair values of our investments could have a material adverse effect on our earnings in future periods.

 

12



Table of Contents

 

Realized Gains and Losses on Investments

 

Gains and losses are determined on the specific identification method. Realized gains were insignificant during the three months ended March 31, 2014 and 2013.

 

D.            Fair Value Measurements

 

The following tables represent the fair value hierarchy as of March 31, 2014 and December 31, 2013 for those assets and liabilities that we measure at fair value on a recurring basis (in thousands):

 

 

 

Fair Value Measurements at March 31, 2014 Using:

 

 

 

 

 

Quoted Prices in Active 
Markets for Identical 
Assets

 

Significant Other

Observable Inputs

 

Significant 
Unobservable 
Inputs

 

 

 

Total

 

(Level 1)

 

(Level 2)

 

(Level 3)

 

Assets:

 

 

 

 

 

 

 

 

 

Money market funds

 

$

196,297

 

$

196,297

 

$

 

$

 

Corporate debt securities

 

132,184

 

$

 

132,184

 

 

U.S. treasury and government agency securities

 

50,875

 

$

 

50,875

 

 

Commercial paper

 

1,498

 

 

1,498

 

 

Total Assets

 

$

380,854

 

$

196,297

 

$

184,557

 

$

 

Liabilities:

 

 

 

 

 

 

 

 

 

Acquisition-related contingent consideration

 

$

15,382

 

 

 

15,382

 

Total Liabilities

 

$

15,382

 

$

 

$

 

$

15,382

 

 

 

 

Fair Value Measurements at December 31, 2013 Using:

 

 

 

 

 

Quoted Prices in Active 
Markets for Identical 
Assets

 

Significant Other
Observable Inputs

 

Significant 
Unobservable 
Inputs

 

 

 

Total

 

(Level 1)

 

(Level 2)

 

(Level 3)

 

Assets:

 

 

 

 

 

 

 

 

 

Money market funds

 

$

18,767

 

$

18,767

 

$

 

$

 

Corporate debt securities

 

134,123

 

 

134,123

 

 

U.S. treasury and government agency securities

 

52,680

 

 

52,680

 

 

Total Assets

 

$

205,570

 

$

18,767

 

$

186,803

 

$

 

Liabilities:

 

 

 

 

 

 

 

 

 

Acquisition-related contingent consideration

 

$

14,550

 

$

 

$

 

$

14,550

 

Total Liabilities

 

$

14,550

 

$

 

$

 

$

14,550

 

 

With the exception of our money market funds and our acquisition-related contingent consideration, the fair value of our investments is primarily determined from independent pricing services. Independent pricing services normally derive security prices from recently reported trades for identical or similar securities, making adjustments based upon other significant observable market transactions. At the end of each reporting period, we perform quantitative and qualitative analyses of prices received from third parties to determine whether prices are reasonable estimates of fair value. After completing our analyses, we did not adjust or override any fair value measurements provided by our pricing services as of March 31, 2014. In addition, there were no transfers or reclassifications of any securities between Level 1 and Level 2 during the three months ended March 31, 2014.

 

Contingent consideration

 

We are accounting for the acquisition of the MuGard Rights as a business combination under the acquisition method of accounting. Additional details regarding the Access License Agreement and the

 

13



Table of Contents

 

MuGard Rights can be found in Note H. The fair value measurements of contingent consideration obligations arising from business combinations are determined using unobservable, or Level 3, inputs. These inputs include (a) the estimated amount and timing of projected cash flows; (b) the probability of the achievement of the factors on which the contingency is based; and (c) the risk-adjusted discount rate used to present value the probability-weighted cash flows. Significant increases (decreases) in any of those inputs in isolation could result in a significantly lower or higher fair value measurement.

 

The following table presents a reconciliation of contingent consideration obligations related to our acquisition of the MuGard Rights measured on a recurring basis using Level 3 inputs as of March 31, 2014 (in thousands):

 

Balance as of December 31, 2013

 

$

14,550

 

Payments made

 

(31

)

Adjustments to fair value of contingent consideration

 

789

 

Other adjustments

 

74

 

Balance as of March 31, 2014

 

$

15,382

 

 

During the three months ended March 31, 2014, we recorded $0.8 million in expense related to the increase in fair value of the contingent consideration liability. This expense principally represents the time value of money impact of the contingent consideration fair value assessment as of March 31, 2014 and is included in selling, general and administrative expenses in our condensed consolidated statements of operations. As of March 31, 2014, we estimate that the undiscounted royalty amounts we could pay under the Access License Agreement may range from $28.0 million to $34.0 million over a ten year period, which is our best estimate of the period over which we expect the majority of the asset’s cash flows to be derived. This measure is based on significant Level 3 inputs not observable in the market. Key assumptions include a discount rate of approximately 15%. We have classified $1.3 million of the contingent consideration as a short-term liability, which was included in accrued expenses in our condensed consolidated balance sheet as of March 31, 2014.

 

Debt

 

In February 2014, we issued $200.0 million of 2.5% convertible senior notes due February 15, 2019, or the Convertible Notes. Interest is payable semi-annually in arrears on February 15 and August 15 of each year, beginning on August 15, 2014. The fair value of our Convertible Notes, which differs from their carrying values, is influenced by interest rates and our stock price and stock price volatility and is determined by prices for the Convertible Notes observed in market trading, which are Level 2 inputs. The estimated fair value of the Convertible Notes at March 31, 2014 was $161.8 million. In addition, in connection with the pricing of the Convertible Notes, we entered into convertible bond hedge transactions, or convertible bond hedges, and separate warrant transactions, or warrants, as discussed in more detail in Note P, “ Debt. ” The carrying value of long-term debt approximated fair value at March 31, 2014 due to the recent issuance of the Convertible Notes.

 

E.            Accounts Receivable, Net

 

Our net accounts receivable were $10.1 million and $6.8 million as of March 31, 2014 and December 31, 2013, respectively, and primarily represented amounts due from wholesalers and distributors to whom we sell Feraheme directly. Accounts receivable are recorded net of reserves for estimated chargeback obligations, prompt payment discounts and any allowance for doubtful accounts.

 

Customers which represented greater than 10% of our accounts receivable balances as of March 31, 2014 and December 31, 2013 were as follows:

 

14



Table of Contents

 

 

 

March 31, 2014

 

December 31, 2013

 

AmerisourceBergen Drug Corporation

 

52

%

49

%

McKesson Corporation

 

27

%

27

%

Cardinal Health, Inc.

 

15

%

16

%

 

F.              Inventories

 

Our major classes of inventories were as follows as of March 31, 2014 and December 31, 2013 (in thousands):

 

 

 

March 31, 2014

 

December 31, 2013

 

Raw materials

 

$

4,116

 

$

3,157

 

Work in process

 

8,929

 

8,322

 

Finished goods

 

7,759

 

5,738

 

Total inventories

 

$

20,804

 

$

17,217

 

 

During the three months ended March 31, 2014, we expensed $1.1 million of commercial inventory, which we determined would be solely used in manufacturing process and development activities at our third-party suppliers, which we have recorded in research and development expenses. In addition, we expensed $0.3 million of commercial inventory deemed no longer saleable, which we have recorded in cost of goods sold.

 

G.            Property and Equipment, Net

 

Property and equipment consisted of the following as of March 31, 2014 and December 31, 2013 (in thousands):

 

 

 

March 31, 2014

 

December 31, 2013

 

 

 

 

 

 

 

Furniture and fixtures

 

$

1,489

 

$

1,536

 

Leasehold improvements

 

430

 

430

 

Laboratory and production equipment

 

493

 

376

 

 

 

2,412

 

2,342

 

Less - accumulated depreciation

 

(575

)

(496

)

Property and equipment, net

 

$

1,837

 

$

1,846

 

 

H.            Business Combination

 

As part of our strategy to expand our portfolio with additional commercial-stage specialty products, in June 2013, we entered into the Access License Agreement pursuant to which we obtained an exclusive, royalty-bearing license, with the right to grant sublicenses, to certain intellectual property rights, including know-how, patents and trademarks, to use, import, offer for sale, sell, manufacture and commercialize MuGard in the U.S. Territory for the management of all diseases or conditions of the oropharyngeal cavity, including mucositis.

 

In consideration for the license, we paid Access an upfront payment of $3.3 million in June 2013. We are required to pay royalties to Access on future net sales of MuGard until the later of (a) the expiration of the licensed patents or (b) the tenth anniversary of the first commercial sale of MuGard under the Access License Agreement in the U.S. Territory, or the Royalty Term. These tiered, double-digit royalty rates

 

15



Table of Contents

 

decrease for any part of the Royalty Term occurring after the expiration of the licensed patents and are subject to off-set against certain of our expenses. After the expiration of the Royalty Term, the license shall become a fully paid-up, royalty-free and perpetual license in the U.S. Territory. In addition to making an upfront payment of $3.3 million, we also acquired $0.2 million of existing MuGard inventory from Access, which was included in our condensed consolidated balance sheet as of the Acquisition Date.

 

We did not assume any pre-existing liabilities related to the MuGard business, contingent or otherwise, arising prior to the Acquisition Date. We are accounting for the acquisition of the MuGard Rights as a business combination under the acquisition method of accounting. The following table summarizes the total consideration for the MuGard Rights (in thousands):

 

Consideration:

 

 

 

Cash

 

$

3,434

 

Acquisition-related contingent consideration

 

13,700

 

Total consideration

 

$

17,134

 

 

The $17.1 million total consideration includes the estimated fair value of the contingent consideration at the Acquisition Date.

 

The following table summarizes the estimated fair values of the assets acquired related to the business combination as of the Acquisition Date (in thousands):

 

Assets Acquired:

 

 

 

MuGard intangible asset

 

$

16,893

 

Inventory

 

241

 

Net identifiable assets acquired

 

$

17,134

 

 

Transaction costs are not included as a component of consideration transferred and are expensed as incurred. We incurred approximately $0.8 million of acquisition-related costs in the second quarter of 2013. These costs were primarily related to professional and legal fees and are included in selling, general and administrative expenses in our condensed consolidated statements of operations for the second quarter of 2013.

 

I.                    Intangible Assets, Net

 

In June 2013, we acquired the MuGard Rights from Access and recorded $16.9 million to finite-lived intangible assets based on the estimated fair value of the MuGard Rights as of the Acquisition Date.

 

We will amortize the MuGard Rights using an economic consumption model over ten years, which represents our best estimate of the period over which we expect the majority of the asset’s cash flows to be derived. We believe this is the best approximation of the period over which we will derive the majority of value of the MuGard Rights. We recorded less than $0.1 million of amortization related to the MuGard Rights in cost of product sales in our condensed consolidated statements of operations for the three months ended March 31, 2014 and as a result, our intangible asset related to the MuGard Rights was $16.8 million as of March 31, 2014.

 

Intangible assets are reviewed for impairment at least annually and whenever facts or circumstances suggest that the carrying value of these assets may not be recoverable. Our policy is to identify and record impairment losses, if necessary, on intangible assets when events and circumstances indicate that the

 

16



Table of Contents

 

assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amounts of those assets.

 

J.                  Income Taxes

 

Deferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using future enacted rates. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized.

 

For the three months ended March 31, 2014 and 2013, we did not recognize any tax expense or benefit due to our continued net operating loss position. Due to the uncertainty surrounding the realization of favorable tax attributes in future tax returns, we have recorded a full valuation allowance against our otherwise recognizable net deferred tax assets.

 

The interest expense related to the Convertible Notes is deductible for income tax purposes, subject to certain limitations.

 

K.            Accumulated Other Comprehensive Loss

 

The changes in accumulated other comprehensive loss, net of tax, for the three months ended March 31, 2014 and 2013 consisted of the following (in thousands):

 

 

 

Three Months Ended March 31,

 

 

 

2014

 

2013

 

Beginning Balance

 

$

(3,491

)

$

(3,247

)

Other comprehensive income (loss) before reclassifications

 

77

 

(87

)

Gain (loss) reclassified from other accumulated comprehensive loss

 

 

(6

)

Ending Balance

 

$

(3,414

)

$

(3,340

)

 

The amounts reclassified from other comprehensive loss for the three months ended March 31, 2014, primarily represented realized gains on investments, which are included in our condensed consolidated statement of operations under “Gains on investments, net.”

 

L.             Net Loss per Share

 

We compute basic net loss per share by dividing net loss by the weighted average number of common shares outstanding during the relevant period.

 

In February 2014, in connection with the issuance of the Convertible Notes, we entered into convertible bond hedges. The convertible bond hedges are not included for purposes of calculating the number of diluted shares outstanding, as their effect would be anti-dilutive. The convertible bond hedges are generally expected, but not guaranteed, to reduce the potential dilution and/or offset the cash payments we are required to make upon conversion of the Convertible Notes. See Note P, “ Debt, ” for additional information. As we have a choice to settle the conversion obligation under the Convertible Notes in cash, shares or any combination of the two, we have determined that we intend to settle the

 

17



Table of Contents

 

accreted principal value of the Convertible Notes in cash and the excess conversion premium in shares. While the dilutive effect of the conversion premium will be considered in the calculation of diluted net income per share using the treasury stock method, the accreted principal value of the Convertible Notes will not be included in the calculation of diluted income per share, as we intend to settle this in cash.

 

The components of basic and diluted net loss per share were as follows (in thousands, except per share data):

 

 

 

Three Months Ended March 31,

 

 

 

2014

 

2013

 

Net loss

 

$

(7,102

)

$

(3,895

)

Weighted average common shares outstanding

 

21,824

 

21,544

 

Net loss per share:

 

 

 

 

 

Basic and diluted

 

$

(0.33

)

$

(0.18

)

 

The following table sets forth the potential common shares issuable upon the exercise of outstanding options, the vesting of RSUs and warrants (prior to consideration of the treasury stock method), which were excluded from our computation of diluted net loss per share because such instruments were anti-dilutive (in thousands):

 

 

 

Three Months Ended March 31,

 

 

 

2014

 

2013

 

Options to purchase shares of common stock

 

3,335

 

2,750

 

Shares of common stock issuable upon the vesting of restricted stock units

 

481

 

510

 

Warrants

 

7,382

 

 

Total

 

11,198

 

3,260

 

 

We have determined that we have the intent and ability to settle the debt component of the Convertible Notes in cash and the excess conversion spread in shares. Therefore, the effect of the Convertible Notes reflected in diluted earnings per share is limited to the conversion premium, which is reflected in the calculation of diluted earnings per share as if it were a freestanding written call option on our shares. During the three months ended March 31, 2014, the weighted average common stock price was below the conversion price of the Convertible Notes.

 

The dilutive effect of the stock options, RSUs, and warrants is calculated using the treasury stock method. During the three months ended March 31, 2014, the warrants were excluded from diluted shares outstanding because the weighted average common stock price was below the exercise price.

 

M.             Equity-Based Compensation

 

We currently maintain two equity compensation plans, including our Third Amended and Restated 2007 Equity Incentive Plan, or the 2007 Plan, and our Amended and Restated 2000 Stock Plan, or the 2000 Plan. During the three months ended March 31, 2014, we also granted equity to certain newly hired executive officers through inducement grants outside of these plans.

 

Third Amended and Restated 2007 Equity Incentive Plan

 

Our 2007 Plan was originally approved by our stockholders in November 2007. In each of May 2009, May 2010, and May 2013 our stockholders approved proposals to amend and restate our 2007 Plan to,

 

18



Table of Contents

 

among other things, increase the number of shares authorized for issuance thereunder by 600,000, 800,000 and 1,100,000 shares, respectively.

 

As of March 31, 2014, we have granted options and RSUs covering 7,076,175 shares of common stock under our 2007 Plan, of which 2,712,957 stock options and 661,811 RSUs have expired or terminated, and of which 210,524 options have been exercised and 500,871 shares of common stock have been issued pursuant to RSUs that became fully vested. The number of options and RSUs outstanding under this plan as of March 31, 2014, was 2,684,438 and 305,574, respectively. The remaining number of shares available for future grants as of March 31, 2014 was 1,514,760, not including shares subject to outstanding awards under the 2000 Plan, which will be added to the total number of shares available for issuance under the 2007 Plan to the extent that such awards expire or terminate for any reason prior to exercise. All outstanding stock options granted under our 2007 Plan have an exercise price equal to the closing price of a share of our common stock on the grant date and have either a seven or ten-year term.

 

Amended and Restated 2000 Stock Plan

 

Our 2000 Plan provided for the grant of options and other equity-based awards to our directors, officers, employees and consultants. The terms and conditions of each such grant, including, but not limited to, the number of shares, the exercise price, term of the option/award and vesting requirements, were determined by our Board or the Compensation Committee of our Board. As of March 31, 2014, we have granted stock options and RSUs covering 2,182,700 shares of common stock under the 2000 Plan, of which 984,339 stock options and 1,500 RSUs have expired or terminated, and of which 1,052,045 stock options have been exercised and 42,500 shares of common stock have been issued pursuant to RSUs that became fully vested. The remaining number of shares underlying outstanding stock options which were issued pursuant to our 2000 Plan as of March 31, 2014, was 102,316. There were no remaining restricted RSUs which were issued pursuant to our 2000 Plan as of March 31, 2014. All outstanding stock options granted under the 2000 Plan have an exercise price equal to the closing price of our common stock on the grant date and have a ten year term. In November 2007, the 2000 Plan was succeeded by our 2007 Plan and, accordingly, no further grants may be made under this plan. Any shares that remained available for issuance under the 2000 Plan as of the date of adoption of the 2007 Plan are included in the number of shares that may be issued under the 2007 Plan. Any shares subject to outstanding awards granted under the 2000 Plan that expire or terminate for any reason prior to exercise will be added to the total number of shares available for issuance under the 2007 Plan.

 

Other Equity Compensation Grants

 

During the three months ended March 31, 2014, our Board granted options to purchase 90,000 shares of our common stock to certain members of our senior management to induce them to accept employment with us. These options were granted at an exercise price equal to the fair market value of a share of our common stock on the respective grant dates. The options will be exercisable in four equal annual installments beginning on the first anniversary of the respective grant dates. In addition, during the three months ended March 31, 2014, our Board granted 35,000 RSUs to certain members of our senior management to induce them to accept employment with us. These grants will vest in four equal annual installments beginning on the first anniversary of the respective grant dates. The foregoing grants were made pursuant to inducement grants outside of our 2007 Plan as permitted under the NASDAQ Global Market rules. We assessed the terms of these awards and determined there was no possibility that we would have to settle these awards in cash and therefore, equity accounting was applied.

 

Equity-based compensation expense

 

Equity-based compensation expense for the three months ended March 31, 2014 and 2013, consisted of the following (in thousands):

 

19



Table of Contents

 

 

 

Three Months Ended March 31

 

 

 

2014

 

2013

 

Cost of product sales

 

$

28

 

$

23

 

Research and development

 

449

 

932

 

Selling, general and administrative

 

1,453

 

1,328

 

Total equity-based compensation expense

 

$

1,930

 

$

2,283

 

 

We reduce the compensation expense being recognized to account for estimated forfeitures, which we estimate based primarily on historical experience, adjusted for unusual events such as corporate restructurings, which may result in higher than expected turnover and forfeitures. Under current accounting guidance, forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

 

N.                Commitments and Contingencies

 

Legal Proceedings

 

We accrue a liability for legal contingencies when we believe that it is both probable that a liability has been incurred and that we can reasonably estimate the amount of the loss. We review these accruals and adjust them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel and other relevant information. To the extent new information is obtained and our views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in our accrued liabilities would be recorded in the period in which such determination is made. For the matters referenced below, the liability is not probable or the amount cannot be reasonably estimated and, therefore, accruals have not been made. In addition, in accordance with the relevant authoritative guidance, for any matters in which the likelihood of material loss is at least reasonably possible, we will provide disclosure of the possible loss or range of loss. If a reasonable estimate cannot be made, however, we will provide disclosure to that effect.

 

A purported class action complaint was originally filed on March 18, 2010 in the U.S. District Court for the District of Massachusetts, entitled Silverstrand Investments et. al. v. AMAG Pharm., Inc., et. al., Civil Action No. 1:10-CV-10470-NMG, and was amended on September 15, 2010 and on December 17, 2010. The second amended complaint, or SAC, filed on December 17, 2010 alleged that we and our former President and Chief Executive Officer, former Chief Financial Officer, the then-members of our Board, and certain underwriters in our January 2010 offering of common stock violated certain federal securities laws, specifically Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended, and that our former President and Chief Executive Officer and former Chief Financial Officer violated Section 15 of such Act, respectively, by making certain alleged omissions in a registration statement filed in January 2010. The plaintiffs sought unspecified damages on behalf of a purported class of purchasers of our common stock pursuant to our common stock offering on or about January 21, 2010. On August 11 and 15, 2011, respectively, the District Court issued an Opinion and Order dismissing the SAC with prejudice for failure to state a claim upon which relief could be granted. On September 14, 2011, the plaintiffs filed a Notice of Appeal to the U.S. Court of Appeals for the First Circuit, or the Court of Appeals. The Court of Appeals heard oral argument on May 11, 2012. On February 4, 2013, the Court of Appeals affirmed in part and reversed in part the District Court’s Opinion and Order and remanded the case to the District Court. On February 19, 2013, we filed a Petition for Panel Rehearing and Rehearing En Banc , which was denied on March 15, 2013. On March 22, 2013, we filed a Motion to Stay the Mandate remanding the case to the District Court pending review by the U.S. Supreme Court of the Court of Appeals’ February 4, 2013 decision. The Court of Appeals granted the Motion to Stay the Mandate on April 8, 2013. On June 13, 2013, we filed a Petition for a Writ of Certiorari, or the Petition, with the U.S. Supreme Court seeking

 

20



Table of Contents

 

review of the Court of Appeal’s decision and to have that decision overturned. On October 7, 2013 the U.S. Supreme Court denied our Petition, resulting in the case’s return to the District Court for further proceedings relative to the SAC’s surviving claims. On November 6, 2013, we filed a renewed Motion to Dismiss the SAC’s surviving claims. On December 6, 2013, the plaintiffs filed a brief in opposition to our Motion to Dismiss and we filed a reply brief in support of our Motion on December 27, 2013. On April 7, 2014, the District Court denied our renewed Motion to Dismiss. A status conference is scheduled for May 14, 2014. We are currently unable to predict the outcome or reasonably estimate the range of potential loss associated with this matter, if any, and have therefore not recorded any potential estimated liability as we do not believe that such a liability is probable nor do we believe that a range of loss is currently estimable.

 

In July 2010, Sandoz GmbH, or Sandoz, filed with the European Patent Office, or the EPO, an opposition to a previously issued patent which covers ferumoxytol in EU jurisdictions. In October 2012, at an oral hearing, the Opposition Division of the EPO revoked this patent. In December 2012, our notice of appeal of that decision was recorded with the EPO, which also suspended the revocation of our patent. On May 13, 2013, we filed a statement of grounds of appeal and on September 27, 2013, Sandoz filed a response to that statement. We filed a reply to that response on March 17, 2014. We will continue to defend the validity of this patent throughout the appeals process, which we expect to take two to three years. However, in the event that we do not experience a successful outcome from the appeals process, under EU regulations ferumoxytol would still be entitled to eight years of data protection and ten years of market exclusivity from the date of approval, which we believe would create barriers to entry for any generic version of ferumoxytol into the EU market until sometime between 2020 and 2022. This decision had no impact on our revenues for the three months ended March 31, 2014. However, any future unfavorable outcome in this matter could negatively affect the magnitude and timing of future revenues, including royalties and milestone payments we may receive from Takeda pursuant to our collaboration agreement with Takeda. We do not expect to incur any related liability regardless of the outcome of the appeal and therefore have not recorded any liability as of March 31, 2014. We continue to believe the patent is valid and intend to vigorously appeal the decision.

 

We may periodically become subject to other legal proceedings and claims arising in connection with ongoing business activities, including claims or disputes related to patents that have been issued or that are pending in the field of research on which we are focused. Other than the above actions, we are not aware of any material claims against us at March 31, 2014. We expense legal costs as they are incurred.

 

O.            Collaborative Agreements

 

Our commercial strategy includes the formation of collaborations with other pharmaceutical companies to facilitate the sale and distribution of Feraheme/Rienso , primarily outside of the U.S., as well as expanding our portfolio through the in-license or purchase of additional specialty pharmaceutical products.

 

Takeda

 

In March 2010, we entered into the Takeda Agreement with Takeda under which we granted exclusive rights to Takeda to develop and commercialize Feraheme/Rienso as a therapeutic agent in Europe, certain Asia-Pacific countries (excluding Japan, China and Taiwan), the Commonwealth of Independent States, Canada, India and Turkey. In June 2012, we entered into an amendment to the Takeda Agreement, or the Amended Takeda Agreement, which removed the Commonwealth of Independent States from the territories under which Takeda has the exclusive rights to develop and commercialize Feraheme/Rienso. In addition, the Amended Takeda Agreement modified the timing and pricing arrangements for a supply agreement to be entered into between us and Takeda, and which was entered into in February 2014 and discussed below, the terms related to primary and secondary

 

21



Table of Contents

 

manufacturing for drug substance and drug product, certain patent-related provisions, and the re-allocation of certain of the agreed-upon milestone payments. We analyzed the Amended Takeda Agreement and determined that the amended terms did not result in a material modification of the original Takeda Agreement (and thus did not require us to change our accounting model) because (a) there were no changes to the deliverables under the original Takeda Agreement as a result of the amendment, and (b) the change in arrangement consideration as a result of the amendment was not quantitatively material in relation to the total arrangement consideration.

 

In connection with the execution of the original Takeda Agreement, we received a $60.0 million upfront payment from Takeda in April 2010, which we recorded as deferred revenue, as well as approximately $1.0 million reimbursed to us during 2010 for certain expenses incurred prior to entering the agreement, which we considered an additional upfront payment. Because we cannot reasonably estimate the total level of effort required to complete the obligations under the combined deliverable, we are recognizing the entire $60.0 million upfront payment, the $1.0 million reimbursed to us in 2010, as well as any non-substantive milestone payments that are achieved into revenues on a straight-line basis over a period of ten years from March 31, 2010, the date on which we originally entered the Takeda Agreement, which represents the then-current patent life of Feraheme/Rienso and our best estimate of the period over which we will substantively perform our obligations. We continue to believe that the then-current patent life of Feraheme/Rienso is our best estimate of the period over which we will substantively perform our obligations under this agreement.

 

In addition, the remaining milestone payments we may be entitled to receive under the Amended Takeda Agreement could over time equal up to $186.0 million. For any milestone payments we may receive based upon the approval by certain regulatory agencies, we have determined that these will be deemed substantive milestones and, therefore, will be accounted for as revenue in the period in which they are achieved. We have also determined that any non-substantive milestone payments will be accounted for in accordance with our revenue attribution method for the upfront payment, as described above. During the three months ended March 31, 2014, we recorded $2.0 million in revenues associated with the amortization of the upfront payments in license fee and other collaboration revenues in our condensed consolidated statement of operations. Any potential non-substantive milestone payments that may be received in the future will be recognized as revenue on a cumulative catch up basis when they become due and payable.

 

Under the terms of the Amended Takeda Agreement, Takeda is responsible for reimbursing us for certain out-of-pocket regulatory and clinical trial supply costs associated with carrying out our regulatory and clinical research activities under the collaboration agreement. Because we are acting as the principal in carrying out these services, any reimbursement payments received from Takeda are recorded in license fee and other collaboration revenues in our condensed consolidated statement of operations to match the costs that we incur during the period in which we perform those services. We recorded $0.1 million and less than $0.1 million for the three months ended March 31, 2014 and 2013, respectively, associated with other reimbursement revenues received from Takeda.

 

22



Table of Contents

 

At the time of shipment, we defer recognition of all revenue for Feraheme/Rienso sold to Takeda in our condensed consolidated balance sheets. We recognize revenues from product sales to Takeda, the related cost of goods sold, and any royalty revenues due from Takeda, in our condensed consolidated statement of operations at the time Takeda reports to us that sales have been made its customers. During the three months ended March 31, 2014, we recognized $0.2 million in product sales and royalty revenue related to the Amended Takeda Agreement and we have included this revenue in other product sales and royalties in our condensed consolidated statement of operations. As of March 31, 2014, we had approximately $2.3 million in deferred revenue related to product shipped to Takeda but not yet sold through to Takeda’s customers, of which $1.2 million was classified as short-term and $1.1 million was classified as long-term. In addition, we had $2.2 million in deferred cost of product sales, of which $1.1 million was classified as short-term and $1.1 million was classified as long-term. These deferred revenue and deferred cost of product sales are recorded in our condensed consolidated balance sheet as of March 31, 2014.

 

In February 2014, we entered into a Supply Agreement with Takeda pursuant to which we will sell Feraheme to Takeda , to meet Takeda’s requirements for commercial use of Feraheme in the Licensed Territory. Under the Supply Agreement, Takeda is obligated to periodically provide us with demand forecasts of Takeda’s future Feraheme requirements, which will direct the forecasting and ordering process as well as our supply obligations. Takeda may order Feraheme for commercial use in excess of the forecasts, which we will use commercially reasonable efforts to supply. In addition, the Supply Agreement provides the minimum quantity of Feraheme that shall be ordered in each purchase order for commercial supply. Takeda shall have the right to use the Feraheme ordered under the Supply Agreement for clinical use, provided that the product be subject to all of the terms of the Supply Agreement, including commercial specifications. Takeda shall be solely responsible for labeling and packaging vials of the product in accordance with the terms of the Supply Agreement and the Amended Takeda Agreement. If we are unable, for any reason beyond our reasonable control (including an unanticipated increase in demand beyond the production capacity of the manufacturing sites), to supply sufficient quantities of Feraheme , we agree to promptly establish an allocation procedure with respect to the available supply of Feraheme for the Licensed Territory and outside the Licensed Territory. Takeda may obtain Feraheme from a designated second source established by us if necessary to meet increased demand, or upon the occurrence of certain defined insolvency events. If we are unable to perform its supply obligations under the Supply Agreement after a negotiated period of time following an insolvency event, Takeda can seek permanent alternative supply sources and the parties’ supply and purchase obligations under the Supply Agreement will terminate. The Supply Agreement provides that it will otherwise remain in place for the duration of the Amended Takeda Agreement.

 

The Supply Agreement provides pricing terms and also provides that Takeda will reimburse us for certain capital expenditures and shall pay us a per-vial manufacturing fee. In addition, the Supply Agreement specifies cost-sharing arrangements relating to future process changes or improvements to the manufacturing process for Feraheme . We generally agree to indemnify Takeda and its affiliates for damages resulting from the willful misconduct or gross negligence by us or a designated second source with respect to the manufacture of Feraheme , or resulting from our breach of the Supply Agreement. Takeda generally agrees to indemnify us, our affiliates and any designated second source for damages resulting with respect to the manufacture of Feraheme by Takeda or its affiliates, or resulting from Takeda’s breach of the Supply Agreement. The Supply Agreement includes quality control and testing terms, representations and warranties of the parties and other provisions customary for an agreement of this type.

 

3SBio, Inc.

 

In 2008, we entered into a Collaboration and Exclusive License Agreement with 3SBio Inc., or 3SBio, for the development and commercialization of Feraheme as an IV iron replacement therapeutic agent in China. In consideration of the grant of the license, we received an upfront payment of $1.0 million. In late January 2014, we mutually terminated the agreement with 3SBio, effective immediately, due to the fact that, despite the best efforts of the parties, regulatory approval in China could not be obtained within the agreed upon time period. During the three months ended March 31, 2014, we recognized the $1.0 million upfront payment into revenue as we have no future continuing obligations and have included it in license fee and other collaboration revenues in our condensed consolidated statements of operations.

 

Access

 

Please refer to Note H, “ Business Combinations,” for a detailed description of the Access License Agreement.

 

23



Table of Contents

 

P.              Debt

 

2.5% Convertible Notes

 

On February 14, 2014, we issued $200.0 million aggregate principal amount of Convertible Notes, which includes $25.0 million principal amount of Convertible Notes issued pursuant to the full exercise of an over-allotment option granted to the underwriters in the offering. We received net proceeds of $193.3 million from the sale of the Convertible Notes, after deducting fees and expenses of $6.7 million. We used $14.1 million of the net proceeds from the sale of the Convertible Notes to pay the cost of the convertible bond hedges, as described below (after such cost was partially offset by the proceeds to us from the sale of warrants in the warrant transactions described below).

 

The Convertible Notes are governed by the terms of an indenture between us, as issuer, and Wilmington Trust, National Association, as the trustee. The Convertible Notes are senior unsecured obligations and bear interest at a rate of 2.5% per year, payable semi-annually in arrears on February 15 and August 15 of each year, beginning on August 15, 2014. The Convertible Notes will mature on February 15, 2019, unless earlier repurchased or converted. The Convertible Notes will be convertible into cash, shares of our common stock, or a combination thereof, at our election, at an initial conversion rate of approximately 36.9079 shares of common stock per $1,000 principal amount of the Convertible Notes, which corresponds to an initial conversion price of approximately $27.09 per share of our common stock and represents a conversion premium of approximately 35% based on the last reported sale price of our common stock of $20.07 on February 11, 2014, the date the notes offering was priced.

 

The conversion rate is subject to adjustment from time to time upon the occurrence of certain events, including, but not limited to, the issuance of stock dividends and payment of cash dividends. At any time prior to the close of business on the business day immediately preceding May 15, 2018, holders may convert their Convertible Notes at their option only under the following circumstances:

 

(1)          during any calendar quarter commencing after the calendar quarter ended on March 31, 2014 (and only during such calendar quarter), if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day;

 

(2)          during the five business day period after any five consecutive trading day period, or the measurement period, in which the trading price per $1,000 principal amount of the Convertible Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day; or

 

(3)          upon the occurrence of specified corporate events. On or after May 15, 2018 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or any portion of their Convertible Notes, in multiples of $1,000 principal amount, at the option of the holder regardless of the foregoing circumstances.

 

If a make-whole fundamental change, as described in the indenture, occurs and a holder elects to convert its Convertible Notes in connection with such make-whole fundamental change, such holder may be entitled to an increase in the conversion rate as described in the indenture.

 

We may not redeem the Convertible Notes prior to the maturity date and no “sinking fund” is provided for the Convertible Notes, which means that we are not required to periodically redeem or retire the Convertible Notes. Upon the occurrence of certain fundamental changes involving us, holders of the

 

24



Table of Contents

 

Convertible Notes may require us to repurchase for cash all or part of their Convertible Notes at a repurchase price equal to 100% of the principal amount of the Convertible Notes to be repurchased, plus accrued and unpaid interest.

 

The indenture does not contain any financial or maintenance covenants or restrictions on the payments of dividends, the incurrence of indebtedness or the issuance or repurchase of securities by us or any of our subsidiaries. The indenture contains customary terms and covenants and events of default. If an event of default (other than certain events of bankruptcy, insolvency or reorganization involving us) occurs and is continuing, the Trustee by notice to us, or the holders of at least 25% in principal amount of the outstanding Convertible Notes by written notice to us and the Trustee, may declare 100% of the principal of and accrued and unpaid interest, if any, on all of the Convertible Notes to be due and payable. Upon such a declaration of acceleration, such principal and accrued and unpaid interest, if any, will be due and payable immediately. Upon the occurrence of certain events of bankruptcy, insolvency or reorganization involving us, 100% of the principal of and accrued and unpaid interest, if any, on all of the Convertible Notes will become due and payable automatically. Notwithstanding the foregoing, the indenture provides that, to the extent we elect and for up to 270 days, the sole remedy for an event of default relating to certain failures by us to comply with certain reporting covenants in the indenture consists exclusively of the right to receive additional interest on the Convertible Notes.

 

In accordance with accounting guidance for debt with conversion and other options, we separately account for the liability and equity components of the Convertible Notes by allocating the proceeds between the liability component and the embedded conversion option, or equity component, due to our ability to settle the Convertible Notes in cash, common stock or a combination of cash and common stock, at our option. The carrying amount of the liability component was calculated by measuring the fair value of a similar liability that does not have an associated convertible feature. The allocation was performed in a manner that reflected our non-convertible debt borrowing rate for similar debt. The equity component of the Convertible Notes was recognized as a debt discount and represents the difference between the proceeds from the issuance of the Convertible Notes and the fair value of the liability of the Convertible Notes on their respective dates of issuance. The excess of the principal amount of the liability component over its carrying amount, or debt discount, is amortized to interest expense using the effective interest method over five years, or the life of the Convertible Notes. The equity component is not remeasured as long as it continues to meet the conditions for equity classification.

 

Our outstanding convertible note balances as of March 31, 2014 consisted of the following:

 

 

 

March 31, 2014

 

Liability component:

 

 

 

Principal

 

$

200,000

 

Less: debt discount, net

 

(37,439

)

Net carrying amount

 

$

162,561

 

Equity component

 

$

38,188

 

 

In connection with the issuance of the Convertible Notes, we incurred approximately $6.7 million of debt issuance costs, which primarily consisted of underwriting, legal and other professional fees, and allocated these costs to the liability and equity components based on the allocation of the proceeds. Of the total $6.7 million of debt issuance costs, $1.3 million were allocated to the equity component and recorded as a reduction to additional paid-in capital and $5.4 million were allocated to the liability component and recorded as assets on the balance sheet. The portion allocated to the liability component is amortized to interest expense over the expected life of the Convertible Notes using the effective interest method.

 

25



Table of Contents

 

We determined the expected life of the debt was equal to the five year term on the Convertible Notes. As of March 31, 2014, the carrying value of the Convertible Notes was $162.6 million and approximated their fair value due to the recent issuance of such Convertible Notes. The effective interest rate on the liability component was 7.23% for the period from the date of issuance through March 31, 2014. The following table sets forth total interest expense recognized related to the Convertible Notes during the three months ended March 31, 2014 (in thousands):

 

 

 

March 31, 2014

 

Contractual interest expense

 

$

625

 

Amortization of debt issuance costs

 

102

 

Amortization of debt discount

 

749

 

Total interest expense

 

$

1,476

 

 

Convertible Bond Hedge and Warrant Transactions

 

In connection with the pricing of the Convertible Notes and in order to reduce the potential dilution to our common stock and/or offset cash payments due upon conversion of the Convertible Notes, on February 11, 2014 and February 13, 2014, we entered into convertible bond hedge transactions covering approximately 7.4 million shares of our common stock underlying the $200.0 million aggregate principal amount of the Convertible Notes, including the exercise of the over-allotment option, with JPMorgan Chase Bank, National Association, London Branch, Morgan Stanley & Co. International plc and Royal Bank of Canada, or together the Call Spread Counterparties. The convertible bond hedges have an exercise price of approximately $27.09 per share, subject to adjustment upon certain events, and are exercisable when and if the Convertible Notes are converted. If upon conversion of the Convertible Notes, the price of our common stock is above the exercise price of the convertible bond hedges, the Call Spread Counterparties will deliver shares of our common stock and/or cash with an aggregate value approximately equal to the difference between the price of our common stock at the conversion date and the exercise price, multiplied by the number of shares of our common stock related to the convertible bond hedges being exercised. The convertible bond hedges are separate transactions entered into by us and are not part of the terms of the Convertible Notes or the warrants, discussed below. Holders of the Convertible Notes will not have any rights with respect to the convertible bond hedges. We paid $39.8 million for these convertible bond hedges and recorded this amount as a reduction to additional paid-in capital, net of tax.

 

At the same time, we also entered into separate warrant transactions with each of the Call Spread Counterparties relating to, in the aggregate, approximately 7.4 million shares of our common stock underlying the $200.0 million aggregate principal amount of the Convertible Notes, including the exercise of the over-allotment option. The initial exercise price of the warrants is $34.12 per share, subject to adjustment upon certain events, which is 70% above the last reported sale price of our common stock of $20.07 on February 11, 2014. The warrants would separately have a dilutive effect to the extent that the market value per share of our common stock, as measured under the terms of the warrants, exceeds the applicable exercise price of the warrants. The warrants were issued to the Call Spread Counterparties pursuant to the exemption from registration set forth in Section 4(a)(2) of the Securities Act. We received $25.7 million for these warrants and recorded this amount to additional paid-in capital.

 

Aside from the initial payment of a $39.8 million premium to the Call Spread Counterparties under the convertible bond hedges, which amount is partially offset by the receipt of a $25.7 million premium under the warrants, we are not required to make any cash payments to the Call Spread Counterparties under the convertible bond hedges and will not receive any proceeds if the warrants are exercised.

 

26



Table of Contents

 

Q.            Stockholders’ Equity

 

In connection with the pricing of the Convertible Notes, on February 11, 2014, we and American Stock Transfer & Trust Company, LLC, or the Rights Agent, entered into an amendment, or the Amendment, to the Rights Agreement, dated as of September 4, 2009, between us and the Rights Agent. The Amendment, among other things, provides that, notwithstanding anything in the Rights Agreement to the contrary, each Call Spread Counterparty shall be deemed not to beneficially own any common shares underlying, or synthetically owned pursuant to, any Warrant held by such Call Spread Counterparty, any common shares held by such Call Spread Counterparty (or any affiliate thereof) to hedge its exposure with respect to the convertible bond hedges and warrants, any common shares underlying, or synthetically owned pursuant to, any Derivative Securities (as such term is defined in the Rights Agreement), including the Convertible Notes, held, or entered into, by such Call Spread Counterparty (or any affiliate thereof) to hedge its exposure with respect to the convertible bond hedges and warrants or any Convertible Notes held by such Call Spread Counterparty (or any affiliate thereof) in its capacity as underwriter in the notes offering.

 

Total stockholders’ equity increased $18.7 million compared to December 31, 2013. This increase was primarily driven by $38.2 million allocated to the equity portion of our Convertible Notes, as described in Note P, “ Debt ,” and $1.9 million in stock-based compensation expense. These increases were partially offset by our net loss of $7.1 million, $14.1 million paid for the cost of the convertible bond hedges, net of the sale of warrants, and $1.3 million in debt issuance costs that were allocated to the equity component of the Convertible Notes, also described further in Note P.

 

R.                                     Recently Issued and Proposed Accounting Pronouncements

 

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption.

 

27



Table of Contents

 

Item 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

The following information should be read in conjunction with the unaudited financial information and the notes thereto included in this Quarterly Report on Form 10-Q and the audited financial information and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2013, or our Annual Report.

 

Except for the historical information contained herein, the matters discussed in this Quarterly Report on Form 10-Q may be deemed to be forward-looking statements that involve risks and uncertainties. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. In this Quarterly Report on Form 10-Q, words such as “may” “will,” “expect,” “intend,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements.

 

Examples of forward-looking statements contained in this report include, among others, statements regarding the following: our plan to grow Feraheme in the U.S. chronic kidney disease market and through international expansion, IV iron market expansion and potential label expansion; the expansion of our portfolio through the in-license or purchase of additional specialty pharmaceutical products and companies; expectations regarding our supplemental New Drug Application for Feraheme and our plans for addressing the complete response letter from the FDA and the path forward for Feraheme in the broad IDA patient population; the timing of the opinion of the European Medicines Agency and the related decision by the European Commission regarding Takeda Pharmaceutical Company Limited’s application

 

28



Table of Contents

 

for Type II Variation of the marketing authorization for Rienso in the EU; our expectations regarding the timing for enrollment in and commencement of our pediatric studies and a post-approval trial to assess the safety and efficacy of repeat doses of Feraheme for the treatment of iron deficiency anemia; our expectation of costs to be incurred in connection with and revenue sources to fund our future operations; our expectation for the patient population for Feraheme in the U.S.; our expectations regarding the success of our collaboration with Takeda Pharmaceutical Company Limited, including any potential milestone payments, product sales or royalties we may receive; our expectations regarding the manufacture of all Feraheme/Rienso drug substance and drug product at our third-party manufacturers; our expectations regarding customer returns and other revenue-related reserves and accruals; variations of the labeling and other elements of the marketing authorization for Rienso in the EU that may be expected as a result of the review by the EMA Committee for Medicinal Products for Human Use of IV iron-containing medications used to treat iron deficiency anemia; our expectations regarding the validity of our European ferumoxytol patent and timing of the appeals process; our expectations regarding government regulations, including the Branded Drug Fee under the Health Care Reform Act and the Medicare reimbursement rate for Feraheme and estimates for Medicaid rebates; our expectations regarding our license fee and other collaboration revenues; expected customer mix and utilization rates; the impact of volume rebates and other incentives; provider purchase patterns and use of competitive products; expectations regarding MuGard and our license arrangement with Access Pharmaceuticals, Inc.; the valuation of certain intangible assets, contingent consideration, debt and other assets and liabilities, including our methodology and assumptions regarding fair value measurements; our gross-to-net sales adjustments; our expectations regarding competitive pressures and the impact on growth in our product sales; our Citizen Petition; our expectations for product sales and fluctuations in net revenue per gram of Feraheme and our costs of product sales as a percentage of net product sales and royalties, our research and development expenses, external expenses and the timing of our planned research and development projects, and selling, general and administrative expenses; expectations for our debt, including the Convertible Notes and use of proceeds; our belief regarding the potential impact of the adoption of newly issued and future accounting guidance on our financial statements; our expectations for our cash, cash equivalents and investments balances and information with respect to any other plans and strategies for our business. Our actual results and the timing of certain events may differ materially from the results discussed, projected, anticipated or indicated in any forward-looking statements.

 

Any forward-looking statement should be considered in light of the factors discussed in Part II, Item 1A below under “Risk Factors” in this Quarterly Report on Form 10-Q and in Part I, Item 1A in our Annual Report. We caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. We disclaim any obligation, except as specifically required by law and the rules of the U.S. Securities and Exchange Commission to publicly update or revise any such statements to reflect any change in company expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

 

Overview

 

AMAG Pharmaceuticals, Inc., a Delaware corporation, was founded in 1981. We are a specialty pharmaceutical company that markets Feraheme ® (ferumoxytol) Injection for Intravenous, or IV, use to treat iron deficiency anemia, or IDA, in adult patients with chronic kidney disease, or CKD, and MuGard ®  Mucoadhesive Oral Wound Rinse for the management of oral mucositis. Along with driving organic growth of our products, we intend to expand our portfolio with additional commercial-stage specialty products. Our primary goal is to bring to market therapies that provide clear benefits and improve patients’ lives.

 

Currently, our principal source of revenue is from the sale of Feraheme , which was approved for marketing in the U.S. in June 2009 by the U.S. Food and Drug Administration, or the FDA, for use as an

 

29



Table of Contents

 

IV iron replacement therapy for the treatment of IDA in adult patients with CKD. We began selling Feraheme in the U.S. in July 2009 through our own commercial organization, including a specialty sales force. We sell Feraheme to authorized wholesalers and specialty distributors, who in turn, sell Feraheme to healthcare providers who administer Feraheme primarily within hospitals, hematology and oncology centers, and nephrology clinics. We are working to continue to grow Feraheme in the U.S. CKD market and to drive additional growth of Feraheme through international expansion, IV iron market expansion and potential label expansion. We are also focusing a portion of our efforts on marketing and selling MuGard in the U.S.

 

Portfolio Expansion

 

To further build our business, we intend to continue to expand our portfolio through the in-license or purchase of additional specialty pharmaceutical products or companies. In particular, we are seeking complementary products that will leverage our commercial infrastructure and focus on hematology and oncology centers, hospital infusion centers or other sites of care where IV iron is administered or where IDA patients are diagnosed or treated. We are also evaluating products in other strategic areas of interest, such as gastroenterology or rheumatology. Since patients within these specialties have high rates of co-morbid IDA, these new call points could be synergistic with the potential label expansion of Feraheme , if regulatory approval is obtained. In addition, we are contemplating transactions that would be financially beneficial to us, by providing an additional revenue stream from products that are approved for one or more indication, but that would be accretive to earnings and allow us to eliminate duplicative infrastructure, and potentially optimize after-tax cash flows. Finally, we may opportunistically look at commercial products in other indications or products that we believe entail lower-risk late stage development.

 

As an example of a product acquisition with a synergistic call point to Feraheme , in June 2013, we entered into a License Agreement with Access Pharmaceuticals, Inc., or Access, under which we acquired the U.S. commercial rights to MuGard , or the Access License Agreement. MuGard was launched in the U.S. by Access in 2010 after receiving 510(k) clearance from the FDA and is indicated for the management of oral mucositis/stomatitis (that may be caused by radiotherapy and/or chemotherapy) and all types of oral wounds (mouth sores and injuries), including aphthous ulcers/canker sores and traumatic ulcers, such as those caused by oral surgery or ill-fitting dentures or braces. Under the Access License Agreement, we obtained an exclusive, royalty-bearing license, with the right to grant sublicenses, to certain intellectual property rights, including know-how, patents and trademarks, to use, import, offer for sale, sell, manufacture and commercialize MuGard in the U.S. and its territories, or the U.S. Territory, for the management of all diseases or conditions of the oropharyngeal cavity, including mucositis, or the MuGard Rights. We sell MuGard to wholesalers and specialty and retail pharmacies. See Note H, “ Business Combination, to our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q for additional information regarding the Access License Agreement and the MuGard Rights .

 

Label Expansion of Ferumoxytol

 

In addition to expanding our portfolio through the in-license or purchase of additional specialty pharmaceutical products or companies, we believe that a significant opportunity exists in the U.S. for Feraheme beyond the treatment of IDA in adult patients with CKD. In the U.S., approximately 851,000 grams of IV iron were administered for the treatment of non-dialysis patients with IDA in 2013. We believe that approximately half, or 425,000 grams, of the IV iron administered in the U.S. was for the treatment of non-dialysis patients with CKD and the other half was for non-CKD patients with IDA due to other causes, including patients with gastrointestinal diseases or disorders, abnormal uterine bleeding, inflammatory diseases, and chemotherapy-induced anemia.

 

30



Table of Contents

 

In December 2012, we submitted a supplemental new drug application, or sNDA, to the FDA, seeking approval for Feraheme for the treatment of IDA in adult patients who had failed or could not use oral iron. The sNDA included data from two controlled, multi-center Phase III clinical trials, or IDA-301 and IDA-302, including more than 1,400 patients, which evaluated the safety and efficacy of ferumoxytol for the treatment of IDA in this broader patient population. Both studies met the primary efficacy endpoints related to improvements in hemoglobin. In these studies no new safety signals were observed with Feraheme treatment and the types of reported adverse events were consistent with those seen in previous studies and those contained in the approved U.S. package insert for Feraheme . In addition, patients from IDA-301 were eligible to enroll in an open-label extension study, or IDA-303, and receive treatment with Feraheme, as defined in the protocol.

 

On January 21, 2014, we received a complete response letter from the FDA for the sNDA informing us that our sNDA could not be approved in its present form and stating that we have not provided sufficient information to permit labeling of Feraheme for safe and effective use for the proposed broader indication. The FDA indicated that its decision was based on the cumulative ferumoxytol data, including the global Phase III IDA program and global post-marketing safety reports for the currently indicated CKD patient population. The FDA suggested, among other things, that we submit additional clinical trial data in the proposed broad IDA patient population with a primary composite safety endpoint of serious hypersensitivity/anaphylaxis, cardiovascular events and death, events that are included in the labels of Feraheme and other IV irons and that have been reported in the post-marketing environment for Feraheme . Additionally, the FDA proposed potentially evaluating alternative dosing and/or administration of Feraheme as well as potential additions to labeling that would be intended to reduce the risk of serious hypersensitivity reactions associated with Feraheme . We are in the process of developing a proposal that we believe would be responsive to the points raised in the complete response letter, including proposed additions to labeling on our current CKD indication, and that we determine would be economically viable. Once we have finalized our proposal we plan to (a) meet with FDA to discuss our proposal and explore the range of possible approaches to the points raised in the complete response letter (currently expected to be scheduled in mid-2014); and (b) assess the FDA’s feedback on our proposal and make a final determination on a possible program that would adequately address the FDA’s concerns. Until we have further discussions with the FDA and receive its input, we cannot predict the path forward, if any, for Feraheme in the broad IDA patient population, including the related timing and cost of any clinical trials.

 

International Expansion of Ferumoxytol

 

Outside of the U.S., ferumoxytol has been granted marketing approval in Canada, Switzerland and the European Union, or EU, for use as an IV iron replacement therapy for the treatment of IDA in adult patients with CKD. The marketing authorization granted in the EU is valid in the 28 EU Member States as well as in Iceland, Liechtenstein and Norway. The trade name for ferumoxytol in Canada is Feraheme and in the EU and Switzerland it is Rienso ®  30mg/ml solution for Injection. The EU competent authorities, and recently Canadian regulatory authorities, have implemented class labeling including stronger safety warnings for IV iron products, such as Feraheme/Rienso . Under our amended agreement with Takeda Pharmaceutical Company Limited, or Takeda, discussed below, Takeda has an exclusive license to market and sell ferumoxytol in Canada, the EU and Switzerland, as well as certain other geographic territories.

 

In June 2013, Takeda filed an application for Type II Variation of the marketing authorization for Rienso in the EU, which is the EU equivalent of a U.S. sNDA, with the European Medicines Agency, or EMA, seeking marketing authorization for an additional therapeutic indication for Rienso for the treatment of IDA in adult patients. Takeda currently expects an opinion from the EMA’s Committee for Medicinal Products for Human Use, or CHMP, in the second quarter of 2014. The related ratification of the CHMP opinion by the EMA would then be expected in the third quarter of 2014. If the CHMP issues a positive opinion for Rienso for the treatment of IDA generally without limit to a specific patient population or sub-population and the European Commission adopts a decision approving this variation, we expect that a significant milestone

 

31



Table of Contents

 

payment from Takeda will become payable. In addition, in October 2013, Takeda filed a Supplemental New Drug Submission, or sNDS, with Health Canada seeking marketing approval for Feraheme for the treatment of IDA in a broad range of patients.

 

Takeda Collaboration

 

In March 2010, we entered into a License, Development and Commercialization Agreement, or the Takeda Agreement, which was amended in June 2012, or the Amended Takeda Agreement, with Takeda under which we granted exclusive rights to Takeda to develop and commercialize Feraheme/Rienso as a therapeutic agent in Europe, certain Asia-Pacific countries (excluding Japan, China and Taiwan), Canada, India and Turkey. In February 2014, we entered into the supply agreement with Takeda, which provides the terms under which we will sell Feraheme to Takeda in order for Takeda to meet its requirements for commercial use of Feraheme in its licensed territories. The Takeda Agreement and related Supply Agreement are discussed in further detail in Note O, “ Collaborative Agreements ,”  to our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.

 

Post-Marketing Commitments of Feraheme in CKD

 

We have initiated a randomized, active-controlled pediatric study of Feraheme for the treatment of IDA in pediatric CKD patients to meet our FDA post-approval Pediatric Research Equity Act requirement to support pediatric labeling of Feraheme in the U.S . The study covers both dialysis-dependent and non-dialysis dependent CKD pediatric patients and will assess the safety and efficacy of Feraheme treatment as compared to oral iron in approximately 288 pediatric patients.

 

Our pediatric investigation plan, which was a requirement for submission of the Marketing Authorization Application, or MAA, for ferumoxytol, was approved by the EMA in December 2009 and amended in 2012, and includes the pediatric study as described above, and two additional pediatric studies requested by the EMA. These additional studies include a rollover extension study in pediatric CKD patients and a study in pediatric patients with IDA regardless of the underlying cause. The rollover study is open for enrollment. The pediatric IDA study will commence once the appropriate dose of Feraheme is determined from the study data resulting from the pediatric study of Feraheme , described above.

 

As part of our obligations under the Amended Takeda Agreement and as part of our post-approval commitments to the EMA, we initiated a multi-center clinical trial to determine the safety and efficacy of repeat doses of ferumoxytol for the treatment of IDA in patients with hemodialysis-dependent CKD. As part of the commitment we made to the EMA as a condition of the marketing authorization for ferumoxytol in the EU, this study includes a treatment arm with iron sucrose using a magnetic resonance imaging, or MRI, sub-analysis to evaluate the potential for iron to accumulate in the body following treatment with IV iron, specifically in the heart and liver, and, where possible, other major organs following repeated IV iron administration over a two year period. Enrollment is currently ongoing and we believe enrollment could be completed by the end of 2014. The costs related to the MRI portion of this study are subject to our established cost-sharing arrangement with Takeda.

 

In addition, certain clinical trials may be necessary to secure desired pricing in the EU Member States and other European markets. If so, the cost of any future trials may be allocated between us and Takeda according to the cost-sharing arrangement under the Amended Takeda Agreement.

 

Convertible Notes Offering

 

To help facilitate the activities described above, in February 2014, we issued $200.0 million of

 

32



Table of Contents

 

2.5% convertible senior notes due February 15, 2019, or the Convertible Notes. Interest is payable semi-annually in arrears on February 15 and August 15 of each year, beginning on August 15, 2014. The initial conversion rate is 36.9079 shares of our common stock per $1,000 principal amount of the Convertible Notes, which corresponds to an initial conversion price of approximately $27.09 per share of our common stock and represents a conversion premium of approximately 35% based on the last reported sale price of our common stock of $20.07 on February 11, 2014, the date the Convertible Notes offering was priced. In addition, in connection with the pricing of the Convertible Notes and in order to reduce the potential dilution to our common stock and/or offset cash payments due upon conversion of the Convertible Notes, we also entered into convertible bond hedge and warrant transactions in February 2014. The initial exercise price of the warrants is $34.12 per share, subject to adjustment upon certain events, which is 70% above the last reported sale price of our common stock of $20.07 on February 11, 2014. Please refer to Note P, “ Debt ,” to our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q for additional information regarding the Convertible Notes and the bond hedge and warrant transactions.

 

Results of Operations – Three Months Ended March 31, 2014 and 2013

 

Revenues

 

Total revenues for the three months ended March 31, 2014 and 2013 consisted of the following (in thousands):

 

 

 

Three Months Ended March 31,

 

 

 

 

 

 

 

2014

 

2013

 

$ Change

 

% Change

 

U.S. Feraheme product sales, net

 

$

17,375

 

$

15,578

 

$

1,797

 

12

%

License fee and other collaboration revenues

 

3,120

 

2,003

 

1,117

 

56

%

Other product sales and royalties

 

340

 

299

 

41

 

14

%

Total

 

$

20,835

 

$

17,880

 

$

2,955

 

17

%

 

Our total revenues during the three months ended March 31, 2014 increased by $3.0 million, or 17%, as compared to the same period in 2013, primarily as the result of a $1.8 million increase in U.S. net Feraheme product sales and a $1.1 million increase in license fee revenues primarily due to the recognition of a $1.0 million upfront payment received from our former partner 3SBio, Inc., or 3SBio, as the result of the termination of our license agreement in January 2014. We have no further obligations under the agreement with 3SBio.

 

U.S. Feraheme Product Sales, Net

 

U.S. Feraheme product sales and product sales allowances and accruals for the three months ended March 31, 2014 and 2013 consisted of the following (in thousands):

 

 

 

Three Months Ended March 31,

 

 

 

 

 

 

 

2014

 

Percent of
gross U.S.
Feraheme
product
sales

 

2013

 

Percent of
gross U.S.
Feraheme
product
sales

 

$ Change

 

% Change

 

Gross U.S. Feraheme product sales

 

$

31,321

 

 

 

$

25,651

 

 

 

$

5,670

 

22

%

Less provision for product sales allowances and accruals:

 

 

 

 

 

 

 

 

 

 

 

 

 

Discounts and chargebacks

 

10,533

 

34

%

7,493

 

29

%

 

 

 

 

Government and other rebates

 

3,187

 

10

%

2,387

 

9

%

 

 

 

 

Returns

 

226

 

1

%

193

 

1

%

 

 

 

 

Total

 

13,946

 

45

%

10,073

 

39

%

 

 

 

 

Net U.S. Feraheme product sales

 

$

17,375

 

 

 

$

15,578

 

 

 

$

1,797

 

12

%

 

33



Table of Contents

 

Our gross U.S. Feraheme product sales increased by $5.7 million, or 22%, during the three months ended March 31, 2014 as compared to the same period in 2013. Of the $5.7 million increase, $3.8 million was due to price increases and $1.9 million was due to increased units sold. This increase was partially offset by $3.9 million of additional allowances and accruals in the first quarter of 2014. As a result, total net U.S. Feraheme product sales increased by $1.8 million, or 12%, during the three months ended March 31, 2014 as compared to the same period in 2013. We anticipate increasing competitive pressures in 2014 may lead to a slower growth rate in product sales as compared to the growth rate in 2013.

 

Total discounts and chargebacks for the three months ended March 31, 2014 were $10.5 million, or 34% of total gross U.S. Feraheme product sales, as compared to $7.5 million, or 29%, in the same period in 2013. The increase in total discounts and chargebacks as a percentage of total gross U.S. Feraheme product sales was related primarily to a change in our customer mix.

 

Total government and other rebates were $3.2 million, or 10% of total gross U.S. Feraheme product sales, in the three months ended March 31, 2014 as compared to $2.4 million, or 9%, in the three months ended March 31, 2013. The increase in total government and other rebates as a percentage of gross U.S. Feraheme product sales was related primarily to increased sales to clinics and hospitals that had volume or market share contracts with us during the first quarter of 2014 as compared to the same period in 2013 and changes in the structure of our performance rebate programs.

 

For further details related to our revenue recognition and related sales allowances policy, please refer to our critical accounting policies included in Part II, Item 7 “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our Annual Report and Note B to our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.

 

An analysis of the amount of, and change in, reserves for the three months ended March 31, 2014 and 2013 is as follows (in thousands):

 

 

 

Discounts and
Chargebacks

 

Government
and Other
Rebates

 

Returns

 

Total

 

Balance at January 1, 2014

 

$

2,683

 

$

2,837

 

$

1,962

 

$

7,482

 

Current provisions relating to sales in current year

 

10,533

 

3,187

 

226

 

13,946

 

Payments/returns relating to sales in current year

 

(6,900

)

(386

)

 

(7,286

)

Payments/returns relating to sales in prior years

 

(2,792

)

(2,049

)

(70

)

(4,911

)

Balance at March 31, 2014

 

$

3,524

 

$

3,589

 

$

2,118

 

$

9,231

 

 

 

 

Discounts and
Chargebacks

 

Government
and Other
Rebates

 

Returns

 

Total

 

Balance at January 1, 2013

 

$

1,771

 

$

2,430

 

$

1,018

 

$

5,219

 

Current provisions relating to sales in current year

 

7,493

 

2,387

 

193

 

10,073

 

Payments/returns relating to sales in current year

 

(6,620

)

(282

)

 

(6,902

)

Payments/returns relating to sales in prior years

 

(306

)

(1,470

)

 

(1,776

)

Balance at March 31, 2013

 

$

2,338

 

$

3,065

 

$

1,211

 

$

6,614

 

 

During the first quarter of 2014 and 2013, we implemented gross price increases for Feraheme, some portion of which were discounted back to customers under volume or market share based contracts. When portions of price increases are discounted back to customers, it can have the effect of widening the gross to net

 

34



Table of Contents

 

adjustment percentage while still resulting in greater net revenue per gram. In 2014, we expect discounts, chargebacks and government and other rebates to continue to increase as a percentage of gross sales due to increasing competitive pressure caused by the recent approval of Injectafer ®  in the U.S., our contracting and discounting strategy and the mix of business for Feraheme . As a result, we expect the average net revenue per gram for the remaining quarters of 2014 to be relatively consistent with the average net revenue per gram for the first quarter of 2014.

 

In addition, our results of operations, including, in particular, product sales, fluctuate from quarter to quarter due to the demand patterns of wholesalers, distributors, clinics and hospitals, the reasons for which may vary. We also have limited or no visibility into our customers’ buying decisions, which may be affected from time to time by incentives we make available to clinics, hospitals and GPOs including volume rebates. During the first quarter of 2014, our increased Feraheme product sales resulted in part from a contracting strategy that provided incentives for clinics and hospitals to have Feraheme available. We expect clinics and hospitals to continue to take advantage of such incentives in the future, which may result in uneven purchasing patterns, causing Feraheme sales to fluctuate in subsequent quarters.

 

There are a number of factors that make it difficult to predict the magnitude of future Feraheme sales, including but not limited to, the following:

 

·                   The magnitude and timing of adoption and utilization of Feraheme by physicians, hospitals and other healthcare payors and providers;

 

·                   Any expansion or contraction of the overall size of the IV iron market, which could result from a number of factors including but not limited to, changes in treatment guidelines or practices related to IDA;

 

·                   The introduction of new competitive products in the iron replacement therapeutic market, such as the July 2013 U.S. approval of Injectafer ®  for a broad patient population or potential generic versions of new or currently available drug therapies;

 

·                   The impact of and any actions taken by us or our competitors to address pricing and reimbursement considerations related to Feraheme or products that compete with Feraheme;

 

·                   The impact of any actual or perceived safety or efficacy issues with Feraheme and any related product recalls or potential changes to our current label based on post-marketing safety data;

 

·                   The fees charged, and reserves required, related to fees for services provided to wholesalers, distributors, GPOs and others involved in the purchase or distribution of Feraheme ;

 

·                   The effect of federal and other legislation such as The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or the Health Care Reform Act, and the Budget Control Act of 2011, including the effect of the recent federal budget sequester on Medicare reimbursement rates which may cause a shift in where patients are treated to sites of care that have a lower mandated price for Feraheme , such as 340B institutions;

 

·                   The inventory levels maintained by and purchasing cycles of Feraheme wholesalers, distributors and clinics or hospitals;

 

·                   The frequency of re-orders by existing customers; and

 

·                   The impact of any difficulties, disruptions or delays in the manufacturing process for Feraheme/Rienso .

 

35



Table of Contents

 

As a result of these and other factors, future Feraheme sales could vary significantly from quarter to quarter and, accordingly, our Feraheme net product revenues in current or previous quarters may not be indicative of future Feraheme net product revenues. In addition, we cannot predict whether or when we will be able to satisfactorily address the issues raised in the complete response letter we received from the FDA in January 2014 related to our sNDA for Feraheme for the treatment of IDA in a broad range of patients.

 

Healthcare Reform Legislation

 

The Health Care Reform Act was enacted in the U.S. in March 2010 and includes certain cost containment measures including an increase to the minimum rebates for products covered by Medicaid programs and the extension of such rebates to drugs dispensed to Medicaid beneficiaries enrolled in Medicaid managed care organizations as well as the expansion of the 340B Drug Discount Program under the Public Health Service Act. This legislation contains provisions that can affect the operational results of companies in the pharmaceutical industry, including us, and other healthcare related industries by imposing on them additional costs.

 

The Health Care Reform Act also requires pharmaceutical manufacturers to pay a prorated share of the overall Branded Drug Fee, based on the dollar value of its branded prescription drug sales to certain federal programs identified in the legislation. The amount of our annual share of the Branded Drug Fee for 2014 and 2013 was less than $0.1 million and these payments were non-deductible for income tax purposes. We have included these amounts in selling, general and administrative expense in our condensed consolidated statements of operations. The amount of this annual payment could increase in future years due to both higher eligible Feraheme sales and the increasing amount of the overall fee assessed across manufacturers, but any such increases are not expected to be material to our results of operations or financial condition.

 

In addition, the number of 340B institutions, which provide drugs at reduced rates, was expanded by the Health Care Reform Act to include additional hospitals. As a result, the volume of Feraheme business sold to 340B eligible entities has increased since the implementation of the Health Care Reform Act. Because these institutions are eligible for federal pricing discounts, the revenue realized per unit of Feraheme sold to 340B institutions is lower than from our other customers.

 

Further, under the sequestration required by the Budget Control Act of 2011, as amended by the American Taxpayer Relief Act of 2012, Medicare payments for all items and services under Parts A and B incurred on or after April 1, 2013 have been reduced by up to 2%. Therefore, after adjustment for deductible and co-insurance, the reimbursement rate for physician-administered drugs, including Feraheme , under Medicare Part B has been reduced from average selling price, or ASP, plus 6% to ASP plus 4.3%. Because the majority of our business is through hematology/oncology clinics and out-patient hospital infusion centers, this reduction in the Medicare reimbursement payment for Feraheme may adversely impact our future revenues. Beginning in April 2013, we amended certain of our customer contracts to try to partially address the impact of sequestration on our customers and their patients. These amendments have led to increased discounts and rebates in the first quarter of 2014 as compared to the first quarter of 2013.

 

We were not materially impacted by recent healthcare reform legislation during the first quarter of 2014 or 2013. Presently, we have not identified any provisions that could materially impact our business but we continue to monitor future legislative developments.

 

36



Table of Contents

 

License Fee and Other Collaboration Revenues

 

License fee and other collaboration revenues for the three months ended March 31, 2014 and 2013 consisted of the following (in thousands):

 

 

 

Three Months Ended March 31,

 

 

 

 

 

 

 

2014

 

2013

 

$ Change

 

% Change

 

Deferred license fee revenues recognized from Takeda

 

$

1,974

 

$

1,974

 

$

 

0

%

Deferred revenues recognized from 3SBio termination

 

1,000

 

 

1,000

 

N/A

 

Reimbursement revenues from Takeda

 

146

 

29

 

117

 

>100

%

Total

 

$

3,120

 

$

2,003

 

$

1,117

 

56

%

 

Our license fee and other collaboration revenues in the three months ended March 31, 2014 increased by $1.1 million as compared to the same period in 2013 primarily as the result of the recognition of a $1.0 million upfront payment we received from 3SBio in 2008 in connection with our license agreement, which was mutually terminated in January 2014. In each of the three months ended March 31, 2014 and 2013, we also recorded $2.0 million, of revenues associated with the amortization of the upfront payments and the milestone payments we have received since the inception of our agreement with Takeda. As of March 31, 2014, we had approximately $47.4 million remaining in deferred revenues related to the $61.0 million in upfront payments and the $18.0 million in non-substantive milestone payments received from Takeda, of which $7.9 million was classified as short-term and $39.5 million was classified as long-term.

 

Under the terms of the Amended Takeda Agreement, Takeda is responsible for reimbursing us for certain out-of-pocket development costs we incur in the conduct of certain activities we manage under the agreement. Because we are acting as the principal in carrying out these activities, any reimbursement payments received from Takeda are recorded in license fee and other collaboration revenues and offset the costs that we incur during the period in which we perform those services. During the three months ended March 31, 2014 and 2013, we recorded $0.1 million and less than $0.1 million, respectively, of revenues associated with certain out-of pocket development costs in connection with the Amended Takeda Agreement.

 

We anticipate that, excluding the one-time recognition of the $1.0 million milestone payment from 3SBio, our license fee and other collaboration revenues will remain relatively constant in the remaining quarters of 2014 as compared to the first quarter of 2014. However, our license fees and other collaboration revenues will increase significantly if Takeda receives approval of its Type II Variation in the EU for Rienso in the indication for the treatment of IDA generally without limit to a specific patient population or sub-population to the extent that such approval triggers a significant milestone payment. There can be no assurances as to whether or when Takeda will receive such approval or the terms and scope of any approval it may receive in the EU for Rienso .

 

Other Product Sales and Royalties

 

Other product sales and royalties for the three months ended March 31, 2014 included product sales and royalties of Feraheme/Rienso from Takeda and net product sales of MuGard. Other product sales and royalties for the three months ended March 31, 2013 included product sales and royalties of Feraheme/Rienso from Takeda and product sales of GastroMARK to our licensees . For the three months ended March 31, 2014 as compared to the same period in 2013, other product sales and royalties increased by less than $0.1 million.

 

As of March 31, 2014, we had approximately $2.3 million in deferred revenue related to product shipped to Takeda, but not yet sold through to Takeda’s customers, of which $1.2 million was classified as short-term and $1.1 million was classified as long-term. In addition, we had $2.2 million in deferred

 

37



Table of Contents

 

cost of product sales, of which $1.1 million was classified as short-term and $1.1 million was classified as long-term. These deferred revenues and deferred cost of product sales are recorded in our condensed consolidated balance sheet as of March 31, 2014.

 

We expect other product sales and royalties to increase in the remaining quarters of 2014 as compared to first quarter of 2014 due to increased MuGard sales and increased sales and royalty revenue associated with the Amended Takeda Agreement, particularly if Takeda receives approval of its Type II Variation in the EU for Rienso for the treatment of IDA regardless of the underlying cause.

 

Costs and Expenses

 

Cost of Product Sales

 

Cost of product sales for the three months ended March 31, 2014 and 2013 consisted of the following (in thousands):

 

 

 

Three Months Ended March 31,

 

 

 

 

 

 

 

2014

 

2013

 

$ Change

 

% Change

 

Cost of Product Sales

 

$

2,837

 

$

2,942

 

$

(105

)

-4

%

Percentage of Net Product Sales and Royalties

 

16

%

19

%

 

 

 

 

 

Our cost of product sales are primarily comprised of costs of managing our contract manufacturers, and costs for quality assurance and quality control associated with our sales of Feraheme and MuGard in the U.S., sales of Feraheme/Rienso to Takeda. The $0.1 million decrease in our cost of product sales for the three months ended March 31, 2014 as compared to the same period in 2013 was attributable to the following factors:

 

·                   $0.6 million decrease due to a lower average cost per vial sold, partially offset by $0.2 million increase due to a higher volume of Feraheme vials sold in 2014; and

 

·                   $0.3 million increase due to a write-down of inventory that was deemed not commercially saleable in the three months ended March 31, 2014.

 

We expect our cost of product sales as a percentage of net product sales and royalties to remain relatively consistent for the remaining quarters of 2014 as compared to the first quarter 2014.

 

Research and Development Expenses

 

Research and development expenses for the three months ended March 31, 2014 and 2013 consisted of the following (in thousands):

 

38



Table of Contents

 

 

 

Three Months Ended March 31,

 

 

 

 

 

 

 

2014

 

2013

 

$ Change

 

% Change

 

External Research and Development Expenses

 

 

 

 

 

 

 

 

 

Feraheme to treat IDA in CKD patients

 

$

1,772

 

$

820

 

$

952

 

>100

%

Feraheme manufacturing process development and materials

 

1,632

 

273

 

1,359

 

>100

%

Other external costs

 

188

 

704

 

(516

)

-73

%

Total

 

$

3,592

 

$

1,797

 

$

1,795

 

100

%

 

 

 

 

 

 

 

 

 

 

Internal Research and Development Expenses

 

 

 

 

 

 

 

 

 

Compensation, payroll taxes, benefits and other expenses

 

2,457

 

2,675

 

(218

)

-8

%

Equity-based compensation expense

 

449

 

932

 

(483

)

-52

%

Total

 

$

2,906

 

$

3,607

 

$

(701

)

-19

%

 

 

 

 

 

 

 

 

 

 

Total Research and Development Expenses

 

$

6,498

 

$

5,404

 

$

1,094

 

20

%

 

Total research and development expenses incurred in the three months ended March 31, 2014 increased by $1.1 million, or 20%, as compared to the same period in 2013. The increase was primarily due to a $1.8 million increase in external research and development costs in the three months ended March 31, 2014, offset by reduced internal research and development costs of $0.7 million in the three months ended March 31, 2014 as compared to the same period in 2013.

 

The $1.8 million, or 100%, increase in our external research and development expenses was due primarily to a $1.4 million increase in manufacturing process development and materials-related costs, including $1.1 million of commercial inventory, which we determined would be solely used in manufacturing process and development activities at our third-party suppliers. In addition, the $1.8 million increase was due to a $1.0 million increase in costs incurred associated with our CKD-related trials, partially offset by a $0.5 million decrease in costs related to our Phase III clinical development program for Feraheme to treat IDA regardless of the underlying cause and reflected in other external costs in the table above.

 

The $0.7 million, or 19%, decrease in our internal research and development expenses was primarily attributable to the decrease in compensation and related benefit costs and equity-based compensation expense in the three months ended March 31, 2014 as compared to the same period in 2013, primarily related to the severance and other related costs following the departure of our chief medical officer in the first quarter of 2013.

 

We expect research and development expenses to decrease slightly in the remaining quarters of 2014 as compared to the first quarter of 2014 primarily due to a slight decrease in development costs related to manufacturing process improvement activities, partially offset by a slight increase in expenses associated with our ongoing clinical trials to determine the safety and efficacy of repeat doses of ferumoxytol for the treatment of IDA in patients with hemodialysis-dependent CKD. In addition, research and development expenses could increase depending on the outcome of discussions with the FDA on the regulatory path forward for Feraheme in the broad IDA indication and any resulting clinical trials or development efforts that we may undertake.

 

Research and Development Activities

 

We do not track our internal costs by project since our research and development personnel work on a number of projects concurrently and much of our fixed costs benefit multiple projects or our operations in general. We track our external costs on a major project basis, in most cases through the later of the completion of the last trial in the project or the last submission of a regulatory filing to the FDA or

 

39



Table of Contents

 

applicable foreign regulatory body. The following major research and development project was ongoing as of March 31, 2014:

 

·                   Feraheme to treat IDA in CKD patients . This project currently includes: (a) a completed clinical study evaluating Feraheme treatment as compared to treatment to another IV iron to support the 2010 MAA submission; (b) a pediatric study that is being conducted as part of our post-approval Pediatric Research Equity Act requirement to support pediatric CKD labeling of Feraheme ; (c) two additional pediatric studies to be completed in accordance with our approved pediatric investigation plan to support the MAA submission; and (d) an ongoing multi-center clinical trial to be conducted to determine the safety and efficacy of repeat doses of Feraheme for the treatment of IDA in patients with hemodialysis dependent CKD, including a treatment arm with iron sucrose using an MRI sub-analysis to evaluate the potential for iron to accumulate in the body following repeated IV iron administration.

 

Through March 31, 2014, we have incurred aggregate external research and development expenses of approximately $30.0 million related to our current program for the development of Feraheme to treat IDA in CKD patients. We currently estimate that the total remaining external costs associated with this development project will be in the range of approximately $20.0 to $30.0 million over the next several years.

 

In accordance with our policy of tracking external research and development costs through the later of the completion of the last trial in a project or the last submission of a regulatory filing to the FDA, we discontinued tracking our expenses related to Feraheme to treat IDA regardless of the underlying cause in the third quarter of 2013, at which point we had incurred $57.8 million of external research and development expenses. In January 2014, we received a complete response letter from the FDA in response to our sNDA submission for Feraheme for the treatment of IDA in adult patients who had failed or could not use oral iron. We are currently unable to estimate with any certainty the future costs we will incur, if any, related to our project for Feraheme to treat IDA regardless of the cause. In future periods, we may resume the disclosure of such expected future costs as the facts and circumstances warrant.

 

Selling, General and Administrative Expenses

 

Selling, general and administrative expenses for the three months ended March 31, 2014 and 2013 consisted of the following (in thousands):

 

 

 

Three Months Ended March 31,

 

 

 

 

 

 

 

2014

 

2013

 

$ Change

 

% Change

 

Compensation, payroll taxes and benefits

 

$

6,742

 

$

6,026

 

$

716

 

12

%

Sales and marketing consulting, professional fees, and other expenses

 

3,729

 

2,947

 

782

 

27

%

General and administrative consulting, professional fees and other expenses expenses

 

5,567

 

3,704

 

1,863

 

50

%

Equity-based compensation expense

 

1,453

 

1,328

 

125

 

9

%

Total

 

$

17,491

 

$

14,005

 

$

3,486

 

25

%

 

Total selling, general and administrative expenses incurred in the three months ended March 31, 2014 increased by $3.5 million, or 25%, as compared to the same period in 2013 for the following reasons:

 

·                   $0.7 million increase in compensation, payroll taxes and benefits;

 

40



Table of Contents

 

·                   $0.8 million increase in sales and marketing consulting, professional fees, and other expenses primarily due to increased consulting costs related to the integration and commercialization of MuGard , which we did not have in the first quarter of 2013;

 

·                   $1.9 million increase in general and administrative consulting, professional fees and other expenses primarily due to $1.6 million of increased costs associated with business development, consulting and other legal-related activities in support of portfolio expansion and a $0.8 million adjustment to the fair value of our contingent consideration liability related to the MuGard Rights. These increased costs in the first quarter of 2014 were partially offset by the following decreased costs related to general and administrative consulting, professional fees and other expenses: $0.4 million of accelerated depreciation expense related to certain leasehold improvements and furniture and fixtures associated with our prior office facility during the first quarter of 2013 and $0.2 million of costs related to the closure of our Cambridge, Massachusetts manufacturing facility; and

 

·                   $0.1 million increase in equity-based compensation expense due primarily to the expense associated with equity awards to new and existing employees.

 

We expect total selling, general and administrative expenses will decrease during the remaining quarters of 2014 as compared to the first quarter of 2014 as the result of a decline in certain non-recurring business development-related legal and professional expenses incurred during the first quarter of 2014.

 

Other Income (Expense)

 

Other income (expense) for the three months ended March 31, 2014 and 2013 consisted of the following (in thousands):

 

 

 

Three Months Ended March 31,

 

 

 

 

 

 

 

2014

 

2013

 

$ Change

 

% Change

 

Interest Expense

 

$

(1,476

)

$

 

(1,476

)

N/A

 

Interest and dividend income, net

 

265

 

271

 

(6

)

-2

%

Gains on sale of asset

 

100

 

299

 

(199

)

-67

%

Gains on investments, net

 

 

6

 

(6

)

-100

%

Total

 

$

(1,111

)

$

576

 

$

(1,687

)

<(100

)%

 

Other income (expense) for the three months ended March 31, 2014 decreased by $1.7 million as compared to the same period in 2013 primarily as the result of the recognition of $1.5 million of interest expense, which was comprised of the amortization of debt discount, 2.5% contractual interest expense and amortization of debt issuance costs in connection with the issuance of the Convertible Notes.

 

Net Loss

 

For the reasons stated above, we incurred a net loss of $7.1 million and $3.9 million, or $0.33 and $0.18 per basic and diluted share, for the three months ended March 31, 2014 and 2013, respectively.

 

Liquidity and Capital Resources

 

General

 

We finance our operations primarily from the sale of Feraheme/Rienso and MuGard , including payments from our licensees, cash generated from our investing activities and the sale of our common

 

41



Table of Contents

 

stock. We expect to continue to incur significant expenses as we and our partners continue to manufacture, market and sell Feraheme/Rienso as an IV iron replacement therapy for use in adult CKD patients in the U.S., Canada, Switzerland and the EU, as we market and sell MuGard in the U.S. and as we further develop and seek regulatory approval for Feraheme/Rienso for the treatment of IDA in a broad range of patients in and outside of the U.S.

 

As of March 31, 2014, our investments consisted of corporate debt securities, U.S. treasury and government agency securities and commercial paper. We place our cash in instruments that meet high credit quality and diversification standards, as specified in our investment policy. Our investment policy also limits the amount of our credit exposure to any one issue or issuer, excluding U.S. government entities, and seeks to manage these assets to achieve our goals of preserving principal, maintaining adequate liquidity at all times, and maximizing returns.

 

Cash, cash equivalents, investments and certain financial obligations as of March 31, 2014 and 2013 consisted of the following (in thousands):

 

 

 

March 31, 2014

 

December 31, 2013

 

$ Change

 

% Change

 

Cash and cash equivalents

 

$

200,916

 

$

26,986

 

$

173,930

 

>100

%

Investments

 

184,557

 

186,803

 

(2,246

)

-1

%

Total

 

$

385,473

 

$

213,789

 

$

171,684

 

80

%

 

 

 

 

 

 

 

 

 

 

Outstanding principal on convertible notes

 

$

200,000

 

$

 

$

200,000

 

N/A

 

Total

 

$

200,000

 

$

 

$

200,000

 

N/A

 

 

The $171.7 million increase in cash, cash equivalents and investments as of March 31, 2014, as compared to December 31, 2013, was primarily due to net proceeds of $179.1 million received in the first quarter of 2014 in connection with issuance of $200.0 million aggregate principal amount of the Convertible Notes, net of (a) $6.7 million in fees and expenses associated with the issuance of the Convertible Notes and (b) $14.1 million to pay the cost of convertible bond hedges (after such cost was partially offset by the proceeds to us from the sale of warrants). We issued the Convertible Notes to help facilitate our corporate, clinical and commercial activities and which, along with the convertible bond hedge transactions, are discussed in greater detail in Note P, “ Debt ,” to our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q. In addition, the increase in cash was partially offset by net cash expended to fund our operations and working capital.

 

We expect that our cash, cash equivalents and investments balances, in the aggregate, may increase slightly due to positive cash flows from operations for the remaining quarterly periods of 2014. Our expectation assumes our continued investment in the development and commercialization of Feraheme and the continued pursuit of business development transactions. We believe that our cash, cash equivalents and investments as of March 31, 2014, and the cash we currently expect to receive from sales of Feraheme and MuGard , earnings on our investments, and potential product sales and milestone and royalty payments from Takeda will be sufficient to satisfy our cash flow needs for at least the next twelve months.

 

42



Table of Contents

 

Cash flows from operating activities

 

During the three months ended March 31, 2014, our use of $11.1 million of cash in operations was attributable principally to our net loss of approximately $7.1 million, adjusted for the following:

 

·                   Non-cash operating items of $5.7 million including equity-based compensation expense, a write-down of inventory, amortization of debt discount and debt issuance costs, amortization of premium/discount on purchased securities, change in fair value of contingent consideration, depreciation and amortization, and other non-cash items;

 

·                   $2.8 million of cash used in operating activities due to decreases in deferred revenues and other long-term liabilities;

 

·                   $1.1 million of cash used in operating activities due to decreases in accounts payable and accrued expenses;

 

·                   $6.7 million of cash used in operating activities due to increases in accounts receivable, prepaid assets and inventories; and

 

·                   $0.9 million of cash provided by operating activities due to decreases in other long-term assets.

 

Our net loss of $7.1 million was primarily the result of our costs to operate our business, including compensation to employees, commercialization expenses, including marketing and promotion costs, costs to manufacture our products, research and development costs, including costs associated with our clinical trials, and general and administrative costs, partially offset by net product sales and collaboration revenues.

 

Cash flows from investing activities

 

Cash provided by investing activities during the three months ended March 31, 2014 totaled $4.5 million and was primarily attributable to $2.9 million that was returned to us by an escrow agent related to a 2013 business development transaction that we did not complete, as well as proceeds from the sales and maturities of our investments, partially offset by the purchases of investments.

 

Cash flows from financing activities

 

Cash provided by financing activities during the three months ended March 31, 2014, was $180.5 million and was primarily attributable to the $179.1 million in net proceeds received from the issuance of the Convertible Notes in February 2014 and $1.0 million in proceeds received from the exercise of stock options.

 

Off-Balance Sheet Arrangements

 

As of March 31, 2014, we did not have any off-balance sheet arrangements as defined in Regulation S-K, Item 303(a)(4)(ii).

 

Contractual Obligations

 

During the quarter ended March 31, 2014, we issued $200.0 million of 2.5% Convertible Notes due February 15, 2019. The Convertible Notes are governed by the terms of an indenture between us, as issuer, and Wilmington Trust, National Association, as the trustee. The Convertible Notes are senior unsecured obligations and bear interest at a rate of 2.5% per year, payable semi-annually in arrears on February 15 and August 15 of each year, beginning on August 15, 2014. The Convertible Notes will mature on February 15, 2019, unless earlier repurchased or converted. The Convertible Notes will be convertible into cash, shares of our common stock, or a combination thereof, at our election, at an initial conversion rate of approximately 36.9079 shares of common stock per $1,000 principal amount of the Convertible Notes, which corresponds to an initial conversion price of approximately $27.09 per share of our common stock and represents a conversion premium of approximately 35% based on the last reported sale price of our common stock of $20.07 on February 11, 2014, the date the notes offering was priced.  In addition, in connection with the pricing of the Convertible Notes, we entered into convertible bond hedge transactions and separate warrant transactions.

 

43



Table of Contents

 

Impact of Recently Issued and Proposed Accounting Pronouncements

 

None.

 

Item 3.  Quantitative and Qualitative Disclosures About Market Risk.

 

In February 2014, we issued $200.0 million of 2.5% Convertible Notes due February 15, 2019. The Convertible Notes have a fixed annual interest rate of 2.5% and we, therefore, do not have economic interest rate exposure on the Convertible Notes. However, the fair value of the Convertible Notes is exposed to interest rate risk. We do not carry the Convertible Notes at fair value but present the fair value of the principal amount for disclosure purposes. Generally, the fair value of the Convertible Notes will increase as interest rates fall and decrease as interest rates rise. These Convertible Notes are also affected by the price and volatility of our common stock and will generally increase or decrease as the market price of our common stock changes. As of March 31, 2014, the fair value of the Convertible Notes was estimated by us to be $161.8 million. We determined the estimated fair value of the Convertible Notes by using quoted market prices. Other than the above market risk, there have been no material changes with respect to the information appearing in Part II, Item 7A, “Quantitative and Qualitative Disclosures About Market Risk,” of our Annual Report.

 

Item 4.  Controls and Procedures.

 

Managements’ Evaluation of our Disclosure Controls and Procedures

 

Our principal executive officer and principal financial officer, after evaluating the effectiveness of our “disclosure controls and procedures” (as defined in the Exchange Act Rule 13a-15(e), or Rule 15d-15(e)), with the participation of our management, have each concluded that, as of the end of the period covered by this Quarterly Report on Form 10-Q, our disclosure controls and procedures were effective and were designed to ensure that information we are required to disclose in the reports that we file or submit under the Securities Exchange Act of 1934, as amended, is accumulated and communicated to management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure, and is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission rules and forms. It should be noted that any system of controls is designed to provide reasonable, but not absolute, assurances that the system will achieve its stated goals under all reasonably foreseeable circumstances. Our principal executive officer and principal financial officer have each concluded that our disclosure controls and procedures as of the end of the period covered by this report are effective at a level that provides such reasonable assurances.

 

Changes in Internal Control Over Financial Reporting

 

There were no changes in our internal control over financial reporting (as such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) that occurred during the three months ended March 31, 2014 that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.

 

PART II. OTHER INFORMATION

 

Item 1. Legal Proceedings

 

See Note N, “ Commitments and Contingencies ,” to our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q for information regarding our legal proceedings, including how we accrue liabilities for legal contingencies.

 

44



Table of Contents

 

Item 1A. Risk Factors:

 

We are primarily dependent on the success of Feraheme/Rienso.

 

We currently derive and expect to continue to derive substantially all of our revenue from sales of Feraheme/Rienso by us in the U.S. and by our licensees, including Takeda Pharmaceutical Company Limited, or Takeda, outside of the U.S. and, therefore, our ability to become profitable is primarily dependent on our and our licensees’ successful commercialization and development of Feraheme/Rienso. Accordingly, if we are unable to generate sufficient revenues from sales of Feraheme/Rienso, or from milestone payments and royalties we may receive related to Feraheme/Rienso , we may never be profitable, our financial condition will be materially adversely affected, and our business prospects will be limited.

 

We intend to continue to dedicate significant resources to the commercialization of Feraheme/Rienso . However, we or Takeda may not be successful in our efforts to successfully commercialize Feraheme/Rienso in its current indication for adult patients with iron deficiency anemia, or IDA, associated with chronic kidney disease, or CKD, or to expand the approved indication of Feraheme/Rienso to include additional indications. In December 2012, we filed a supplemental New Drug Application, or sNDA, in the U.S. for Feraheme in patients with IDA who had failed or could not use oral iron. In January 2014, we received a complete response letter from the U.S. Food and Drug Administration, or the FDA, for the sNDA informing us that our sNDA could not be approved in its present form and stating that we have not provided sufficient information to permit labeling of Feraheme for safe and effective use for the proposed broader indication. The FDA indicated that its decision was based on the cumulative ferumoxytol data, including the global Phase III IDA program and global post-marketing safety reports since the launch in 2009. The FDA suggested, among other things, that we submit additional clinical trial data in the proposed broad IDA patient population with a primary composite safety endpoint of serious hypersensitivity/anaphylaxis, cardiovascular events and death, events that are included in the labels of Feraheme and other IV irons and that have been reported in the post-marketing environment for Feraheme . Additionally, the FDA proposed potentially evaluating alternative dosing and/or administration of Feraheme as well as potential additions to labeling that would be intended to reduce the risk of serious hypersensitivity reactions associated with Feraheme. We are in the process of developing a proposal that we believe would be responsive to the points raised in the complete response letter, including proposed additions to labeling on our current CKD indication, and that we determine would be economically viable. Once we have finalized our proposal we plan to (a) meet with FDA to discuss our proposal and explore the range of possible approaches to the points raised in the complete response letter; and (b) assess the FDA’s feedback on our proposal and make a final determination on a possible program that would adequately address the FDA’s concerns. Depending upon the outcome of such evaluations and discussions, we may decide not to pursue regulatory approval for the broader indication. Until we have further discussions with the FDA and receive its input, we cannot predict the path forward, if any, for Feraheme in the broad IDA patient population, including the related timing and cost of any clinical trials. Generating additional clinical trial data is typically costly and time-consuming. Responding to the issues raised by the FDA in the complete response letter and any other issues or requests for information that may be raised by the FDA will likely cause us to incur significant additional costs, experience further delays and may even prevent us from obtaining U.S. regulatory approval for Feraheme in the broader IDA population or narrow our currently approved indications, as discussed in more detail in the following risk factor. Any of these results would, in turn, materially adversely impact our cash position, our ability to increase revenues, our ability to achieve profitability, and the future prospects of our business.

 

In June 2013, Takeda filed an application for Type II Variation of the marketing authorization for Rienso in the EU, which is the European Union, or EU, equivalent of a U.S. sNDA, with the European Medicines Agency, or EMA, seeking marketing authorization for an additional therapeutic indication for Rienso for the treatment of IDA in adult patients. In addition, in October 2013, Takeda filed a supplemental New Drug Submission, or sNDS, with Health Canada seeking marketing approval for Feraheme for the treatment of IDA in a broad range of patients. However, we have little control over Takeda’s interactions with the EU or Canadian regulatory agencies and we cannot be assured when or if the EMA will issue a positive opinion for the application for variation of the marketing authorization for Rienso in the EU.

 

45



Table of Contents

 

Neither can we be assured when or if the European Commission will adopt a decision approving this variation or Health Canada will approve the filings. Any failure by Takeda to gain marketing approval for Feraheme/Rienso for the treatment of IDA regardless of the underlying cause in a timely manner, or at all, could adversely affect our revenues and cash milestones from Takeda, which in turn would adversely affect results of operations or the future prospects of our business.

 

We are not currently conducting or sponsoring research to expand our product development pipeline beyond Feraheme/Rienso. However, we expect to continue with our efforts to complete additional business development transactions, such as in-licensing, acquisitions or collaborations that would be complementary to our business. For example, in June 2013, we entered into a license agreement with Access Pharmaceuticals, Inc., or Access, pursuant to which we acquired the U.S. commercial rights to market and sell MuGard ® Mucoadhesive Oral Wound Rinse for the management of oral mucositis, or the MuGard Rights. Even if we continue to expand our product portfolio, our revenues and operations may not be as diversified as some of our competitors who may have numerous products or product candidates.

 

Our ability to grow revenues from U.S. sales of Feraheme is limited to the IDA-CKD market given that we have not received regulatory approval to market and sell Feraheme to the broader IDA patient population and may be further limited if we are required to provide additional warnings and/or restrictions related to Feraheme’s current or future indications.

 

As discussed above, in December 2012, we submitted an sNDA to the FDA for Feraheme for the treatment of IDA in a broad range of patients and we received a complete response letter from the FDA in January 2014 informing us that our sNDA could not be approved in its present form. In the letter, the FDA stated that we have not provided sufficient information to permit labeling of Feraheme for safe and effective use for the proposed indication. This decision by the FDA represents a significant set-back in our efforts to obtain U.S. approval for Feraheme for a broader indication as the issues raised and information requested by the FDA may be costly and time-consuming to address. Further, there is no guarantee that any efforts that we decide to undertake will meet the FDA’s requirements, and we may not receive approval at all for Feraheme in a broader indication.

 

Evaluation of the content and recommendations of the FDA’s complete response letter and further discussions with the FDA may cause us to decide not to pursue regulatory approval for the broader indication. If we continue to pursue approval in the U.S. for the commercial marketing and sale of Feraheme for the broad IDA indication, we will have to demonstrate, through the submission of clinical study reports and data sets from one or more prospective, multicenter, randomized controlled trials, or the proposed clinical trials, that the benefit of Feraheme use in the proposed population would warrant the risks associated with Feraheme , including the potential for adverse events, including anaphylaxis, cardiovascular events, and death. The FDA advised that such trials should address mechanisms to reduce the risk for serious, including fatal, hypersensitivity reactions. Conducting these and other clinical trials is a complex, time-consuming and expensive process that requires adherence to a wide range of regulatory requirements. Depending on the incidence rate of the safety end-point being studied, these studies could require a significant number of patients such that the study cannot be enrolled in a reasonable time or at a reasonable cost to support commercialization. The FDA has substantial discretion in the approval process and may decide that the results of any such additional trials and the information we submit seeking approval in the broader patient population or other information reviewed, such as post-marketing safety data, including reports of serious anaphylaxis, cardiovascular events, and death, or any information we provide in response to FDA requests, are insufficient for approval or that Feraheme is not effective or safe for the proposed broader indication. For example, in our Phase III clinical trial in the broader patient population, Feraheme -treated patients experienced a 0.6% rate of related serious adverse events, or SAEs, as compared to a 0.2% rate of related SAEs from our current Feraheme label for the treatment of IDA in adult patients with CKD. The FDA indicated that its decision outlined in the complete response letter was based on the cumulative ferumoxytol data, including the global Phase III IDA program and global post-marketing safety reports.

 

46



Table of Contents

 

In addition, clinical and other data is often susceptible to varying interpretations, and many companies that have believed their product candidates performed satisfactorily in clinical trials have nonetheless failed to obtain FDA approval for their products. The clinical trials for the broader patient population included patients with various underlying conditions, or subpopulations, in addition to having IDA, and any additional clinical trials will likely have a similar mix of patients. There is no guarantee that the FDA will determine that the results of our clinical trials of Feraheme for the treatment of IDA in adult patients who have failed or could not tolerate oral iron (including any proposed clinical trials) will adequately support approval of Feraheme in this broader patient population, or any of the individual subpopulations of IDA patients, to grant approval.

 

The FDA could also determine that our clinical trials (including any proposed clinical trials) and/or our manufacturing processes were not properly designed, did not include enough patients or appropriate administration, were not conducted in accordance with applicable laws and regulations, or were otherwise not properly managed. In addition, under the FDA’s current good clinical practices regulations, or cGCP, we are responsible for conducting, recording and reporting the results of clinical trials to ensure that the data and results are credible and accurate and that the trial participants are adequately protected. The FDA may conduct inspections of clinical investigator sites which are involved in our clinical development programs to ensure their compliance with cGCP regulations. If the FDA determines that we, our clinical research organizations, or CROs, or our study sites fail to comply with applicable cGCP regulations, the clinical data generated in our clinical trials (including the proposed clinical trials) may be deemed unreliable and the FDA may disqualify certain data generated from those sites or require us to perform additional clinical trials before approving our marketing application, which could further adversely impact our ability to obtain marketing approval in the U.S. for Feraheme in the broad IDA indication. Any such deficiency in the design, implementation or oversight of our clinical development programs could cause us to incur significant additional costs, experience further delays or prevent us from obtaining marketing approval for Feraheme for the broad IDA indication.

 

As a result of any information submitted to the FDA in our regulatory filings or in response to any information requests or issues raised by the FDA during the review of our regulatory filings, including the FDA’s review of post-marketing safety data in connection with our sNDA and any reevaluation by the FDA of existing data, such as reports of serious anaphylaxis, cardiovascular events, and death, the FDA may request additional information. The additional information may include technical or scientific information, new studies or reanalysis of existing data or risk evaluation and mitigation strategies in the current indication, or we may be required to provide additional warnings and/or restrictions on our current or future Feraheme package inserts, notify healthcare providers of changes to the package insert, narrow our currently approved or proposed indications, alter or terminate current or future trials for Feraheme or incur significant costs related to post-marketing requirements/commitments, which could put us at a disadvantage to our competitors. Our efforts to obtain approval for the broad IDA indication could adversely affect the commercialization of Feraheme in its current indication.

 

If, for any of these or other reasons, we do not obtain U.S. approval to market and sell Feraheme for the treatment of IDA in a broad range of patients, if our current indication is narrowed, if we are required to include additional warnings and/or restrictions on the Feraheme/Rienso package insert, including a boxed warning in the U.S. or similar warnings outside of the U.S., or if we experience additional significant delays or setbacks in obtaining approval, or if we receive approval with significant restrictions to our current or proposed package inserts, or are required to incur significant costs as post-marketing commitments, our cash position, our ability to increase revenues, our ability to achieve profitability, and the future prospects of our business could be materially adversely affected.

 

Significant safety or drug interaction problems, or the evaluation or reevaluation of existing or future data by the FDA or other regulators, could result in restrictions in the Feraheme/Rienso label, recalls, withdrawal of Feraheme/Rienso from the market, an adverse impact on Feraheme/Rienso sales, our need

 

47



Table of Contents

 

to alter or terminate current or future Feraheme development programs, and/or a negative impact on the approval and/or timing of our current or future sNDAs, any of which would adversely impact our future business prospects.

 

Significant safety or drug interaction problems with respect to Feraheme/Rienso , including an increase in the severity or frequency of known problems or the discovery of previously unknown problems, or the evaluation or reevaluation of existing or future data by the FDA or other regulators, could result in a variety of adverse regulatory actions. In the U.S., under the Federal Food, Drug and Cosmetic Act , the FDA has broad authority to force drug manufacturers to take any number of actions if safety or drug interaction problems arise, including, but not limited to the following:

 

·                   Requiring manufacturers to conduct post-approval clinical studies to assess known risks or signals of serious risks, or to identify unexpected serious risks;

 

·                   Mandating labeling changes to a product based on new safety information; or

 

·                   Requiring manufacturers to implement a Risk Evaluation Mitigation Strategy where necessary to assure safe use of the drug.

 

Similar laws and regulations exist in countries outside of the U.S. In addition, unknown safety or drug interaction problems could result in product recalls, restrictions on the product’s permissible uses, a negative impact on our current or future sNDAs or withdrawal of the product from the U.S. and/or foreign markets.

 

For example, in November 2010, following discussions with the FDA, we revised the Feraheme package insert, which includes essential information regarding the FDA-approved use of Feraheme , including, among other things, the approved indication, side effects, and dosage instructions, to include bolded warnings and precautions that describe events that have been reported during post-marketing review after Feraheme administration, including life-threatening hypersensitivity reactions and clinically significant hypotension. We notified healthcare providers of the changes to the Feraheme package insert. In June 2011, we made further changes to the Feraheme package insert based on additional post-marketing data. These or any future changes to the Feraheme/Rienso package insert could adversely impact our or Takeda’s ability to successfully compete in the IV iron market and could have an adverse impact on potential sales of Feraheme/Rienso and our future business prospects.

 

Also, on June 27, 2013 the EMA’s Committee for Medicinal Products for Human Use, or CHMP, completed a review of IV iron-containing medications used to treat iron deficiency and anemia. The CHMP concluded that the benefits of these medications are greater than their risks, provided that adequate measures are taken to ensure the early detection and effective management of allergic reactions that may occur. The measures include ensuring that these products be given in an environment where patients who develop an allergic reaction can be treated immediately, ceasing to rely on a lack of allergic reaction to a test dose as an indication of tolerance of larger doses and amendments to the package leaflet. The CHMP recommendation was sent to the European Commission, which on September 13, 2013 endorsed it and adopted a final decision that is legally binding throughout the EU. Although Rienso was not included in the evaluation, Takeda is in the process of adopting the recommendations, including updates to the label in the EU to harmonize Rienso’s label with those of other IV irons included in the review. In addition, both the FDA and the EMA are currently conducting studies and/or assessments to evaluate the safety profiles of IV irons as a class.

 

The data submitted to both the FDA as part of our NDA and sNDA and to the EMA as part of the Marketing Authorization Application for Feraheme/Rienso in the CKD indication was obtained in controlled clinical trials of limited duration. New safety or drug interaction issues may arise as Feraheme/Rienso is used over longer periods of time by a wider group of patients, some of whom may be

 

48



Table of Contents

 

taking other medicines or by patients with additional underlying health problems. As previously discussed, the FDA recently issued a complete response letter for our sNDA that sought expansion of the indication for Feraheme ; the complete response letter concluded that the sNDA could not be approved as submitted because we have not provided sufficient information to permit labeling of Feraheme for safe and effective use for the proposed indication. The FDA indicated that its decision was based on the cumulative ferumoxytol data, including the global Phase III IDA program and global post-marketing safety reports. In addition, as we conduct and complete other clinical trials for Feraheme , new safety issues may be identified which could negatively impact our ability to successfully complete these studies, the use and/or regulatory status of Feraheme/Rienso for the treatment of IDA in patients with CKD in the U.S., EU or other territories, and the prospects for approval if we continue to pursue a broader indication for Feraheme for the treatment of IDA regardless of the underlying cause. For example, even if we conduct additional clinical studies, the FDA may determine that any application for Feraheme for the treatment of IDA in adult patients who have failed or could not tolerate oral iron does not establish a sufficiently acceptable safety profile for the approval of a broader Feraheme label in the U.S.

 

As more data become available and an increased number of patients are treated with Feraheme/Rienso , new or increased safety or drug interaction issues may require us to, among other things, provide additional warnings and/or restrictions on the Feraheme/Rienso package insert, including a boxed warning in the U.S. or similar warnings outside of the U.S., notify healthcare providers of new safety information, narrow our approved indications, alter or terminate current or future trials for additional uses of Feraheme , or even remove Feraheme/Rienso from the market, any of which could have a significant adverse impact on potential sales of Feraheme/Rienso or require us to expend significant additional funds. For example, in May 2013, Takeda recalled a single batch of Rienso from the Swiss market after becoming aware of four post-marketing adverse event reports relating to potential anaphylaxis/hypersensitivity reactions of varying severity following the administration of Rienso . One of these cases included a report of a fatality. The marketing authorization for Rienso and other IV iron formulations include, among their special warnings and precautions for use, an indication that the products may cause hypersensitivity reactions including serious and life-threatening anaphylactic/anaphylactoid reactions. The recalled batch was only distributed to and sold in Switzerland and the recall was limited to the specific batch in Switzerland. We and Takeda have completed an investigation regarding the specific Swiss batch of Rienso, which we believe did not identify any issues which would have impacted the quality of the recalled batch, and we gathered all available information for the reported adverse events. Takeda has filed a report with SwissMedic, the Swiss Agency for Therapeutic Products, and we and Takeda are awaiting feedback on SwissMedic’s review of the findings from the investigation. We and Takeda are unable to predict when or if Rienso will be reintroduced into the Swiss market.

 

Competition in the pharmaceutical and biopharmaceutical industries is intense. If we fail to compete effectively, our business and market position will suffer.

 

The pharmaceutical and biopharmaceutical industries are intensely competitive and subject to rapid technological change. Many of our competitors are large, well-known pharmaceutical companies and may benefit from significantly greater financial, sales and marketing capabilities, greater technological or competitive advantages, and other resources. Our competitors may develop products that are more widely accepted than ours and may receive patent protection that dominates, blocks or adversely affects our product development or business.

 

The markets for our current products are highly sensitive to several factors including, but not limited to the following:

 

·                   The actual and perceived safety and efficacy profile of the available products;

 

·                   The approved indication for each of the available products;

 

49



Table of Contents

 

·                   The ability to obtain appropriate insurance coverage and reimbursement rates and terms;

 

·                   Price competitiveness; and

 

·                   Product characteristics such as convenience of administration and dosing regimens.

 

The introduction by our competitors of alternatives to Feraheme/Rienso or MuGard that would be, or are perceived to be, more efficacious, safer, less expensive, easier to administer, available for a broader patient population, or provide more favorable insurance coverage or reimbursement could reduce our revenues and the value of our product development efforts.

 

Feraheme/Rienso may not receive the same level of market acceptance as competing iron replacement therapy products, in part because most of these products have been on the market longer and are currently widely used by physicians in the U.S. and abroad. In addition, the recent CHMP review of IV iron-containing medications used to treat iron deficiency and anemia (which concluded that the benefits of these medications are greater than their risks, provided that adequate measures are taken to ensure the early detection and effective management of allergic reactions that may occur, including ensuring that these products be given in an environment where patients who develop an allergic reaction can be treated immediately and ceasing to rely on a lack of allergic reaction to a test dose as an indication of tolerance of larger doses) could cause physicians to elect non-IV iron alternatives which may be easier to administer or dose or which may be perceived as less risky.

 

In addition, Feraheme currently competes with several IV iron replacement therapies in the U.S., certain of which are approved for the treatment of IDA in a broader group of patients than Feraheme. For example , in July 2013, Injectafer ® , which is known as Ferinject ® in Europe and is discussed below, was approved by the FDA for the treatment of IDA in adult patients who have an unsatisfactory response to oral iron or who have intolerance to oral iron, which is a broader indication than our current Feraheme indication. Injectafer ®  is approved in the U.S. with a recommended dose of two slow injections or infusions of 750 milligrams each separated by at least seven days apart for a total of 1,500 milligrams. While this dosing regimen is different from Feraheme , it does offer similar convenience benefits to Feraheme for patients and healthcare providers. Injectafer ®  is also priced at a significant premium to many other IV irons, providing more opportunity to offer discounts, incentives and rebates to new or existing customers to attract new business. The recent decision by the FDA that we have not provided sufficient information to permit labeling of Feraheme for safe and effective use for the proposed indication will likely make it more difficult for us to compete with Injectafer ®  for certain customers in the U.S. because Injectafer ®  has been approved for a broader patient population than Feraheme . Even if we continue to seek and eventually obtain labeling of Feraheme in a broader population, Injectafer ®  will have already been available for a considerable period of time. During this period, physicians may increase their use of Injectafer ®  and gain familiarity with the product, making it more difficult for us to cause these physicians to use Feraheme in the future. In addition, Injectafer ®  may enter into commercial contracts with key customers or group purchasing organizations, or GPOs, during this period, which could prevent or make it more difficult for Feraheme to retain its existing customers, gain sales to new customers and gain market share in its existing indication with customers or GPOs, if we were to continue to seek and receive approval for the broader patient population in the future. Injectafer ® ’s U.S. approval or the approval of any other iron replacement product for a broader IDA indication than Feraheme , could adversely affect our efforts to market and sell Feraheme in the U.S. and our ability to generate additional revenues and achieve profitability.

 

Feraheme/Rienso also competes with a number of branded IV iron replacement and certain other iron dextran and iron sucrose products outside of the U.S., such as Ferinject ® (ferric carboxymaltose injection), which is an IV iron replacement therapy currently approved for marketing in approximately 47 countries worldwide for the treatment of IDA where oral iron is ineffective or cannot be used. If Takeda is unable to

 

50



Table of Contents

 

convince physicians and other healthcare providers to switch from using the competing IV iron products to Feraheme/Rienso, our ability to generate revenues from royalties we may receive from Takeda will be limited and our operating results will be negatively affected. In addition, all other IV iron products currently approved and marketed and sold in the EU are approved for marketing to a broader group of patients with IDA. Feraheme/Rienso was approved only for use in adult CKD patients, which could put Feraheme/Rienso at a competitive disadvantage unless and until it receives approval for a broader indication outside of the U.S. If we or Takeda are not able to differentiate Feraheme/Rienso from other marketed IV iron products, our ability to maintain a premium price, our ability to generate revenues and achieve and maintain profitability, and our long-term business prospects could be adversely affected.

 

There are other companies in the U.S. commercializing products for the management or treatment of oral mucositis that may compete with MuGard, including (a) NeutraSal ®  (supersaturated calcium phosphate rinse), a prescription mouth rinse marketed by Invado Pharmaceuticals, LLC; (b) Caphosol ®  a supersaturated calcium phosphate artificial saliva used as an adjunct to other oral care which is marketed by Jazz Pharmaceuticals, PLC; and (c) Kepivance ®  (palifermin) an IV human growth factor which is marketed by Swedish Orphan Biovitrum AB. In addition, there are several marketed products available which are indicated for the management of pain associated with oral mucositis including (a) Episil, which is marketed by Cangene BioPharma, Inc.; (b) Gelclair ® , which is marketed by DARA BioSciences; and (c) GelX Oral Gel, which is marketed by Praelia Pharmaceuticals, Inc. If we are not able to differentiate MuGard from other marketed products for the management or treatment of oral mucositis, our ability to generate additional revenues could be adversely affected.

 

We may not be able to further expand our product portfolio by entering into additional business development transactions, such as in-licensing arrangements, acquisitions, or collaborations or if such arrangements are entered into they could disrupt our business, decrease our profitability, result in dilution to our stockholders or cause us to incur debt or significant additional expense.

 

As part of our business strategy to expand our product portfolio and achieve profitability, we are seeking to acquire or in-license other products, or acquire businesses that have a commercialized product or products, that we believe would be complementary to our existing business. For example, in June 2013, we entered into a license agreement with Access, under which we acquired the MuGard Rights. We have limited experience with respect to these business development activities and there can be no assurance that we will be able to identify or complete any such transaction in a timely manner, on a cost-effective basis, or at all, and we may not realize the anticipated financial benefits of any such transaction, including MuGard . The valuation methods that we use for any acquired product or business requires significant judgment and assumptions. Actual results and performance of the product or business that we acquire could differ significantly from our original assumptions, especially during the periods immediately following the closing of the transaction. In addition, acquisitions may cause significant changes to our current structure, organization and operations, may subject us to more rigid or constraining regulations or government oversight and may have negative tax and accounting consequences. These results could have a negative impact on our financial position or results of operations and result in significant charges in future periods. We may not be successful in acquiring or in-licensing a product, product candidate or business that will provide us with commercial, development and/or financial synergies with Feraheme and our current organization such that we will be able to eliminate expenses either from our existing operations or from the cost structure of the acquired product.

 

In addition, proposing, negotiating and implementing collaborations, in-licensing arrangements or acquisition agreements is a lengthy and complex process. Other companies, including those with substantially greater financial, marketing and sales resources, may compete with us for these arrangements, and we may not be able to enter into such arrangements on acceptable terms or at all. Further, any such strategic transactions by us could result in large and immediate write-offs or the incurrence of debt and contingent liabilities, each of which may contain restrictive covenants that could adversely impact or limit

 

51



Table of Contents

 

our ability to grow our business, enter into new agreements, and adversely affect our operating results. Management of a license arrangement, collaboration, or other strategic arrangement and/or integration of an acquired asset or company may also disrupt our ongoing business, require management resources that otherwise would be available for ongoing development of our existing business and our U.S. commercialization of Feraheme . In addition, our cash, cash equivalents and investments may not be sufficient to finance any such strategic transactions, and we may choose to issue shares of our common or preferred stock as consideration, which would result in dilution to our stockholders. Alternatively, it may be necessary for us to raise additional funds through public or private financings, and such additional funds may not be available on terms that are favorable to us, if at all, and our stockholders may experience significant dilution. If we are unable to successfully obtain rights to suitable products or if any acquisition or in-license arrangement we make is not successful, our business, financial condition and prospects for growth could suffer.

 

We may not realize the anticipated benefits of the acquisition of the MuGard Rights or any future acquisitions or product licenses and the integration of the MuGard Rights or any future acquisitions and any products or product candidates acquired or licensed may disrupt our business and management.

 

We have and we may in the future acquire or in-license additional specialty pharmaceutical products such as we did with MuGard . The integration of the operations of acquired products or businesses, including MuGard , requires significant efforts, including the coordination of information technologies, sales and marketing, operations, manufacturing, safety and pharmacovigilance, medical and finance. These efforts result in additional expenses and involve significant amounts of management’s time. In addition, we rely on Access, and may in the future have to rely on such other parties with whom we may enter into a future agreement, to perform certain regulatory filings, oversee certain functions, such as pharmacovigilance or the manufacture of the product we license from them, and any failure of Access or any other party to perform these functions for any reason, including ceasing doing business, could have a material effect on our ability to commercialize MuGard or any other future product we may acquire. We may not realize the anticipated benefits of the MuGard Rights or any future acquisition, license or collaboration, any of which involves numerous risks including the following:

 

·                   Difficulty in integrating the products or product candidates into our business;

 

·                   Entry into markets in which we have no or limited direct prior experience, including device markets, and where competitors in such markets have stronger market positions;

 

·                   Failure to achieve our strategic objectives, including successfully commercializing and marketing MuGard or any other products we may acquire;

 

·                   Our ability to train our sales force, and the ability of our sales force, to successfully incorporate new products and devices, including MuGard , into their call points;

 

·                   Additional legal and/or compliance risk associated with the acquisition of MuGard or any other future product;

 

·                   The introduction by our competitors of alternatives to MuGard or any other future product that would be, or are perceived to be, more efficacious, safer, less expensive, easier to administer, or provide more favorable insurance coverage or reimbursement could reduce our revenues and the value of our product development efforts;

 

·                   Potential write-offs of intangible assets or adjustments to contingent consideration related to estimates we make in the accounting for acquisitions or product licenses, including MuGard , and any resulting impact that may have on our quarterly financial results; and

 

52



Table of Contents

 

·                   Disruption of our ongoing business and distraction of our management and employees from other opportunities or our core business functions, including Feraheme/Rienso .

 

If we cannot successfully integrate the MuGard business, or other businesses we may acquire, into our company, we may experience material negative consequences to our business, financial condition or results of operations. We cannot assure you that, following any such acquisitions, including MuGard , we will achieve the expected synergies to justify the transaction.

 

We are completely dependent on third parties to manufacture our commercial products, including Feraheme/Rienso, and any difficulties, disruptions or delays in the Feraheme/Rienso manufacturing process, including any transition to alternative source manufacturing facilities, could increase our costs, impact our ability to meet our or Takeda’s demand forecasts, or adversely affect our profitability and future business prospects.

 

We do not currently own or operate, and currently do not plan to own or operate, facilities for the manufacture of Feraheme/Rienso or our other commercial products, including MuGard. We currently rely solely on our third-party contract manufacturers to manufacture Feraheme/Rienso for our commercial and clinical use and rely on Access for the manufacture of MuGard . We do not currently have an alternative manufacturer for our Feraheme/Rienso drug substance and finished drug product and we may not be able to enter into agreements with second source manufacturers whose facilities and procedures comply with current good manufacturing practices, or cGMP, regulations and other regulatory requirements on a timely basis and with terms that are favorable to us, if at all.

 

Our ability to have our products, including Feraheme/Rienso and MuGard manufactured in sufficient quantities and at acceptable costs to meet our commercial demand and clinical development needs is dependent on the uninterrupted and efficient operation of our third-party contract manufacturing facilities. Any difficulties, disruptions or delays in the manufacturing process could result in product defects or shipment delays, recall or withdrawal of product previously shipped for commercial or clinical purposes, inventory write-offs or the inability to meet commercial demand in a timely and cost-effective manner. Furthermore, our current third-party manufacturer for Feraheme/Rienso does not manufacture for us exclusively and may exhaust some or all of its resources meeting the demand of other customers. Any potential manufacturing delays resulting from insufficient manufacturing capacity due to scheduling conflicts at our third-party manufacturers to produce sufficient quantities of Feraheme/Rienso to meet our demand forecasts or any other difficulties in our manufacturing process could result in our inability to meet our commercial demand for Feraheme/Rienso .

 

In addition, securing additional third-party contract manufacturers for Feraheme/Rienso will require significant time for transitioning the necessary manufacturing processes, gaining regulatory approval, and for having the appropriate oversight and may increase the risk of certain problems, including cost overruns, process reproducibility, stability issues, the inability to deliver required quantities of product that conform to specifications in a timely manner, or the inability to manufacture Feraheme/Rienso in accordance with cGMP. If we are unable to have Feraheme/Rienso manufactured on a timely or sufficient basis because of these or other factors, we may not be able to meet commercial demand or our clinical development needs for Feraheme/Rienso or may not be able to manufacture Feraheme/Rienso in a cost-effective manner, particularly in light of the current fixed price at which we are required to supply Feraheme/Rienso to Takeda under our License, Development and Commercialization Agreement, as amended in June 2012, or the Amended Takeda Agreement. As a result, we may lose sales, fail to generate increased revenues, fail to launch the product in markets that cannot support a price in excess of our costs, suffer regulatory setbacks and/or we may lose money on our supply of Feraheme/Rienso to Takeda, any of which could have an adverse impact on our potential profitability and future business prospects.

 

53



Table of Contents

 

Contract manufacturers may not be able to operate their manufacturing facilities in compliance with cGMP, release specifications and other FDA and equivalent foreign regulations, which could result in a suspension of our contract manufacturers’ ability to manufacture Feraheme/Rienso or MuGard, the loss of Feraheme/Rienso or MuGard inventory, an inability to manufacture sufficient quantities of Feraheme/Rienso and MuGard to meet U.S. or foreign demand, as applicable, or other unanticipated compliance costs.

 

Our third-party contract manufacturing facilities are subject to cGMP regulations enforced by the FDA and equivalent foreign regulatory regulations and agencies through periodic inspections to confirm such compliance. Similarly, we rely on Access for the manufacture of MuGard and any third-party contract manufacturing facilities engaged by Access are subject to cGMP regulations. Contract manufacturers must continually expend time, money and effort in production, record-keeping and quality assurance and control to ensure that these manufacturing facilities meet applicable regulatory requirements. Failure to maintain ongoing compliance with cGMP or similar regulations and other applicable manufacturing requirements of various U.S. or foreign regulatory agencies could result in, among other things, the issuance of warning letters, fines, the withdrawal or recall of our products, including Feraheme/Rienso and MuGard from the marketplace, total or partial suspension of Feraheme/Rienso or MuGard production, the loss of Feraheme/Rienso inventory or the inability of Access to supply sufficient MuGard inventory, suspension of the review of our current or any future sNDAs or equivalent foreign filings, enforcement actions, injunctions or criminal prosecution. A government-mandated recall or a voluntary recall could divert managerial and financial resources, could be difficult and costly to correct, could result in the suspension of sales of our products, including Feraheme/Rienso and MuGard , and could have a severe adverse impact on our potential profitability and the future prospects of our business. If any U.S. or foreign regulatory agency inspects any of these manufacturing facilities and determines that they are not in compliance with cGMP or similar regulations or our or Access’s contract manufacturers otherwise determine that they are not in compliance with these regulations, as applicable, such contract manufacturers could experience an inability to manufacture sufficient quantities of Feraheme/Rienso to meet U.S. or foreign demand and of MuGar d to meet U.S. demand, or incur unanticipated compliance expenditures.

 

We have also established certain testing and release specifications with the FDA and other foreign regulatory agencies. This release testing must be performed in order to allow the finished product to be used for commercial sale. If our finished product does not meet these release specifications or if the release testing is variable, we may not be able to supply product to meet our projected demand. We monitor each batch of Feraheme/Rienso for ongoing stability after it has been released for commercial sale. If a particular batch exhibits variations in its stability or begins to generate test results that demonstrate an adverse trend against our specifications, we may need to conduct an investigation into the test results, quarantine the product to prevent further use, destroy existing inventory no longer acceptable for commercial sale, or recall the batch. In addition, variations in the regulatory approval of Feraheme/Rienso in the currently approved territories require that our third-party manufacturers follow different manufacturing processes and analytical testing methods. If we are unable to develop, validate, transfer or gain regulatory approval for the new release test, our ability to supply product to the EU will be adversely affected. Such setbacks could have an adverse impact on Feraheme/Rienso sales, our potential profitability and the future prospects of our business.

 

The success of Feraheme and MuGard in the U.S. depends on our ability to maintain the proprietary nature of our technology.

 

We rely on a combination of patents, trademarks and copyrights in the conduct of our business. The patent positions of pharmaceutical and biopharmaceutical firms are generally uncertain and involve complex legal and factual questions. We may not be successful or timely in obtaining any patents for which we submit applications. The breadth of the claims obtained in our patents may not provide sufficient protection

 

54



Table of Contents

 

for our technology. The degree of protection afforded by patents for proprietary or licensed technologies or for future discoveries may not be adequate to preserve our ability to protect or commercially exploit those technologies or discoveries. The patents issued to us may provide us with little or no competitive advantage. In addition, there is a risk that others will independently develop or duplicate similar technology or products or circumvent the patents issued to us.

 

Our Feraheme patents currently expire in 2020, however, our primary U.S. patent for Feraheme may be subject to an extension to 2023 under U.S. patent law and FDA regulations. Our licensed patents relating to MuGard expire in 2022. These and any other patents issued to us may be contested or invalidated. There has been substantial litigation and other proceedings regarding patent and other intellectual property rights in the pharmaceutical and biotechnology industries. We may become a party to patent litigation and other proceedings, including interference and reexamination proceedings declared by the United States Patent and Trademark Office. Further, our licensed patent rights to MuGard may not prevent competitors from independently developing and marketing a competing product that does not infringe our licensed patents or other intellectual property.

 

In addition, claims of infringement or violation of the proprietary rights of others may be asserted against us. If we are required to defend against such claims or to protect our own proprietary rights against others, it could result in substantial financial and business costs, including the business cost attributable to the resulting distraction of our management. An adverse ruling in any litigation or administrative proceeding could prevent us from marketing and selling Feraheme , increase the risk that a generic version of Feraheme could enter the market to compete with Feraheme , limit our development and commercialization of Feraheme , or otherwise harm our competitive position and result in additional significant costs. In addition, any successful claim of infringement asserted against us could subject us to monetary damages or an injunction, preventing us from making or selling Feraheme . We also may be required to obtain licenses to use the relevant technology. Such licenses may not be available on commercially reasonable terms, if at all. Frequently, the unpredictable nature and significant costs of patent litigation leads the parties to settle to remove this uncertainty. Settlement agreements between branded companies and generic applicants may allow, among other things, a generic product to enter the market prior to the expiration of any or all of the applicable patents covering the branded product, either through the introduction of an authorized generic or by providing a license to the applicant for the patents in suit. Moreover, MuGard is subject to many of the same third party infringement risks that Feraheme is subject to.

 

We also rely upon unpatented trade secrets and improvements, unpatented know-how and continuing technological innovation to develop and maintain our competitive position, which we seek to protect, in part, by confidentiality agreements with our corporate licensees, collaborators, contract manufacturers, employees and consultants. These agreements, however, may be breached. We may not have adequate remedies for any such breaches, and our trade secrets might otherwise become known or might be independently discovered by our competitors. In addition, we cannot be certain that others will not independently develop substantially equivalent or superseding proprietary technology, or that an equivalent product will not be marketed in competition with Feraheme or MuGard , thereby substantially reducing the value of our proprietary rights. Our inability to protect Feraheme or MuGard through our patents and other intellectual property rights prior to their expiration could have a material adverse effect on our business, financial condition and prospects.

 

Competitors could file applications seeking a path to U.S. approval of a generic ferumoxytol.

 

Generic ferumoxytol competitors could enter the market through approval of abbreviated new drug applications, or ANDAs, that use Feraheme as a reference listed drug, which would allow generic competitors to rely on Feraheme’s safety and effectiveness trials instead of conducting their own studies. An ANDA may be submitted four years after approval of a subject drug with a five-year exclusivity period if the ANDA contains a certification of patent invalidity or non-infringement, known as a

 

55



Table of Contents

 

“Paragraph IV certification,” with respect to patents listed for Feraheme in the Orange Book. In recent years, generic manufacturers have used Paragraph IV certifications extensively to challenge the protection of Orange Book-listed patents on a wide array of innovative pharmaceuticals, and we expect this trend to continue.

 

Further, in December 2012, the FDA published a draft guidance containing product-specific bioequivalence recommendations for drug products containing ferumoxytol. The FDA generally publishes product-specific bioequivalence guidance after it has received an inquiry from a generic drug manufacturer about submitting an ANDA for the product in question; thus, it is possible that a generic drug manufacturer has approached the FDA requesting guidance about submitting an ANDA for ferumoxytol, the active ingredient in Feraheme , and that such an ANDA may be filed in the near future. The published bioequivalence guidance could encourage a generic entrant seeking a path to approval of a generic ferumoxytol to file an ANDA. As a result, we could face generic competition in the near-term or have to engage in extensive litigation with a generic competitor to protect our patent rights, either of which could adversely affect our business and results of operations. In July 2013, we filed a citizen petition requesting that the FDA not approve any ANDAs for a generic ferumoxytol product until FDA completes certain planned studies addressing concerns with other generic IV iron products and imposes additional bioequivalence requirements for sponsors seeking approval of generic ferumoxytol products. However, we cannot predict when or if the FDA will respond or otherwise take any action with respect to the Citizen Petition. Companies that manufacture generic products typically invest far fewer resources in research and development than the manufacturers of branded products and can therefore price their products significantly lower than those branded products already on the market. Therefore, competition from generic IV iron products could limit our U.S. sales and any royalties and milestones we may receive from Takeda, which would have an adverse impact on our business and results of operations.

 

We are substantially dependent upon our collaboration with Takeda to commercialize Feraheme/Rienso in certain regions outside of the U.S., including Canada, Switzerland and the EU, and if Takeda fails to successfully fulfill its obligations, or is unsuccessful in the regulatory approval process or commercialization of Feraheme/Rienso in its licensed territories, or if our collaboration is terminated, our plans to commercialize Feraheme/Rienso outside of the U.S. may be adversely affected.

 

In March 2010, we entered into our initial agreement with Takeda, which was amended in June 2012, under which we granted exclusive rights to Takeda to develop and commercialize Feraheme/Rienso as a therapeutic agent in Europe, certain Asia-Pacific countries (excluding Japan, China and Taiwan), Canada, India and Turkey, or the Licensed Territories. We are highly dependent on Takeda for certain regulatory filings outside of the U.S. with respect to Feraheme/Rienso and the commercialization of Feraheme/Rienso outside of the U.S. Takeda is in the process of launching Feraheme/Rienso on country by country basis in its territories, for the treatment of IDA in CKD patients. To date, Takeda has launched Feraheme/Rienso in 11 countries (Finland, the Netherlands, Ireland, UK, Norway, Austria, Slovenia, Denmark, Sweden, Canada and Switzerland), and therefore, revenues from sales of Feraheme/Rienso in this territory are not currently a material part of ours or Takeda’s business. In June 2013, Takeda filed an application for Type II Variation of the marketing authorization for Rienso in the EU with the EMA seeking marketing authorization for an additional therapeutic indication for Rienso for the treatment of IDA in adult patients, and in October 2013 Takeda filed a sNDS with Health Canada seeking marketing approval for Feraheme for the treatment of IDA in a broad range of patients. It is unclear whether the FDA’s January 2014 complete response letter regarding our sNDA for Feraheme for the treatment of IDA in a broad range of patients will have any impact on the outcome of Takeda’s efforts, but, any regulatory action taken by the FDA with respect to a product under review in the U.S. has the potential to affect the regulatory requirements or decisions made by certain foreign regulatory bodies with regard to the regulatory approval of products outside of the U.S.

 

To receive regulatory approval outside of the U.S. for the commercial marketing and sale of

 

56



Table of Contents

 

Feraheme/Rienso for the broad IDA indication, Takeda will have to demonstrate that Feraheme/Rienso is of good quality and is safe and effective for use in the broader patient population. The ability to and the extent to which Takeda obtains regulatory approvals for Feraheme/Rienso for the treatment of IDA in a broad range of patients in the Licensed Territories and the level of success of Takeda’s current and future commercialization efforts outside of the U.S. would be significantly harmed as the result of a number of factors, including but not limited to the following:

 

·                   If the currently approved CKD indication is narrowed;

 

·                   If Feraheme/Rienso is linked to serious unexpected adverse reactions in patients;

 

·                   If Takeda experiences significant delays or setbacks in obtaining approval in the broad IDA patient population;

 

·                   If approval is granted with significant restrictions to the current or proposed package inset;

 

·                   If Takeda is required to incur significant costs as post-marketing commitments;

 

·                   If Takeda is unsuccessful in its commercialization of Feraheme/Rienso in the agreed-upon territories;

 

·                   If revenues fail to materialize due to market, competitive or pricing dynamics in Takeda’s territories; and

 

·                   If we fail to effectively manage our relationship with Takeda.

 

All of the above factors would have an adverse effect on future royalties or milestone payments we may receive from Takeda, including a significant milestone payment for the grant of marketing authorization in the EU for Rienso for the treatment of IDA generally without limit to a specific patient population or sub-population.

 

Further, if we fail to fulfill certain of our obligations under the Amended Takeda Agreement, Takeda has the right to assume the responsibility of clinical development and manufacturing of Feraheme/Rienso in the agreed-upon territories, which would increase the cost of and potentially delay the Feraheme/Rienso development program outside of the U.S.

 

Takeda has the unilateral right to terminate the Amended Takeda Agreement under certain conditions, including without cause or if it determines in good faith that the continued development of Rienso would not be in the best interest of patient welfare. If Takeda terminates the agreement and we chose to continue to commercialize Feraheme/Rienso in Takeda’s territories, we would be required to either enter into alternative arrangements with third parties to commercialize Feraheme/Rienso in Takeda’s territories, which we may be unable to do in a timely and cost effective manner, or at all, or to increase our internal infrastructure, both of which would likely result in significant additional expense and the disruption or failure of commercial efforts outside of the U.S. In order to continue commercialization efforts, we would also have to assume the full cost of any post-marketing commitments, both currently and in the future, some of which are Takeda’s responsibility under a cost-sharing arrangement. In addition, such a termination would prevent us from receiving the milestone payments and royalties we may otherwise receive under the Amended Takeda Agreement.

 

The success of Feraheme/Rienso abroad depends on our ability to protect our intellectual property rights and the laws of foreign countries may not provide the same level of protection as do the laws of the U.S.

 

57



Table of Contents

 

The laws of foreign countries may not protect our intellectual property rights to the same extent as do the laws of the U.S. and therefore, in addition to similar risks to those described above under the heading “ The success of Feraheme and MuGard in the U.S. depends on our ability to maintain the proprietary nature of our technology,” our intellectual property rights may be subject to increased risk abroad, including opposition proceedings before the patent offices for other countries, such as the European Patent Office, or the EPO, or similar adversarial proceedings, regarding intellectual property rights with respect to Feraheme/Rienso . For example, in July 2010, Sandoz GmbH, or Sandoz, filed with the EPO an opposition to one of our previously issued patents which covers ferumoxytol in the EU. In October 2012, at an oral hearing, the Opposition Division of the EPO revoked our European ferumoxytol patent. In December 2012, our notice of appeal was recorded with the EPO. The appeals process is costly and time-consuming and if it results in an unfavorable outcome to us, it could result in a loss of proprietary rights in the EU and may allow Sandoz or other companies to use our proprietary technology without a license from us, which may also result in a loss of future royalty or milestone payments to us, as well as the possibility that Takeda may determine that the terms of our agreement are no longer viable. We cannot predict the outcome of our appeal of the EPO decision. This or any future patent interference proceedings involving our patents may result in substantial costs to us, distract our management from day-to-day business operations and responsibilities, prevent us or Takeda from marketing and selling Feraheme/Rienso or increase the risk that a generic version of Feraheme/Rienso could enter the market to compete with Feraheme/Rienso. In countries where we do not have or have not applied for patents for ferumoxytol, we may be unable to prevent others from developing or selling similar products. In addition, in jurisdictions outside the U.S. where we have patent rights, we may be unable to prevent unlicensed parties from selling or importing products or technologies derived elsewhere using our proprietary technology. Any such limitation on our intellectual property rights would cause substantial harm to our competitive position and to our ability to develop and commercialize Feraheme/Rienso. Our inability to protect Feraheme/Rienso through our patents and other intellectual property rights in any territory prior to their expiration could have a material adverse effect on our business, financial condition and prospects.

 

Wholesaler, distributor and customer buying patterns, particularly those who are members of a GPO, and other factors may cause our quarterly results to fluctuate, and these fluctuations may adversely affect our short-term results.

 

Our results of operations, including, in particular, product sales, may vary from period to period due to a variety of factors, including the buying patterns of our U.S. wholesalers, distributors, clinics or hospitals, which vary from quarter to quarter. In addition, our contracts with GPOs often require certain performance from the members of the GPOs, on an individual account level or group level such as growth over prior periods or certain market share attainment goals in order to qualify for discounts off the list price of our products and a GPO may be able to influence the demand for our products from its members in a particular quarter through communications they make to their customers. In the event wholesalers, distributors, clinics or hospitals with whom we do business in the U.S. determine to limit their purchases of our products, our product sales could be adversely affected. Further, in the event wholesalers, distributors, clinics or hospitals purchase increased quantities of our products to take advantage of volume discounts or similar benefits, our quarterly results will fluctuate as re-orders become less frequent, and our overall net pricing may decrease as a result of such discounts and similar benefits. In addition, these contracts are cancellable at any time by our customers, often without notice, and are non-exclusive agreements within the IV iron market. While these contracts are intended to support the use of Feraheme , our competitors could offer better pricing, incentives, higher rebates or exclusive relationships. Because Feraheme is not indicated for the broad IDA population, the incentives in our contracts for a particular site of care are capped based on our estimate of their patients covered by our current CKD label. Because some of our competitors’ products have the broad IDA label, they may provide additional incentives for all of a customer’s IV iron usage, essentially becoming an exclusive provider to that particular customer.

 

Our contracting strategy can also have an impact on the timing of certain purchases causing

 

58



Table of Contents

 

Feraheme sales to vary from quarter to quarter. For example, in advance of an anticipated price increase, following the publication of our quarterly average selling price, or ASP, which affects the rate at which Feraheme is reimbursed, or a reduction in expected rebates or discounts, customers may order Feraheme in larger than normal quantities which could cause Feraheme sales to be lower in subsequent quarters than they would have been otherwise. Further, any changes in purchasing patterns or inventory levels, changes to our contracting strategy, increases in product returns , delays in purchasing products or delays in payment for products by one of our distributors or GPOs could also have a negative impact on our revenue and results of operations.

 

Our products may not be widely adopted by physicians, hospitals, patients, or healthcare payors, which would adversely impact our potential profitability and future business prospects.

 

The commercial success of our products depends upon the level of market adoption by physicians, hospitals, patients, and healthcare payors, including managed care organizations and GPOs. If our products do not achieve or maintain an adequate level of market adoption for any reason, our potential profitability and our future business prospects will be adversely impacted. Feraheme/Rienso and MuGard represent an alternative to other products in their respective markets and might not be adopted if perceived to be no safer, less safe, no more effective, less effective, no more convenient, or less convenient than currently available products. In addition, the pricing and/or reimbursement rates and terms of our products may not be viewed as advantageous to potential prescribers and payors as the pricing and/or reimbursement rates and terms of alternative products.

 

The degree of market acceptance of Feraheme/Rienso in the U.S. and abroad depends on a number of factors, including but not limited to the following:

 

·                   Our and Takeda’s ability to demonstrate to healthcare providers, particularly hematologists, oncologists, hospitals, nephrologists, and others who may purchase or prescribe Feraheme/Rienso , the clinical efficacy and safety of Feraheme/Rienso as an alternative to currently marketed IV iron products which treat IDA in CKD patients;

 

·                   Our and Takeda’s ability to convince physicians and other healthcare providers to use IV iron, and Feraheme/Rienso in particular, rather than oral iron, which is the current treatment of choice of most physicians for treating IDA in CKD patients;

 

·                   The actual or perceived safety and efficacy profile of Feraheme/Rienso as compared to alternative iron replacement therapeutic agents, particularly if unanticipated adverse reactions to Feraheme/Rienso result in further changes to or restrictions in the Feraheme/Rienso package insert, voluntary or involuntary product recalls and/or otherwise create safety concerns among potential prescribers;

 

·                   The relative price and level of reimbursement in the U.S. for Feraheme from payors, including government payors, such as Medicare and Medicaid, and private payors as compared to the price and level of reimbursement for alternative IV iron products;

 

·                   The relative price and/or level of reimbursement of Feraheme/Rienso outside of the U.S. as compared to alternative iron replacement therapeutic agents;

 

·                   The actual or perceived convenience and ease of administration of Feraheme/Rienso as compared to alternative iron replacement therapeutic agents, including iron administered orally;

 

·                   The limitation on the approved indications and the patient populations for Feraheme/Rienso , especially in light of FDA’s decision that we have not provided sufficient information to permit

 

59



Table of Contents

 

labeling of Feraheme for safe and effective use for this population, and the currently approved patient population in Europe; and

 

·                   The effectiveness of our and Takeda’s commercial organizations and distribution networks in marketing, selling and supplying Feraheme/Rienso .

 

The key component of our U.S. commercialization strategy is to market and sell Feraheme for use in non-dialysis adult CKD patients. The current U.S. non-dialysis CKD market is comprised primarily of three sites of care where a substantial number of CKD patients are treated: hospitals, hematology and oncology centers, and nephrology clinics. IV iron therapeutic products are not currently widely used by certain physicians who treat non-dialysis CKD patients in the U.S., particularly nephrologists, due to safety concerns and the inconvenience and often impracticability of administering IV iron therapeutic products in their offices. It is often difficult to change physicians’ existing treatment paradigms even when supportive clinical data is available. In addition, our ability to effectively market and sell Feraheme in the U.S. hospital market depends in part upon our ability to achieve acceptance of Feraheme onto hospital formularies. Since many hospitals and hematology, oncology and nephrology practices are members of GPOs, which leverage the purchasing power of a group of entities to obtain discounts based on the collective bargaining power of the group, our ability to attract customers in these sites of care also depends in part on our ability to effectively promote Feraheme to and enter into pricing agreements with GPOs. The GPOs can also offer opportunities for competitors to Feraheme that provide the ability to quickly gain market share by offering a more attractive price or contracts and incentives that encourage the members of the GPO to use or switch to the competing product. If we are not successful in capturing a significant share of the U.S. non-dialysis CKD market or if we are not successful in securing and maintaining formulary coverage for Feraheme , or if we cannot maintain strong relationships and offer competitive contracts to key customers and GPOs, our potential profitability as well as our long-term business prospects could be adversely affected.

 

We derive a substantial amount of our Feraheme revenue from a limited number of customers and the loss of one or more of these customers, a change in their fee structure, or a decline in revenue from one or more of these customers could have an adverse impact on our results of operations and financial condition.

 

In the U.S., we sell Feraheme primarily to wholesalers and specialty distributors and therefore a significant portion of our revenues is generated by a small number of customers. Four customers accounted for 93% of our total revenues during the three months ended March 31, 2014, and three customers accounted for 94% of our accounts receivable balance as of March 31, 2014. We pay these wholesalers and specialty distributors a fee for the services that they provide to us. Because our business is concentrated with such a small number of wholesalers and specialty distributors, we could be forced to accept increases in their fees in order to maintain the current distribution networks through which Feraheme is sold. Any increase in fees could have a negative impact on our current and future sales of Feraheme in the U.S. and could have a negative impact on the reimbursement rate an individual physician, hospital or clinic would realize upon using Feraheme . In addition, a significant portion of our U.S. Feraheme sales are generated through a small number of contracts with GPOs. For example, approximately 28% of our end-user demand during the first quarter of 2014 was generated by members of a single GPO with which we have contracted. As a result of the significant percentage of our end-user demand being generated by a single GPO, we may be at a disadvantage in future contract or price negotiations with such GPO and that GPO may be able to influence the demand for Feraheme from its members in a particular quarter through communications they make to their customers. In addition, the GPOs can also offer opportunities for competitors to Feraheme that provide the ability to quickly gain market share by offering a more attractive price or contracts and incentives that encourage the members of the GPO to use or switch to the competing product. The loss of some or all of this demand to a competitor, a material reduction in sales volume, or a significant adverse change in our relationship with any of our key wholesalers, distributors or GPOs could have a material adverse effect on our revenue in any given period and may result in significant annual or quarterly revenue

 

60



Table of Contents

 

fluctuations.

 

We depend, to a significant degree, on the availability and extent of reimbursement from third-party payors for the use of our products, and a reduction in the availability or extent of reimbursement could adversely affect our sales revenues and results of operations.

 

Our ability to successfully commercialize our products is dependent, in significant part, on the availability and extent of reimbursement to end-users from third-party payors for the use of our products, including governmental payors, managed care organizations and private health insurers. Reimbursement by third-party payors depends on a number of factors, including the third-party’s determination that the product is competitively priced, safe and effective, appropriate for the specific patient, and cost-effective. Third-party payors are increasingly challenging the prices charged for pharmaceutical products and have instituted and continue to institute cost containment measures to control or significantly influence the purchase of pharmaceutical products. If these entities do not provide coverage and reimbursement for our products or provide an insufficient level of coverage and reimbursement, physicians and other healthcare providers may choose to use alternative products, which would have an adverse effect on our ability to generate revenues.

 

In addition, U.S. and many foreign governments continue to propose and pass legislation designed to reduce the cost of health care for patients. In the U.S., the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or the Health Care Reform Act, was enacted in March 2010 and includes certain cost containment measures including an increase to the minimum rebates for products covered by Medicaid programs, the extension of such rebates to drugs dispensed to Medicaid beneficiaries enrolled in Medicaid managed care organizations and the expansion of the 340B Drug Discount Program under the Public Health Service Act. In addition, the heightened focus on the health care industry by the federal government could result in the implementation of significant federal spending cuts, including cuts in Medicare and other health related spending in the near-term. For example, recent legislation has resulted in Medicare payments being subject to a two percent reduction, referred to as sequestration, until 2023. Because the majority of our Feraheme business is through hematology/oncology clinics and outpatient hospital infusions centers, this reduction in the Medicare reimbursement payment for Feraheme may adversely impact our future revenues. The magnitude of the impact of these laws on our business is uncertain. Further, in recent years some states have also passed legislation to control the prices of drugs as well as begun a move toward managed care to relieve some of their Medicaid cost burden. While Medicare is the predominant payor for Feraheme for treatment of patients with CKD, Medicare payment policy, in time, can also influence pricing and reimbursement in the non-Medicare markets, as private third-party payors and state Medicaid plans frequently adopt Medicare principles in setting reimbursement methodologies. These and any future changes in government regulation or private third-party payors’ reimbursement policies may reduce the extent of reimbursement for our products and adversely affect our future operating results.

 

In January 2011, a prospective payment system for renal dialysis services provided to Medicare beneficiaries who have end-stage renal disease, or ESRD, became effective under which virtually all costs of providing renal dialysis services are reimbursed under a single prospective payment per treatment. This bundled approach to reimbursement has and will likely continue to alter the utilization of physician-administered drugs in the ESRD market as well as put downward pressure on the prices pharmaceutical companies can charge ESRD facilities for such drugs, particularly where alternative products are available. In the U.S., Feraheme is sold at a price that is substantially higher than alternative IV iron products in the dialysis setting, and as a result, the demand for Feraheme in the dialysis setting has largely disappeared. In addition, in the U.S., for the inpatient hospital setting, most drugs are not reimbursed separately within the Medicare prospective payment system based on the drug costs, but are bundled as a per discharge reimbursement based on the diagnosis and/or procedure rather than actual costs incurred in patient treatments, thereby increasing the incentive for a hospital to limit or control expenditures. As a result, we do not expect Feraheme to be broadly used in the inpatient hospital setting.

 

61



Table of Contents

 

Currently, in U.S. physician clinic and hospital outpatient settings, Medicare Part B generally reimburses for physician-administered drugs at a rate of 106% of the drug’s average sales price, or ASP. ASP is defined by statute based on certain historical sales and sales incentive data, including rebates and chargebacks, for a defined period of time. Manufacturers submit the required information to the Centers for Medicare and Medicaid Services, or CMS, on a quarterly basis. In advance of the quarter in which the payment limit for drugs reimbursed under Medicare Part B program will go into effect, CMS calculates and publishes the payment limit. Under this methodology, payment rates change on a quarterly basis, and significant downward fluctuations in ASP, and therefore reimbursement rates, could negatively impact sales of a product. Because ASP is defined by statute, and changes to Medicare payment methodologies require legislative change, it is unclear if and when ASP reimbursement methodology will change for the physician office setting. For hospital outpatient departments, the Medicare payment methodology for many covered Part B drugs also is at 106% of ASP, but CMS could change the payment methodology through regulations, without any intervening legislation. While Medicare is the predominant payor for treatment of patients with CKD, Medicare payment policy, in time, can also influence pricing and reimbursement in the non-Medicare markets, as private third-party payors and state Medicaid plans frequently adopt Medicare principles in setting reimbursement methodologies. We cannot predict the impact that any changes in reimbursement policies may have on our ability to compete effectively.

 

In addition, it is also possible that a “bundled” payment approach, like for renal dialysis services under Medicare, may be applied to other specific disease states other than ESRD. For example, one large insurer in the U.S has attempted to bundle certain costs related to the treatment of cancer patients. Further changes in the Medicare reimbursement rate, which result in lower payment rates from payors, including Medicare payors, would further limit our ability to successfully market and sell our products in the U.S.

 

In countries outside of the U.S., market acceptance of Feraheme/Rienso may also depend, in part, upon the availability of reimbursement within existing healthcare payment systems. Generally, in Europe and other countries outside of the U.S., the government sponsored healthcare system is the primary payor of healthcare costs of patients and therefore enjoys significant market power. Some foreign countries also set prices for pharmaceutical products as part of the regulatory process, and we cannot guarantee that the prices set by such governments will be sufficient to generate substantial revenues or allow sales of Feraheme/Rienso to be profitable in those countries. In addition, Takeda may be unable to obtain favorable pricing in certain countries in Europe making the commercialization impractical and preventing them from launching in those countries. Any such limitations on the reimbursement for Feraheme/Rienso in countries outside of the U.S. would have an adverse impact on Takeda’s ability to generate product sales of Feraheme/Rienso in such territories, which would, in turn, limit the amount of royalties we may receive under our amended agreement with Takeda.

 

In the U.S. there have been, and we expect there will continue to be, a number of federal and state legislative initiatives implemented to reform the healthcare system in ways that could adversely impact our business and our ability to sell our products profitably.

 

In the U.S., there have been, and we expect there will continue to be, a number of legislative and regulatory proposals aimed at changing the U.S. healthcare system. For example, the Health Care Reform Act contains a number of provisions that significantly impact the pharmaceutical industry and may negatively affect our potential revenues. Changes that may affect our business include those governing enrollment in federal healthcare programs, reimbursement changes, rules regarding prescription drug benefits under the health insurance exchanges, expansion of the 340B program, and fraud and abuse and enforcement. These changes will impact existing government healthcare programs and will result in the development of new programs, including Medicare payment for performance initiatives and improvements to the physician quality reporting system and feedback program.

 

62



Table of Contents

 

The Healthcare Reform Act made significant changes to the Medicaid program, including an increase to the minimum rebates for products covered by Medicaid programs from 15.1% to 23.1% of the average manufacturer price for most innovator products and the expansion of the 340B Drug Discount Program under the Public Health Service Act. Effective March 2010, the Health Care Reform Act expanded manufacturer rebate liability under the Medicaid program from fee-for-service Medicaid utilization to include the utilization of Medicaid managed care organizations as well. In addition, the Healthcare Reform Act and subsequent legislation changed the definition of average manufacturer price. Finally, the Healthcare Reform Act requires pharmaceutical manufacturers of branded prescription drugs to pay a branded prescription drug fee to the federal government beginning in 2011. Each individual pharmaceutical manufacturer pays a prorated share of the branded prescription drug fee of $3.0 billion in 2014 (and set to increase in ensuing years), based on the dollar value of its branded prescription drug sales to certain federal programs identified in the law. Substantial new provisions affecting compliance have also been added, which may require us to modify our business practices with healthcare providers and potentially incur additional costs. While we are continuing to evaluate this legislation and its potential impact on our business, this legislation may adversely affect the demand for Feraheme in the U.S. or cause us to incur additional expenses and therefore adversely affect our financial position and results of operations.

 

Many of the Healthcare Reform Act’s most significant reforms do not take effect until 2014. In 2012, CMS, the federal agency that administers the Medicare and Medicaid program, issued proposed regulations to implement the changes to the drug rebate components of the Medicaid program under the Healthcare Reform Act but has not yet issued final regulations. CMS is currently expected to release the final regulations in 2014.

 

The Healthcare Reform Act also expanded the Public Health Service’s 340B drug pricing discount program. The 340B pricing program requires participating manufacturers to agree to charge statutorily-defined covered entities no more than the 340B “ceiling price” for the manufacturer’s covered outpatient drugs. The Healthcare Reform Act expanded the 340B program to include additional types of covered entities: certain free-standing cancer hospitals, critical access hospitals, rural referral centers and sole community hospitals, each as defined by the Healthcare Reform Act. For example, the percentage of Feraheme business sold to 340B institutions has grown from 11% in 2011 to 15% in 2013. Since these institutions are granted lower prices than those offered to our other customers, any further growth in the 340B business may have a negative impact on our sales price per gram and gross margins.

 

The Healthcare Reform Act also obligates the Secretary of the Department of Health and Human Services to create regulations and processes to improve the integrity of the 340B program and to update the agreement that manufacturers must sign to participate in the 340B program to obligate a manufacturer to offer the 340B price to covered entities if the manufacturer makes the drug available to any other purchaser at any price and to report to the government the ceiling prices for its drugs. HRSA is expected to issue a comprehensive proposed regulation in 2014 that will address many aspects of the 340B program. When that regulation is finalized, it could affect our obligations under the 340B program in ways we cannot anticipate. In addition, legislation may be introduced that, if passed, would further expand the 340B program to additional covered entities or would require participating manufacturers to agree to provide 340B discounted pricing on drugs used in the inpatient setting.

 

Moreover, legislative changes to the Healthcare Reform Act remain possible. We expect that the Healthcare Reform Act, as currently enacted or as it may be amended in the future, and other healthcare reform measures that may be adopted in the future, could have a material adverse effect on our industry generally and on our ability to maintain or increase our product sales. In addition, various healthcare reform proposals have emerged at the state level in the U.S. We cannot predict the impact that newly enacted laws or any future legislation or regulation will have on us. We expect that there will continue to be a number of U.S. federal and state proposals to implement governmental pricing controls and limit the growth of healthcare costs. These efforts could adversely affect our business by, among other things, limiting the

 

63



Table of Contents

 

prices that can be charged for Feraheme or the amount of reimbursement rates and terms available from governmental agencies or third-party payors, limiting the profitability of Feraheme , increasing our rebate liability or limiting the commercial opportunity for Feraheme , including its acceptance by healthcare payors.

 

Our inability to obtain raw and other materials used in the manufacture of Feraheme/Rienso could adversely impact our ability to manufacture sufficient quantities of Feraheme/Rienso, which would have an adverse impact on our business.

 

We and our third-party manufacturers currently purchase certain raw and other materials used to manufacture Feraheme/Rienso from third-party suppliers and at present do not have long-term supply contracts with most of these third parties. These third-party suppliers may cease to produce the raw or other materials used in Feraheme/Rienso or otherwise fail to supply these materials to us or our third-party manufacturers or fail to supply sufficient quantities of these materials to us or our third-party manufacturers in a timely manner for a number of reasons, including but not limited to the following:

 

·       Unexpected demand for or shortage of raw or other materials;

 

·       Adverse financial developments at or affecting the supplier;

 

·       Regulatory requirements or action;

 

·       An inability to provide timely scheduling and/or sufficient capacity;

 

·       Manufacturing difficulties;

 

·       Changes to the specifications of the raw materials such that they no longer meet our standards;

 

·       Labor disputes or shortages; or

 

·       Import or export problems.

 

If any of our third-party suppliers cease to supply certain raw or other materials to us or our third-party manufacturers for any reason we could be unable to manufacture Feraheme/Rienso in sufficient quantities, on a timely basis, or in a cost-effective manner until we are able to qualify an alternative source. For example, one of the key components in ferumoxytol is produced specifically for us by a third-party supplier and if our third-party supplier is no longer able to supply it to us we will be unable to manufacture Feraheme/Rienso until we are able to identify and qualify an alternative supplier. This or any other interruption in our third-party supply chain could adversely affect our ability to satisfy commercial demand and our clinical development needs for Feraheme/Rienso .

 

The qualification of an alternative source may require repeated testing of the new materials and generate greater expenses to us if materials that we test do not perform in an acceptable manner. In addition, we or our third-party manufacturers sometimes obtain raw or other materials from one vendor only, even where multiple sources are available, to maintain quality control and enhance working relationships with suppliers, which could make us susceptible to price inflation by the sole supplier, thereby increasing our production costs. As a result of the high quality standards imposed on our raw or other materials, we or our third-party manufacturers may not be able to obtain such materials of the quality required to manufacture Feraheme/Rienso from an alternative source on commercially reasonable terms, or in a timely manner, if at all.

 

Even if we are able to obtain raw or other materials from an alternative source, if these raw or other

 

64



Table of Contents

 

materials are not available in a timely manner or on commercially reasonable terms, we would be unable to manufacture Feraheme/Rienso , both for commercial sale and for use in our clinical trials, on a timely and cost-effective basis, which could cause us to lose money. Any such difficulty in obtaining raw or other materials could severely hinder our ability to manufacture Feraheme/Rienso and could have a material adverse impact on our ability to generate additional revenues and to achieve profitability. Moreover, Access is likely subject to many of the same third party risks regarding the manufacture and supply of MuGard , which would impact our ability to generate revenues of MuGard in the U.S.

 

If we or Takeda market or distribute Feraheme/Rienso or if we market or distribute MuGard in a manner that violates federal, state or foreign healthcare fraud and abuse laws, marketing disclosure laws or other federal, state or foreign laws and regulations, we may be subject to civil or criminal penalties.

 

In addition to FDA and related regulatory requirements in the U.S. and abroad, we are subject to extensive additional federal, state and foreign healthcare regulation, which includes but is not limited to, the Federal False Claims Act, the Federal Anti-Kickback Statute, the Foreign Corrupt Practices Act, and their state analogues, and similar laws in countries outside of the U.S., laws governing sampling and distribution of products, and government price reporting laws. False claims laws prohibit anyone from knowingly presenting, or causing to be presented for payment to third-party payors, including Medicare and Medicaid, false or fraudulent claims for reimbursed drugs or services, claims for items or services not provided as claimed, or claims for medically unnecessary items or services. Anti-kickback laws make it illegal to solicit, offer, receive or pay any remuneration in exchange for, or to induce, the referral of business, including the purchase or prescription of a particular drug, that is reimbursed by a state or federal program. The Foreign Corrupt Practices Act and similar foreign anti-bribery laws generally prohibit companies and their intermediaries from making improper payments to non-U.S. officials for the purpose of obtaining or retaining business. Similar laws and regulations exist in many other countries throughout the world in which we intend to commercialize Feraheme/Rienso through Takeda. We have developed and implemented a corporate compliance program based on what we believe are current best practices in the pharmaceutical industry, but we cannot guarantee that we, our employees, our consultants or our contractors are or will be in compliance with all federal, state and foreign regulations. If we, our representatives, or Takeda fail to comply with any of these laws or regulations, a range of fines, penalties and/or other sanctions could be imposed on us and/or Takeda, including, but not limited to, restrictions on how we and/or Takeda market and sell Feraheme/Rienso and how we market and sell MuGard , significant fines, exclusions from government healthcare programs, including Medicare and Medicaid, litigation, or other sanctions. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could also have an adverse effect on our business, financial condition and results of operations.

 

In recent years, several U.S. states have enacted legislation requiring pharmaceutical companies to establish marketing and promotional compliance programs or codes of conduct and/or to file periodic reports with the state or make periodic public disclosures on sales, marketing, pricing, clinical trials, and other activities. Similar legislation is being considered by additional states and foreign governments. In addition, as part of the Health Care Reform Act, the federal government has enacted the Physician Payment Sunshine Act and related regulations. Beginning in August 2013, manufacturers of drugs are required to capture information to allow for the public reporting of gifts and payments made to physicians and teaching hospitals. Many of these requirements are new and uncertain, and the penalties for failure to comply with these requirements are unclear. Compliance with these laws is difficult, time consuming and costly, and if we are found to not be in full compliance with these laws, we may face enforcement actions, fines and other penalties, and we could receive adverse publicity which could have an adverse effect on our business, financial condition and results of operations.

 

If we fail to comply with any federal, state or foreign laws or regulations governing our industry, we could be subject to a range of regulatory actions that could adversely affect our ability to commercialize our

 

65



Table of Contents

 

products, harm or prevent sales of our products, or substantially increase the costs and expenses of commercializing and marketing our products , all of which could have a material adverse effect on our business, financial condition and results of operations.

 

If we fail to comply with our reporting and payment obligations under U.S. governmental pricing programs, we could be required to reimburse government programs for underpayments and could pay penalties, sanctions and fines which could have a material adverse effect on our business, financial condition and results of operations.

 

As a condition of reimbursement by various U.S. federal and state healthcare programs for Feraheme , we are required to calculate and report certain pricing information to U.S. federal and state healthcare agencies. We participate in and have certain price reporting obligations to the Medicaid Drug Rebate program, and we have obligations to report Average Sales Price, or ASP, for the Medicare program. Under the Medicaid Drug Rebate program, we are required to pay a rebate to each state Medicaid program for our covered outpatient products that are dispensed to Medicaid beneficiaries and paid for by a state Medicaid program as a condition of having federal funds being made available to the states for our products under Medicaid and Medicare Part B. Those rebates are based on pricing data reported by us on a monthly and quarterly basis to the CMS. These data include the average manufacturer price and, in the case of innovator products such as Feraheme , the best price for each drug.

 

The Medicaid rebate amount is computed each quarter based on our submission to CMS of our current average manufacturer prices and best prices for the quarter. If we become aware that our reporting for a prior quarter was incorrect, or has changed as a result of recalculation of the pricing data, we are obligated to resubmit the corrected data for a period not to exceed twelve quarters from the quarter in which the data originally were due. Such restatements and recalculations increase our costs for complying with the laws and regulations governing the Medicaid program. Any corrections to our rebate calculations could result in an overage or underage in our rebate liability for past quarters, depending on the nature of the correction. Price recalculations also may affect the ceiling price at which we are required to offer our products to certain covered entities, such as safety-net providers, under the 340B drug discount program. The 340B ceiling price is calculated using a statutory formula, which is based on the average manufacturer price and rebate amount for the covered outpatient drug as calculated under the Medicaid rebate program.

 

Federal law also requires that a company that participates in the Medicaid program report ASP information to CMS for certain categories of drugs that are paid under Part B of the Medicare program, such as Feraheme . This ASP information forms the basis for reimbursement for the majority of our current Feraheme business in the U.S. Manufacturers calculate ASP based on a statutorily defined formula and interpretations of the statute by CMS as to what should or should not be considered in computing ASP. An ASP for each National Drug Code for a product that is subject to the ASP reporting requirement must be submitted to CMS no later than 30 days after the end of each calendar quarter. CMS uses these submissions to determine payment rates for drugs under Medicare Part B. Changes affecting the calculation of ASP could affect the ASP calculations for our products and the resulting Medicare payment rate, and could negatively impact our results of operations.

 

Price reporting and payment obligations are highly complex and vary among products and programs. The calculations are complex and are often subject to interpretation by us, governmental or regulatory agencies and the courts. The calculations of average manufacturer price, best price, and ASP include a number of inputs from our contracts with wholesalers, specialty distributors, GPOs and other customers. It also requires us to make an assessment of whether these agreements are deemed to be for bona fide services and that the services are deemed to be at fair market value in our industry and for our products. These calculations are very complex and could involve the need for us to unbundle or reallocate discounts or rebates offered over a multiple quarters or across multiple products. Our processes for estimating amounts

 

66



Table of Contents

 

due under these governmental pricing programs involve subjective decisions and estimates. The unbundling of discounts and rebates across multiple reporting periods can result in a restatement of government price reports and changes to the reimbursement rates for various customers covered under federal programs, such as Medicare, Medicaid or the 340B program.

 

If we have to restate our calculation of government price reports, we may be forced to refund certain monies back to payers to comply with federal pricing agreements. Such a restatement of our government price reports would also adversely impact our reported financial results of operations in the period of such restatement. As a result, our price reporting calculations remain subject to the risk of errors and our methodologies for calculating these prices could be challenged under the Federal False Claims Act or other laws. In addition, the Health Care Reform Act modified the rules related to certain price reports, among other things. Presently, uncertainty exists as many of the specific determinations necessary to implement this new legislation have yet to be decided and communicated to industry participants. This uncertainty in the interpretation of the legislation increases the chances of an error in price reporting, which could in turn lead to a legal challenge, restatement or investigation. If we become subject to investigations, restatements, or other inquiries concerning our compliance with price reporting laws and regulations, we could be required to pay or be subject to additional reimbursements, penalties, sanctions or fines, which could have a material adverse effect on our business, financial condition and results of operations.

 

We are liable for errors associated with our submission of pricing data. In addition to retroactive rebates and the potential for 340B program refunds, if we are found to have knowingly submitted false average manufacturer price, average sales price, or best price information to the government, we may be liable for civil monetary penalties in the amount of $100,000 per item of false information. Our failure to submit monthly/quarterly average manufacturer price, average sales price, and best price data on a timely basis could result in a civil monetary penalty of $10,000 per day for each day the information is late beyond the due date. Such failure also could be grounds for CMS to terminate our Medicaid drug rebate agreement, pursuant to which we participate in the Medicaid program. In the event that CMS terminates our rebate agreement, no federal payments would be available under Medicaid or Medicare Part B for our covered outpatient drugs.

 

If we overcharge the government, we are required to refund the difference to the government. Failure to make necessary disclosures and/or to identify contract overcharges can result in allegations against us under the False Claims Act and other laws and regulations. Unexpected refunds to the government, and responding to a government investigation or enforcement action, would be expensive and time-consuming, and could have a material adverse effect on our business, financial condition, results of operations and growth prospects.

 

We have a history of net losses, and we may not be able to generate sufficient revenues to achieve and maintain profitability in the future.

 

We have a history of significant operating losses, we may not be profitable in the future, and if we do attain profitability, such profitability may not be sustainable. In the past, we have financed our operations primarily from the sale of our equity securities, cash from sales of Feraheme/Rienso , cash generated by our investing activities, and payments from our licensees. As of March 31, 2014, we had an accumulated deficit of approximately $473.4 million. Our losses were primarily the result of compensation to employees, commercialization expenses, including marketing and promotion costs, research and development costs, including costs associated with our clinical trials, and general and administrative costs, partially offset by net product sales and collaboration revenues. We expect to continue to incur significant expenses as we continue to market and sell and contract for the manufacture of Feraheme as an IV iron replacement therapeutic for use in adult CKD patients in the U.S., market and sell MuGard and if we further develop and seek marketing approval for Feraheme for the treatment of IDA in a broad range of patients, which would include conducting additional human trials for which we would incur significant research and development

 

67



Table of Contents

 

costs over a long period of time. As a result, we will need to generate sufficient revenues in future periods to achieve and maintain profitability. There is no guarantee that we will achieve profitability or maintain profitability, if achieved, and there is no guarantee that we will be able to maintain positive cash flow from operations. We anticipate that the majority of any revenue we generate in the next twelve months will be from sales of Feraheme/Rienso as an IV iron replacement therapeutic agent for use in adult CKD patients in the U.S., royalties we may receive with respect to sales of Feraheme/Rienso in the EU and Canada under the Amended Takeda Agreement, and from sales of MuGard . We have never independently marketed or sold any products prior to Feraheme , and we may not be successful in marketing or selling Feraheme or MuGard in the U.S. and Takeda may not be successful in marketing or selling Feraheme/Rienso outside of the U.S. If we or Takeda are not successful in marketing and selling Feraheme/Rienso , if revenues grow more slowly than we anticipate or if our operating expenses exceed our expectations, or if we are otherwise unable to achieve, maintain or increase profitability on a quarterly or annual basis, our business, results of operations and financial condition could be materially adversely affected and the market price of our common stock may decline.

 

We have limited experience independently commercializing a pharmaceutical product and no experience independently commercializing multiple products, and any failure on our part to effectively execute our Feraheme or MuGard commercial plans in the U.S. would have an adverse impact on our business.

 

Prior to our commercialization of Feraheme in the U.S., we had never independently marketed or sold a product as we had relied on our licensees to market and sell our previously approved products. We have an internal commercial infrastructure to market and sell Feraheme and MuGard in the U.S. If we are unsuccessful in maintaining an effective commercial function with multiple products, integrating MuGard into our existing sales infrastructure, or experience a high level of employee turnover for any reason, our ability to attract and retain qualified personnel, maintain sales levels, and support potential sales growth could be harmed, all of which could prevent us from successfully commercializing Feraheme or MuGard in the U.S. Any failure by us to successfully commercialize Feraheme or MuGard in the U.S. could have a material adverse impact on our ability to generate revenues, our ability to achieve profitability, and the future prospects for our business.

 

Our success depends on our ability to attract and retain key employees, and any failure to do so may be disruptive to our operations.

 

We are a pharmaceutical company focused on marketing commercial products and we plan to expand our portfolio with additional commercial-stage products through acquisitions and in-licensing; thus, the range of skills of our executive officers needs to be broad and deep. If we are not able to hire and retain talent to drive commercialization and expansion of our portfolio, we will be unlikely to achieve profitability. Further, because of the specialized nature of our business, our success depends to a significant extent on our ability to continue to attract, retain and motivate qualified sales, technical operations, managerial, scientific, and medical personnel of all levels. We have entered into employment agreements with most of our current senior executives, but such agreements do not guarantee that these executives will remain employed by us for any significant period of time, or at all. For example, in February 2014, our chief commercial officer resigned to pursue another opportunity after only one year with us, which may lead to increased turnover. There is intense competition for qualified personnel in the areas of our activities, and we may not be able to continue to attract and retain the qualified personnel necessary for the development of our business.

 

Previously implemented workforce reductions could residually harm our ability to attract and retain qualified personnel. In addition, any restructuring plans we may initiate in the future may be disruptive to our operations and could harm our ability to attract and retain qualified key personnel. For example, cost saving measures may distract management from our core business, harm our reputation, or yield unanticipated consequences, such as attrition beyond planned reductions in workforce, increased difficulties in our day-to-day operations, reduced employee productivity and a deterioration of employee morale. Any

 

68



Table of Contents

 

workforce reductions could also harm our ability to attract and retain qualified sales, technical operations, managerial, scientific, and medical personnel who are critical to our business. Any future employee turnover, whether occurring as part of a restructuring plan or otherwise, could cause significant disruption if we are unable to implement or maintain a sufficient succession plan for certain personnel or departments. Any failure to attract, retain or replace qualified personnel could prevent us from successfully commercializing and developing our products, impair our ability to maintain sales levels and/or support potential sales growth.

 

Moreover, although we believe it is necessary to closely manage the cost of our operations to improve our performance, these initiatives may preclude us from making potentially significant expenditures that could improve our competitiveness over the longer term. We cannot guarantee that any cost reduction measures, or other measures we may take in the future, will result in the expected cost savings, or that any cost savings will be unaccompanied by these or other unintended consequences.

 

We have limited experience independently distributing a pharmaceutical product, and our commercialization plans could suffer if we fail to effectively manage and maintain our supply chain and distribution network.

 

We do not have significant experience in managing and maintaining a supply chain and distribution network, and we are placing substantial reliance on third parties to perform product supply chain services for us. Such services include packaging, warehousing, inventory management, storage and distribution of Feraheme/Rienso and MuGard . We have contracted with Packaging Coordinators, Inc. (formerly Catalent Pharma Solutions, LLC) to provide certain labeling, packaging and storage services for final U.S., Canadian and Swiss Feraheme/Rienso drug product. In addition, we have contracted with Integrated Commercialization Services, Inc. to be our exclusive third-party logistics provider to perform a variety of functions related to the sale and distribution of Feraheme in the U.S., including services related to warehousing and inventory management, distribution, chargeback processing, accounts receivable management and customer service call center management. If these or any future third-parties are unable to provide uninterrupted labeling, packaging and storage services or supply chain services, respectively, we may incur substantial losses of sales to wholesalers or other purchasers of our products.

 

In addition, the packaging, storage and distribution of our products in the U.S. and abroad requires significant coordination among our, Takeda’s, and Access’s manufacturing, sales, marketing and finance organizations and multiple third parties including our third-party logistics providers, packaging, labeling and storage provider, distributors, and wholesalers. In most cases, we do not currently have back-up suppliers or service providers to perform these tasks. If any of these third parties experience significant difficulties in their respective processes, fail to maintain compliance with applicable legal or regulatory requirements, fail to meet expected deadlines or otherwise do not carry out their contractual duties to us, or encounter physical or natural damages at their facilities, our ability to deliver our products to meet U.S. or foreign commercial demand could be significantly impaired. The loss of any of our third-party providers, together with a delay or inability to secure an alternate distribution source for end-users in a timely manner, could cause the distribution of our products to be delayed or interrupted, which would have an adverse effect on our business, financial condition and results of operations.

 

We rely on third parties in the conduct of our business, including our clinical trials and manufacturing, and if they fail to fulfill their obligations, our commercialization and development plans may be adversely affected.

 

We rely on and intend to continue to rely on third parties, including clinical research organizations , or CROs, third-party manufacturers, third-party logistics providers, packaging and labeling providers, wholesale distributors and certain other important vendors and consultants, including those engaged by Access, in the conduct of our business. In addition, we have contracted and plan to continue to contract with

 

69



Table of Contents

 

certain third parties to provide certain services, including site selection, enrollment, monitoring, data management and other services, in connection with the conduct of our clinical trials and the preparation and filing of our regulatory applications. We have limited experience conducting clinical trials outside the U.S., and, therefore, we are also largely relying on third parties such as CROs to manage, monitor and carry out these clinical trials. Although we depend heavily on these parties, we do not control them and, therefore, we cannot be assured that these third parties will adequately and timely perform all of their contractual obligations to us. If our third-party service providers cannot adequately fulfill their obligations to us in a timely and satisfactory manner, if the quality and accuracy of our clinical trial data or our regulatory submissions are compromised due to poor quality or failure to adhere to our protocols or regulatory requirements or if such third parties otherwise fail to adequately discharge their responsibilities or meet deadlines, our current and future development plans and regulatory submissions both in and outside of the U.S may be delayed or terminated, which would adversely impact our ability to generate revenues from Feraheme/Rienso sales in additional indications and/or outside of the U.S.

 

Our operating results will likely fluctuate so you should not rely on the results of any single quarter to predict how we will perform over time.

 

Our future operating results will likely vary from quarter to quarter depending on a number of factors, some of which we cannot control, including but not limited to:

 

·                  The magnitude of U.S. Feraheme and MuGard sales;

 

·                   The loss of a key customer or GPO;

 

·                   The impact of any pricing or contracting strategies we have implemented or may implement related to our products , including the magnitude of rebates and/or discounts we may offer, or changes in pricing by our competitors or a new entrant into the market;

 

·                   The introduction of new competitive products, such as Injectafer ®  or generic versions of new or currently available drug therapies;

 

·                   Any expansion or contraction of the overall size of the IV iron market, which could result from a number of factors including but not limited to changes in treatment guidelines or practices related to IDA;

 

·                   Changes in the actual or perceived safety or efficacy profile of our products, especially in light of the recent complete response letter we received from the FDA, that could cause customers to decrease or discontinue their use of our products or could affect the regulatory status of our products in the U.S. or elsewhere;

 

·                   Changes in the actual or perceived safety or efficacy profile of products that compete with Feraheme/Rienso or MuGard that could cause our customers to decrease or discontinue their use of our products;

 

·                   The timing and magnitude of costs incurred in connection with business development activities or business development transactions into which we may enter;

 

·                   Any changes to the mix of our business;

 

·                   Changes in buying patterns, fees and inventory levels of our wholesalers, distributors, clinics or hospitals;

 

70



Table of Contents

 

·                   The timing and magnitude of Feraheme/Rienso milestone payments, product sales revenues and royalties we may receive from Takeda under the Amended Takeda Agreement;

 

·                   The initiation or outcome of any material litigation or patent challenges to which we are or become a party and the magnitude of costs associated with such litigation;

 

·                   The timing and magnitude of costs associated with the commercialization of our products in the U.S., including costs associated with pursuing a broader indication of Feraheme , maintaining our commercial infrastructure and executing our promotional and marketing strategies;

 

·                   Changes in accounting estimates related to reserves on revenue, returns, contingent consideration, impairment of long-lived assets or other accruals or changes in the timing and availability of government or customer discounts, rebates and incentives;

 

·                   The timing and magnitude of costs associated with the manufacture of Feraheme/Rienso , including costs of raw and other materials and costs associated with maintaining commercial inventory and qualifying additional manufacturing capacities and alternative suppliers;

 

·                   The timing and magnitude of costs associated with our ongoing and planned clinical studies of Feraheme/Rienso in connection with our pediatric program, our current or future post-marketing commitments for the EMA and other regulatory agencies, our pursuit of additional indications and our development of Feraheme/Rienso in countries outside of the U.S;

 

·                   The costs associated with manufacturing batch failures or inventory write-offs due to out-of-specification release testing or ongoing stability testing that results in a batch no longer meeting specifications;

 

·                   Changes in reimbursement practices and laws and regulations affecting our products from federal, state and foreign legislative and regulatory authorities, government health administration authorities, private health insurers and other third-party payors;

 

·                   The recognition of deferred tax assets during periods in which we generate taxable income; and

 

·                   The implementation of new or revised accounting or tax rules or policies.

 

As a result of these and other factors, our quarterly operating results could fluctuate, and this fluctuation could cause the market price of our common stock to decline. Results from one quarter should not be used as an indication of future performance.

 

If the estimates we make, or the assumptions on which we rely, in preparing our consolidated financial statements prove inaccurate, our actual results may vary from those reflected in our projections and accruals.

 

Our condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of our assets, liabilities, revenues and expenses, the amounts of charges accrued by us, and the related disclosure of contingent assets and liabilities. On an ongoing basis, our management evaluates our critical and other significant estimates and judgments, including among others those associated with revenue recognition related to product sales and collaboration agreements, product sales allowances and accruals, assessing investments for potential other-than-temporary impairment and determining the fair values of our investments, the fair value of our debt obligations, the fair value of assets acquired in a business

 

71



Table of Contents

 

combination, contingent consideration, the impairment of long-lived assets, including intangible assets, accrued expenses, and equity-based compensation expense. We base our estimates on market data, our observance of trends in our industry, and various other assumptions that we believe to be reasonable under the circumstances. If actual results differ from these estimates, there could be a material adverse effect on our financial results and the performance of our stock.

 

As part of our revenue recognition policy, our estimates of product returns, rebates and chargebacks, fees and other discounts require subjective and complex judgments due to the need to make estimates about matters that are inherently uncertain. Any significant differences between our actual results and our estimates could materially affect our financial position and results of operations.

 

In addition, to determine the required quantities of Feraheme and the related manufacturing schedule, we also need to make significant judgments and estimates based on inventory levels, current market trends, anticipated sales, forecasts from Takeda, and other factors. Because of the inherent nature of estimates, there could be significant differences between our and Takeda’s estimates and the actual amount of product need. For example, the level of our access to wholesaler and distributor inventory levels and sales data in the U.S., which varies based on the wholesaler, distributor, clinic or hospital, affects our ability to accurately estimate certain reserves included in our financial statements. Any difference between our estimates and the actual amount of product demand could result in unmet demand or excess inventory, each of which would adversely impact our financial results and results of operations.

 

In connection with our June 2013 acquisition of the MuGard Rights we were and will continue to be required to make estimates related to the fair value of the asset and the related contingent consideration. These estimates require significant judgment and assumptions including but not limited to estimating future cash flows from product sales and developing appropriate discount and probability rates. If these or any other related estimates made in connection with the acquisition of the MuGard Rights or any future acquisitions require adjustment in the future, we could experience significant write-offs or other adjustments and our operating results could be negatively affected.

 

We and/or Takeda are subject to ongoing U.S. and foreign regulatory obligations and oversight of Feraheme/Rienso and MuGard, and any failure by us to maintain compliance with applicable regulations may result in several adverse consequences including the suspension of the manufacturing, marketing and sale of our products, the incurrence of significant additional expense and other limitations on our ability to commercialize our products.

 

We and/or Takeda are subject to ongoing regulatory requirements and review both in the U.S. and in foreign jurisdictions pertaining to the manufacture, labeling, packaging, adverse event reporting, storage, marketing, promotion and record keeping related to our products. Failure to comply with such regulatory requirements or the later discovery of previously unknown problems with our products or our third-party contract manufacturing facilities or processes by which we manufacture our products may result in restrictions on our ability to manufacture, market or sell our products, including potential withdrawal from the market. Any such restrictions could result in a decrease in our product sales, damage to our reputation or the initiation of lawsuits against us, Takeda, or our third-party contract manufacturers. We and/or Takeda may also be subject to additional sanctions, including but not limited to:

 

·                   Warning letters;

 

·                   Civil or criminal penalties;

 

·                   Variation, suspension or withdrawal of regulatory approvals;

 

·                   Changes to the package insert of our products, such as additional warnings regarding potential side

 

72



Table of Contents

 

effects or potential limitations on the current dosage and administration of Feraheme/Rienso or IV irons as a class;

 

·                   Requirements to communicate with physicians and other customers about concerns related to actual or potential safety, efficacy, or other issues involving our products ;

 

·                   Implementation of risk mitigation programs and post-marketing obligations;

 

·                   Restrictions on our continued manufacturing, marketing or sale of our products;

 

·                   Temporary or permanent closing of the facilities of our third-party contract manufacturers; or

 

·                   Recalls or a refusal by regulators to consider or approve applications for additional indications.

 

Any of the above sanctions could have a material adverse impact on our ability to generate revenues and to achieve profitability and cause us to incur significant additional expenses. Moreover, Access is subject to many of the same regulatory requirements and sanctions related to MuGard , which would impact our ability to generate revenues of MuGard in the U.S.

 

The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products. If we are found to have improperly promoted off-label uses, we may become subject to significant fines and other liability.

 

The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product’s approved labeling. If we are found to have promoted such off-label uses, we may become subject to significant government fines and other related liability. For example, the U.S. government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. The government has also required companies to enter into complex corporate integrity agreements and/or non-prosecution agreements that can impose significant restrictions and other burdens on the affected companies.

 

In addition, incentives exist under applicable U.S. law that encourage employees and physicians to report violations of rules governing promotional activities for pharmaceutical products. These incentives could lead to so called whistleblower lawsuits as part of which such persons seek to collect a portion of moneys allegedly overbilled to government agencies due to, for example, promotion of pharmaceutical products beyond labeled claims. Such lawsuits, whether with or without merit, are typically time consuming and costly to defend. Such suits may also result in related shareholder lawsuits, which are also costly to defend.

 

Our stock price has been and may continue to be volatile, and your investment in our stock could decline in value or fluctuate significantly.

 

The market price of our common stock has been, and may continue to be, volatile, and your investment in our stock could decline in value or fluctuate significantly. Our stock price has ranged between $16.49 and $28.42 in the fifty-two week period through April 30, 2014. The stock market has from time to time experienced extreme price and volume fluctuations, particularly in the biotechnology and pharmaceuticals sectors, which have often been unrelated to the operating performance of particular companies. Various factors and events, many of which are beyond our control, may have a significant impact on the market price of our common stock. Factors which may affect the market price of our common stock include, among others:

 

73



Table of Contents

 

·                   Our ability to successfully commercialize Feraheme in the U.S. and Takeda’s ability to successfully commercialize Feraheme/Rienso in licensed territories outside of the U.S.;

 

·                   Our ability to increase or maintain sales and utilization of Feraheme in the current indication or the results of our efforts to expand the indications for Feraheme for the treatment of IDA in adult patients who have failed or could not use oral iron, especially in light of FDA’s recent decision that we have not provided sufficient information to permit labeling of Feraheme for safe and effective use for this population;

 

·                   Fluctuations in our net revenue per unit of Feraheme sold in the U.S. in future periods as a result of our pricing and contracting strategy and the purchase patterns of our customers;

 

·                   Actual or perceived safety concerns related to our products or products or product candidates of our competitors, including as a result of the FDA’s recent complete response letter addressing our sNDA and any actions taken by U.S. or foreign regulatory authorities in connection with safety concerns, or any voluntary or involuntary product recalls;

 

·                   Significant collaboration, product or business acquisitions, joint venture or similar agreements by us or our competitors or the termination of any current or future material collaboration agreements;

 

·                   The timing and magnitude of product revenue and actual or anticipated fluctuations in our operating results;

 

·                   Changes in or our failure to meet financial estimates published by securities analysts or our own publicly disclosed financial guidance;

 

·                   Increases or decreases in our operating expenses or our gross margin on our products;

 

·                   Developments in patents or other proprietary rights by or for the benefit of us or our competitors, such as the recent decision by the EPO regarding our European ferumoxytol patent or an ANDA filing by a generic entrant;

 

·                   Our ability to successfully integrate MuGard with our business and market MuGard in the U.S.;

 

·                   The availability of reimbursement coverage for our products or changes in the reimbursement policies of U.S. or foreign governmental or private payors;

 

·                   Public announcements of U.S. or foreign regulatory actions with respect to our products or products or product candidates of our competitors;

 

·                   The status or results of clinical trials for Feraheme or products or product candidates of our competitors;

 

·                   The acquisition, development or regulatory approvals of technologies, product candidates or products by us or our competitors;

 

·                   Cash milestones earned, if any, under the Amended Takeda Agreement;

 

·                   The initiation or outcome of any material litigation or patent challenges to which we are or may become a party;

 

74



Table of Contents

 

·                   Shareholder activism and attempts to disrupt our strategy by activist investors;

 

·                   General market conditions; and

 

·                   Sales of large blocks of our common stock or the dilutive effect of our Convertible Notes or any other equity or equity-linked financings or alternative strategic arrangements.

 

Thus, as a result of events both within and beyond our control, our stock price could fluctuate significantly or lose value rapidly.

 

If securities analysts downgrade our stock, cease coverage of us, or if our operating results do not meet analysts’ forecasts and expectations, our stock price could decline.

 

The trading market for our common stock relies in part on the research and reports that industry or financial analysts publish about us and our business. As of April 30, 2014, seven financial analysts publish reports about us and our business. We do not control these or any other analysts. Furthermore, there are many large, well-established, publicly traded companies active in our industry and market, which may mean that it is less likely that we will receive widespread analyst coverage. In addition, our future operating results are subject to substantial uncertainty, and our stock price could decline significantly if we fail to meet or exceed analysts’ forecasts and expectations. If any of the analysts who cover us downgrade our stock, lower their price target or issue commentary or observations about us or our stock that are perceived by the market as negative, our stock price would likely decline rapidly. In addition, if these analysts cease coverage of our company, we could lose visibility in the market, which in turn could also cause our stock price to decline.

 

If our operating results do not meet our own publicly disclosed financial guidance our stock price could decline.

 

In February 2014, we publicly provided financial guidance, including expected 2014 total revenues and U.S. Feraheme net sales. If, for any reason, we are unable to realize our projected 2014 revenue, we may not realize our publicly announced revenue and other guidance. If we fail to realize or if we change or update any element of our publicly disclosed financial guidance or other expectations about our business, our stock price could decline in value.

 

Servicing our debt requires a significant amount of cash. We may not have sufficient cash flow from our business to make payments on our debt, and we may not have the ability to raise the funds necessary to settle conversions of our 2.50% Convertible Senior Notes due 2019 or to repurchase the Convertible Notes upon a fundamental change, which could adversely affect our business, financial condition and results of operations.

 

We incurred significant indebtedness in the amount of $200.0 million in aggregate principal with additional accrued interest under our Convertible Notes. Our ability to make scheduled payments of the principal of, to pay interest on or to refinance our indebtedness, including the Convertible Notes, depends on our future performance, which is subject to economic, financial, competitive and other factors that may be beyond our control. Our business may not generate cash flow from operations in the future sufficient to service our debt and make necessary capital expenditures. If we are unable to generate such cash flow, we may be required to adopt one or more alternatives, such as selling assets, restructuring debt or obtaining additional equity capital on terms that may be onerous or highly dilutive. Our ability to refinance our indebtedness will depend on the capital markets and our financial condition at such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our debt obligations, including the Convertible Notes.

 

75



Table of Contents

 

In addition, holders of the Convertible Notes have the right to require us to repurchase their notes upon the occurrence of a fundamental change at a repurchase price equal to 100% of the principal amount of the notes to be repurchased, plus accrued and unpaid interest. Upon conversion of the Convertible Notes, unless we elect to deliver solely shares of our common stock to settle such conversion (other than paying cash in lieu of delivering any fractional share), we will be required to make cash payments in respect of the notes being converted. We may not have enough available cash or be able to obtain financing at the time we are required to make repurchases of Convertible Notes surrendered therefor or at the time Convertible Notes are being converted. Our failure to repurchase Convertible Notes at a time when the repurchase is required by the indenture or to pay any cash payable on future conversions of the Convertible Notes would constitute an event of default. If the repayment of any indebtedness were to be accelerated because of such event of default (whether under the Convertible Notes or otherwise), we may not have sufficient funds to repay the indebtedness and repurchase the Convertible Notes or make cash payments upon conversions thereof.

 

In addition, our significant indebtedness, combined with our other financial obligations and contractual commitments, could have other important consequences. For example, it could:

 

·                   make us more vulnerable to adverse changes in general U.S. and worldwide economic, industry and competitive conditions and adverse changes in government regulation;

 

·                   limit our flexibility in planning for, or reacting to, changes in our business and our industry;

 

·                   place us at a disadvantage compared to our competitors who have less debt; and

 

·                   limit our ability to borrow additional amounts for working capital and other general corporate purposes, including to fund possible acquisitions of, or investments in, complementary businesses, products, services and technologies.

 

Any of these factors could materially and adversely affect our business, financial condition and results of operations. In addition, if we incur additional indebtedness, the risks related to our business and our ability to service or repay our indebtedness would increase.

 

We may need additional capital to achieve our business objectives.

 

We have expended and will continue to expend substantial funds to successfully commercialize and develop Feraheme . Our long-term capital requirements will depend on many factors, including, but not limited to:

 

·                   Our ability to successfully commercialize Feraheme in the U.S. and Takeda’s ability to successfully commercialize Feraheme/Rienso in its licensed territories outside of the U.S.;

 

·                   Our ability to obtain regulatory approval for Feraheme/Rienso to treat IDA regardless of the underlying cause both within the U.S. and outside of the U.S., particularly in the EU, especially in light of FDA’s recent decision that we have not provided sufficient information to permit labeling of Feraheme for safe and effective use for this population and the need to undertake additional clinical trials in order to pursue the broader indication;

 

·                   The magnitude and growth rate of U.S. Feraheme sales over prior periods;

 

The magnitude of Feraheme/Rienso sales and royalties we may receive from Takeda outside of the U.S.;

 

76



Table of Contents

 

·                   The success, costs and structure of any business or corporate development initiatives to bring additional products into our portfolio;

 

·                   The outcome of and costs associated with any material litigation or patent challenges to which we are or may become a party;

 

·                   Our ability to achieve the various milestones and receive the associated payments under the Amended Takeda Agreement;

 

·                   Costs associated with the U.S. commercialization of our products, including costs associated with maintaining our commercial infrastructure, executing our promotional and marketing strategies , and conducting our required pediatric clinical studies and any post-marketing clinical studies for Feraheme;

 

·                   The timing and magnitude of costs associated with qualifying additional manufacturing capacities and alternative suppliers;

 

·                   Our ability to maintain successful collaborations with our licensees and/or to enter into additional alternative strategic relationships, if necessary; and

 

·                   Our ability to raise additional capital on terms and within a timeframe acceptable to us, if necessary.

 

We estimate that our cash resources as of March 31, 2014, combined with cash we currently expect to receive from sales of Feraheme/Rienso and MuGard, earnings on our investments, and royalty and milestone payments we may receive from Takeda will be sufficient to finance our currently planned operations for at least the next twelve months. We may require additional funds or need to establish additional alternative strategic arrangements to execute a business development transaction. We may at any time seek funding through additional arrangements with collaborators through public or private equity or debt financings. We may not be able to obtain financing or to secure alternative strategic arrangements on acceptable terms or within an acceptable timeframe, if at all.

 

The Convertible Notes are and any additional equity or equity-linked financings or alternative strategic arrangements would be dilutive to our stockholders. In addition, the terms of any additional debt financing could greatly restrict our ability to raise additional capital and may provide rights and preferences to the investors in any such financing which are senior to those of, and not available to, current stockholders, impose restrictions on our day-to-day operations or place limitations on our ability to enter into combination transactions with other entities. Our inability to raise additional capital on terms and within a timeframe acceptable to us when needed could force us to dramatically reduce our expenses and delay, scale back or eliminate certain of our activities and operations, including our commercialization and development activities, any of which would have a material adverse effect on our business, financial condition and future business prospects.

 

The investment of our cash is subject to risks, which may cause losses or adversely affect the liquidity of these investments and our results of operations, liquidity and financial condition.

 

As of March 31, 2014, we had $200.9 million in cash and cash equivalents and $184.6 million in investments. These investments are subject to general credit, liquidity, market and interest rate risks, which have been and may, in the future, be exacerbated by a U.S. and/or global financial crisis. We may realize losses in the fair value of certain of our investments or a complete loss of these investments if the credit markets tighten, which would have an adverse effect on our results of operations, liquidity and

 

77



Table of Contents

 

financial condition.

 

The condition of the credit markets can be unpredictable. As a result, we may experience a reduction in value or loss of liquidity with respect to our investments. In addition, should our investments cease paying or reduce the amount of interest paid to us, our interest income would suffer. Further, as part of our determination of the fair value of our investments, we consider credit ratings provided by independent investment rating agencies as of the valuation date. These ratings are subject to change. These market risks associated with our investment portfolio may have an adverse effect on our results of operations, cash position, liquidity and overall financial condition.

 

We are subject to increasingly complex corporate governance, public disclosure and accounting requirements that could adversely affect our business and financial results.

 

We are subject to changing rules and regulations of U.S. federal and state government as well as the stock exchange on which our common stock is listed. These entities, including the Public Company Accounting Oversight Board, the NASDAQ Stock Market, or NASDAQ, and the Securities and Exchange Commission, or the SEC, have issued a significant number of new and increasingly complex requirements and regulations over the last several years and continue to develop additional regulations and requirements in response to laws enacted by Congress. Our efforts to comply with these requirements have resulted in, and are likely to continue to result in, an increase in our expenses and a diversion of management’s time from other business activities.

 

Our ability to use net operating loss carryforwards and tax credit carryforwards to offset future taxable income may be limited as a result of future transactions involving our common stock.

 

In general, under Section 382 of the Internal Revenue Code of 1986, as amended, a corporation that undergoes an ‘‘ownership change’’ is subject to limitations on its ability to utilize its pre-change net operating losses and certain other tax assets to offset future taxable income. In general, an ownership change occurs if the aggregate stock ownership of certain stockholders increases by more than 50 percentage points over such stockholders’ lowest percentage ownership during the testing period, which is generally three years. An ownership change could limit our ability to utilize our net operating loss and tax credit carryforwards for taxable years including or following such “ownership change.” Limitations imposed on the ability to use net operating losses and tax credits to offset future taxable income could require us to pay U.S. federal income taxes earlier than we have estimated would otherwise be required if such limitations were not in effect and could cause such net operating losses and tax credits to expire unused, in each case reducing or eliminating the benefit of such net operating losses and tax credits and potentially adversely affecting our financial position. Similar rules and limitations may apply for state income tax purposes.

 

Our business could be negatively affected as a result of the actions of activist shareholders.

 

Proxy contests have been waged against many companies in the biopharmaceutical industry over the last few years. For example, in 2011, MSMB Capital Management LLC, or MSMB Capital, filed a preliminary consent solicitation statement with the SEC seeking to remove and replace most of our then-current directors with MSMB Capital’s nominees. The review, consideration and response to efforts by activist shareholders may require the expenditure of significant time and resources by us and may be a significant distraction for our management and employees. The impact of activist shareholders’ efforts due to these or other factors may undermine our business and have a material adverse effect on our results of operations. If faced with a proxy contest, we may not be able to successfully defend against the contest, which would be disruptive to our business.

 

78



Table of Contents

 

If we identify a material weakness in our internal controls over financial reporting, our ability to meet our reporting obligations and the trading price of our stock could be negatively affected.

 

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. Accordingly, a material weakness increases the risk that the financial information we report contains material errors.

 

We regularly review and update our internal controls, disclosure controls and procedures, and corporate governance policies. In addition, we are required under the Sarbanes-Oxley Act of 2002 to report annually on our internal control over financial reporting. Any system of internal controls, however well designed and operated, is based in part on certain assumptions and can provide only reasonable, not absolute, assurances that the objectives of the system are met. If we, or our independent registered public accounting firm, determine that our internal controls over our financial reporting are not effective, or we discover areas that need improvement in the future, or we experience high turnover of our personnel in our financial reporting functions, these shortcomings could have an adverse effect on our business and financial results, and the price of our common stock could be negatively affected.

 

If we cannot conclude that we have effective internal control over our financial reporting, or if our independent registered public accounting firm is unable to provide an unqualified opinion regarding the effectiveness of our internal control over financial reporting, investors could lose confidence in the reliability of our financial statements, which could lead to a decline in our stock price. Failure to comply with reporting requirements could also subject us to sanctions and/or investigations by the SEC, NASDAQ or other regulatory authorities.

 

An adverse determination in any current or future lawsuits in which we are a defendant, including the class action lawsuit to which we are currently a party, could have a material adverse effect on us.

 

A purported class action complaint was originally filed on March 18, 2010 in the U.S. District Court for the District of Massachusetts, entitled Silverstrand Investments et. al. v. AMAG Pharm., Inc., et. al., Civil Action No. 1:10-CV-10470-NMG, and was amended on September 15, 2010 and on December 17, 2010. The second amended complaint, or SAC, filed on December 17, 2010 alleged that we and our former President and Chief Executive Officer, former Chief Financial Officer, the then-members of our Board of Directors, or Board, and certain underwriters in our January 2010 offering of common stock violated certain federal securities laws, specifically Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended, and that our former President and Chief Executive Officer and former Chief Financial Officer violated Section 15 of such Act, respectively, by making certain alleged omissions in a registration statement filed in January 2010. The plaintiffs sought unspecified damages on behalf of a purported class of purchasers of our common stock pursuant to our common stock offering on or about January 21, 2010. On August 11 and 15, 2011, respectively, the District Court issued an Opinion and Order dismissing the SAC with prejudice for failure to state a claim upon which relief could be granted. On September 14, 2011, the plaintiffs filed a Notice of Appeal to the U.S. Court of Appeals for the First Circuit, or the Court of Appeals. The Court of Appeals heard oral argument on May 11, 2012. On February 4, 2013, the Court of Appeals affirmed in part and reversed in part the District Court’s Opinion and Order and remanded the case to the District Court. On February 19, 2013, we filed a Petition for Panel Rehearing and Rehearing En Banc , which was denied on March 15, 2013. On March 22, 2013, we filed a Motion to Stay the Mandate remanding the case to the District Court pending review by the U.S. Supreme Court of the Court of Appeals’ February 4, 2013 decision. The Court of Appeals granted the Motion to Stay the Mandate on April 8, 2013. On June 13, 2013, we filed a Petition for a Writ of Certiorari, or the Petition, with the U.S. Supreme Court seeking review of the Court of Appeal’s decision and to have that decision overturned. On October 7, 2013 the U.S. Supreme Court denied our Petition, resulting in the case’s return to the District Court for further proceedings relative to the SAC’s surviving claims. On November 6, 2013, we filed a renewed Motion to Dismiss the SAC’s surviving claims. On December 6, 2013, the plaintiffs filed a brief in opposition to our Motion to Dismiss and we filed a reply

 

79



Table of Contents

 

brief in support of our Motion on December 27, 2013. On April 7, 2014, the District Court denied our renewed Motion to Dismiss. A status conference is scheduled for May 14, 2014. Whether or not the plaintiff’s appeal is successful, this type of litigation is often expensive and diverts management’s attention and resources, which could adversely affect the operation of our business. If we are ultimately required to pay significant defense costs, damages or settlement amounts, such payments could adversely affect our operations.

 

We may also be the target of similar litigation in the future. Any future litigation could result in substantial costs and divert our management’s attention and resources, which could cause serious harm to our business, operating results and financial condition. Though we maintain liability insurance, if any costs or expenses associated with this or any other litigation exceed our insurance coverage, we may be forced to bear some or all of these costs and expenses directly, which could be substantial.

 

Product liability lawsuits could divert our resources, result in substantial liabilities and reduce the commercial potential of our products.

 

The administration of our products to, or the use of our products by, humans, whether in clinical trials or after approval for commercial use, may expose us to liability claims, whether or not our products are actually at fault for causing an injury. As Feraheme/Rienso is used over longer periods of time by a wider group of patients taking numerous other medicines or by patients with additional underlying health problems, the likelihood of adverse drug reactions or unintended side effects, including death, may increase. While these adverse events are rare, all IV irons, including Feraheme/Rienso , can cause patients to experience serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and/or fatal. Although we maintain product liability insurance coverage for claims arising from the use of our products in clinical trials and commercial use, coverage is expensive, and we may not be able to maintain sufficient insurance at a reasonable cost, if at all. Product liability claims, whether or not they have merit, could also decrease demand for our products, subject us to product recalls or harm our reputation, cause us to incur substantial costs, and divert management’s time and attention.

 

Our shareholder rights plan, certain provisions in our charter and by-laws, certain contractual relationships and certain Delaware law provisions could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders, and may prevent attempts by our stockholders to replace or remove the current members of our Board.

 

We have a shareholder rights plan, the provisions of which are intended to deter a hostile takeover by making any proposed hostile acquisition of us more expensive and less desirable to a potential acquirer by enabling our stockholders (other than the potential hostile acquiror) to purchase significant amounts of additional shares of our common stock at dilutive prices. The rights issued pursuant to our shareholder rights plan become exercisable generally upon the earlier of 10 days after a person or group acquires 20% or more of our outstanding common stock or 10 business days after the announcement by a person or group of an intention to acquire 20% of our outstanding common stock via tender offer or similar transaction. The shareholder rights plan could delay or discourage transactions involving an actual or potential change in control of us or our management, including transactions in which stockholders might otherwise receive a premium for their shares over then-current prices.

 

In addition, certain provisions in our certificate of incorporation and our by-laws may discourage, delay or prevent a change of control or takeover attempt of our company by a third-party as well as substantially impede the ability of our stockholders to benefit from a change of control or effect a change in management and our Board. These provisions include:

 

·                   The ability of our Board to increase or decrease the size of the Board without stockholder approval;

 

80



Table of Contents

 

·                   Advance notice requirements for the nomination of candidates for election to our Board and for proposals to be brought before our annual meeting of stockholders;

 

·                   The authority of our Board to designate the terms of and issue new series of preferred stock without stockholder approval;

 

·                   Non-cumulative voting for directors; and

 

·                   Limitations on the ability of our stockholders to call special meetings of stockholders.

 

As a Delaware corporation, we are subject to the provisions of Section 203 of the Delaware General Corporation Law, or Section 203, which prevents us from engaging in any business combination with any “interested stockholder,” which is defined generally as a person that acquires 15% or more of a corporation’s outstanding voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in the manner prescribed in Section 203. These provisions could have the effect of delaying or preventing a change of control, whether or not it is desired by, or beneficial to, our stockholders.

 

In addition to the above factors, an acquisition of our company could be made more difficult by employment agreements we have in place with our executive officers, as well as a company-wide change of control policy, which provide for severance benefits as well as the full acceleration of vesting of any outstanding options or restricted stock units in the event of a change of control and subsequent termination of employment. Further, our Third Amended and Restated 2007 Equity Incentive Plan generally permits our Board to provide for the acceleration of vesting of options granted under that plan in the event of certain transactions that result in a change of control.

 

Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds.

 

The following table provides certain information with respect to our purchases of shares of our stock during the three months ended March 31, 2014:

 

Period

 

Total Number
of Shares
Purchased (1)

 

Average Price
Paid per
Share

 

Total Number of Shares Purchased
as Part of Publicly Announced
Plans or Programs (2)

 

Maximum Number of
Shares that May Yet Be
Purchased Under the
Plans or Programs (2)

 

 

 

 

 

 

 

 

 

 

 

January 1, 2014 through January 31, 2014

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

February 1, 2014 through February 28, 2014

 

3,296

 

$

20.12

 

 

 

 

 

 

 

 

 

 

 

 

 

March 1, 2014 through March 31, 2014

 

443

 

$

19.36

 

 

 

 

 

 

 

 

 

 

 

 

 

Total

 

3,739

 

$

20.03

 

 

 

 


(1)          Represents shares of our common stock withheld by us to satisfy the minimum tax withholding obligations in connection with the vesting of restricted stock units held by our employees.

 

81



Table of Contents

 

(2)          We do not currently have any publicly announced repurchase programs or plans.

 

Item 6.  Exhibits

 

(a)                                  List of Exhibits

 

82



Table of Contents

 

Exhibit
Number

 

 

Description

 

 

 

 

4.1

 

 

Base Indenture, dated as of February 14, 2014, by and between AMAG Pharmaceuticals, Inc. and Wilmington Trust, National Association (incorporated herein by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed February 14, 2014, File No. 001-10865).

 

 

 

 

4.2

 

 

First Supplemental Indenture, dated as of February 14, 2014, by and between AMAG Pharmaceuticals, Inc. and Wilmington Trust, National Association (incorporated herein by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed February 14, 2014, File No. 001-10865).

 

 

 

 

4.3

 

 

Form of 2.50% Convertible Senior Note due 2019 (included in Exhibit 4.2)

 

 

 

 

4.4

 

 

Amendment to Rights Agreement, dated as of February 11, 2014, by and between the Company and American Stock Transfer & Trust Company, LLC (incorporated herein by reference to Exhibit 4.4 to the Company’s Current Report on Form 8-K filed February 14, 2014, File No. 001-10865).

 

 

 

 

10.1

+

 

Supply Agrreement, dated February 7, 2014, by and between the Company and Takeda Pharmaceuticals International, GMBH A/S, an affiliate of Takeda Pharmaceutical Company Limited. (Certain confidential information contained in this exhibit was omitted by means of redacting a portion of the text and replacing it with [***]. This exhibit has been filed separately with the SEC without any redactions pursuant to a Confidential Treatment Request under Rule 24b-2 of the Securities and Exchange Act of 1934, as amended).

 

 

 

 

10.2*

+‡

 

Form of Employment Agreement between the Company and each executive officer of the Company (other than Mr. Heiden).

 

 

 

 

10.3*

+

 

Employment Agreement dated as of February 7, 2014 between the Company and Mr. Heiden.

 

 

 

 

10.4

 

 

Underwriting Agreement, dated as of February 11, 2014, among AMAG Pharmaceuticals, Inc. and J.P. Morgan Securities LLC, on its own behalf and as representative of the several underwriters named in Schedule 1 thereto (incorporated herein by reference to Exhibit 1.1 to the Company’s Current Report on Form 8-K filed February 14, 2014, File No. 001-10865).

 

 

 

 

10.5

 

 

Base Call Option Transaction Confirmation, dated as of February 11, 2014, between AMAG Pharmaceuticals, Inc. and JPMorgan Chase Bank, National Association, London Branch (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed February 14, 2014, File No. 001-10865).

 

 

 

 

10.6

 

 

Base Call Option Transaction Confirmation, dated as of February 11, 2014, between AMAG Pharmaceuticals, Inc. and Royal Bank of Canada (incorporated herein by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed February 14, 2014, File No. 001-10865).

 

 

 

 

10.7

 

 

Base Call Option Transaction Confirmation, dated as of February 11, 2014, between AMAG Pharmaceuticals, Inc. and Morgan Stanley & Co. International plc (incorporated herein by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed February 14, 2014, File No. 001-10865).

 

 

 

 

10.8

 

 

Base Warrants Confirmation, dated as of February 11, 2014, between AMAG Pharmaceuticals, Inc. and JPMorgan Chase Bank, National Association, London Branch (incorporated herein by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K filed February 14, 2014, File No. 001-10865).

 

 

 

 

10.9

 

 

Base Warrants Confirmation, dated as of February 11, 2014, between AMAG Pharmaceuticals, Inc. and Royal Bank of Canada (incorporated herein by reference to Exhibit 10.5 to the Company’s Current Report on Form 8-K filed February 14, 2014, File No. 001-10865).

 

 

 

 

10.10

 

 

Base Warrants Confirmation, dated as of February 11, 2014, between AMAG Pharmaceuticals, Inc. and Morgan Stanley & Co. International plc (incorporated herein by reference to Exhibit 10.6 to the Company’s Current Report on Form 8-K filed February 14, 2014, File No. 001-10865).

 

 

 

 

10.11

 

 

Additional Call Option Transaction Confirmation, dated as of February 13, 2014, between AMAG Pharmaceuticals, Inc. and JPMorgan Chase Bank, National Association, London Branch (incorporated herein by reference to Exhibit 10.7 to the Company’s Current Report on Form 8-K filed February 14, 2014, File No. 001-10865).

 

83



Table of Contents

 

10.12

 

 

Additional Call Option Transaction Confirmation, dated as of February 13, 2014, between AMAG Pharmaceuticals, Inc. and Royal Bank of Canada (incorporated herein by reference to Exhibit 10.8 to the Company’s Current Report on Form 8-K filed February 14, 2014, File No. 001-10865).

 

 

 

 

10.13

 

 

Additional Call Option Transaction Confirmation, dated as of February 13, 2014, between AMAG Pharmaceuticals, Inc. and Morgan Stanley & Co. International plc (incorporated herein by reference to Exhibit 10.9 to the Company’s Current Report on Form 8-K filed February 14, 2014, File No. 001-10865).

 

 

 

 

10.14

 

 

Additional Warrants Confirmation, dated as of February 13, 2014, between AMAG Pharmaceuticals, Inc. and JPMorgan Chase Bank, National Association, London Branch (incorporated herein by reference to Exhibit 1.1 to the Company’s Current Report on Form 8-K filed February 14, 2014, File No. 001-10865) (incorporated herein by reference to Exhibit 10.10 to the Company’s Current Report on Form 8-K filed February 14, 2014, File No. 001-10865).

 

 

 

 

10.15

 

 

Additional Warrants Confirmation, dated as of February 13, 2014, between AMAG Pharmaceuticals, Inc. and Royal Bank of Canada (incorporated herein by reference to Exhibit 10.11 to the Company’s Current Report on Form 8-K filed February 14, 2014, File No. 001-10865).

 

 

 

 

10.16

 

 

Additional Warrants Confirmation, dated as of February 13, 2014, between AMAG Pharmaceuticals, Inc. and Morgan Stanley & Co. International plc (incorporated herein by reference to Exhibit 10.12 to the Company’s Current Report on Form 8-K filed February 14, 2014, File No. 001-10865).

 

 

 

 

31.1

+

 

Certification Pursuant to Rule 13a-14(a)/15d-14(a) of the Exchange Act, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

 

 

 

31.2

+

 

Certification Pursuant to Rule 13a-14(a)/15d-14(a) of the Exchange Act, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

 

 

 

32.1

++

 

Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

 

32.2

++

 

Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

 

101

+

 

The following materials from AMAG Pharmaceuticals, Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2014, formatted in Extensible Business Reporting Language (XBRL), (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Operations, (iii) Consolidated Statements of Comprehensive Loss, (iv) Consolidated Statements of Cash Flows, and (v) Notes to Consolidated Financial Statements.

 


+                  Exhibits marked with a plus sign (“+”) are filed herewith.

++           Exhibits marked with a double plus sign (“++”) are furnished herewith.

*                  Exhibits marked with a single asterisk reference management contracts, compensatory plans or arrangements.

                 This exhibit includes a schedule identifying the other documents omitted and setting forth the material details in which such documents different from the exhibit, which is a form agreement, in reliance on Instruction 2 to Item 601 of Regulation S-K.

 

84



Table of Contents

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

AMAG PHARMACEUTICALS, INC.

 

 

 

By:

/s/ William K. Heiden

 

 

William K. Heiden

 

 

President and Chief Executive Officer

 

 

 

 

Date: May 5, 2014

 

 

 

 

AMAG PHARMACEUTICALS, INC.

 

 

 

 

By:

/s/ Scott A. Holmes

 

 

Scott A. Holmes

 

 

Chief Accounting Officer,

 

 

Vice President of Finance and Investor Relations and Treasurer

 

 

 

Date: May 5, 2014

 

85



Table of Contents

 

EXHIBIT INDEX

 

Exhibit
Number

 

Description

4.1

 

Base Indenture, dated as of February 14, 2014, by and between AMAG Pharmaceuticals, Inc. and Wilmington Trust, National Association (incorporated herein by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed February 14, 2014, File No. 001-10865).

 

 

 

4.2

 

First Supplemental Indenture, dated as of February 14, 2014, by and between AMAG Pharmaceuticals, Inc. and Wilmington Trust, National Association (incorporated herein by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed February 14, 2014, File No. 001-10865).

 

 

 

4.3

 

Form of 2.50% Convertible Senior Note due 2019 (included in Exhibit 4.2)

 

 

 

4.4

 

Amendment to Rights Agreement, dated as of February 11, 2014, by and between the Company and American Stock Transfer & Trust Company, LLC (incorporated herein by reference to Exhibit 4.4 to the Company’s Current Report on Form 8-K filed February 14, 2014, File No. 001-10865).

 

 

 

10.1

+

Supply Agrreement, dated February 7, 2014, by and between the Company and Takeda Pharmaceuticals International, GMBH A/S, an affiliate of Takeda Pharmaceutical Company Limited. (Certain confidential information contained in this exhibit was omitted by means of redacting a portion of the text and replacing it with [***]. This exhibit has been filed separately with the SEC without any redactions pursuant to a Confidential Treatment Request under Rule 24b-2 of the Securities and Exchange Act of 1934, as amended).

 

 

 

10.2*

+‡

Form of Employment Agreement between the Company and each executive officer of the Company (other than Mr. Heiden).

 

 

 

10.3*

+

Employment Agreement dated as of February 7, 2014 between the Company and Mr. Heiden.

 

 

 

10.4

 

Underwriting Agreement, dated as of February 11, 2014, among AMAG Pharmaceuticals, Inc. and J.P. Morgan Securities LLC, on its own behalf and as representative of the several underwriters named in Schedule 1 thereto (incorporated herein by reference to Exhibit 1.1 to the Company’s Current Report on Form 8-K filed February 14, 2014, File No. 001-10865).

 

 

 

10.5

 

Base Call Option Transaction Confirmation, dated as of February 11, 2014, between AMAG Pharmaceuticals, Inc. and JPMorgan Chase Bank, National Association, London Branch (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed February 14, 2014, File No. 001-10865).

 

 

 

10.6

 

Base Call Option Transaction Confirmation, dated as of February 11, 2014, between AMAG Pharmaceuticals, Inc. and Royal Bank of Canada (incorporated herein by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed February 14, 2014, File No. 001-10865).

 

 

 

10.7

 

Base Call Option Transaction Confirmation, dated as of February 11, 2014, between AMAG Pharmaceuticals, Inc. and Morgan Stanley & Co. International plc (incorporated herein by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed February 14, 2014, File No. 001-10865).

 

 

 

10.8

 

Base Warrants Confirmation, dated as of February 11, 2014, between AMAG Pharmaceuticals, Inc. and JPMorgan Chase Bank, National Association, London Branch (incorporated herein by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K filed February 14, 2014, File No. 001-10865).

 

 

 

10.9

 

Base Warrants Confirmation, dated as of February 11, 2014, between AMAG Pharmaceuticals, Inc. and Royal Bank of Canada (incorporated herein by reference to Exhibit 10.5 to the Company’s Current Report on Form 8-K filed February 14, 2014, File No. 001-10865).

 

 

 

10.10

 

Base Warrants Confirmation, dated as of February 11, 2014, between AMAG Pharmaceuticals, Inc. and Morgan Stanley & Co. International plc (incorporated herein by reference to Exhibit 10.6 to the Company’s Current Report on Form 8-K filed February 14, 2014, File No. 001-10865).

 

 

 

10.11

 

Additional Call Option Transaction Confirmation, dated as of February 13, 2014, between AMAG Pharmaceuticals, Inc. and JPMorgan Chase Bank, National Association, London Branch (incorporated herein by reference to Exhibit 10.7 to the Company’s Current Report on Form 8-K filed February 14, 2014, File No. 001-10865).

 

86



Table of Contents

 

10.12

 

Additional Call Option Transaction Confirmation, dated as of February 13, 2014, between AMAG Pharmaceuticals, Inc. and Royal Bank of Canada (incorporated herein by reference to Exhibit 10.8 to the Company’s Current Report on Form 8-K filed February 14, 2014, File No. 001-10865).

 

 

 

10.13

 

Additional Call Option Transaction Confirmation, dated as of February 13, 2014, between AMAG Pharmaceuticals, Inc. and Morgan Stanley & Co. International plc (incorporated herein by reference to Exhibit 10.9 to the Company’s Current Report on Form 8-K filed February 14, 2014, File No. 001-10865).

 

 

 

10.14

 

Additional Warrants Confirmation, dated as of February 13, 2014, between AMAG Pharmaceuticals, Inc. and JPMorgan Chase Bank, National Association, London Branch (incorporated herein by reference to Exhibit 1.1 to the Company’s Current Report on Form 8-K filed February 14, 2014, File No. 001-10865) (incorporated herein by reference to Exhibit 10.10 to the Company’s Current Report on Form 8-K filed February 14, 2014, File No. 001-10865).

 

 

 

10.15

 

Additional Warrants Confirmation, dated as of February 13, 2014, between AMAG Pharmaceuticals, Inc. and Royal Bank of Canada (incorporated herein by reference to Exhibit 10.11 to the Company’s Current Report on Form 8-K filed February 14, 2014, File No. 001-10865).

 

 

 

10.16

 

Additional Warrants Confirmation, dated as of February 13, 2014, between AMAG Pharmaceuticals, Inc. and Morgan Stanley & Co. International plc (incorporated herein by reference to Exhibit 10.12 to the Company’s Current Report on Form 8-K filed February 14, 2014, File No. 001-10865).

 

 

 

31.1

+

Certification Pursuant to Rule 13a-14(a)/15d-14(a) of the Exchange Act, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

 

 

31.2

+

Certification Pursuant to Rule 13a-14(a)/15d-14(a) of the Exchange Act, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

 

 

32.1

++

Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

32.2

++

Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

101

+

The following materials from AMAG Pharmaceuticals, Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2014, formatted in Extensible Business Reporting Language (XBRL), (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Operations, (iii) Consolidated Statements of Comprehensive Loss, (iv) Consolidated Statements of Cash Flows, and (v) Notes to Consolidated Financial Statements.

 


+                  Exhibits marked with a plus sign (“+”) are filed herewith.

++           Exhibits marked with a double plus sign (“++”) are furnished herewith.

*                  Exhibits marked with a single asterisk reference management contracts, compensatory plans or arrangements.

                 This exhibit includes a schedule identifying the other documents omitted and setting forth the material details in which such documents different from the exhibit, which is a form agreement, in reliance on Instruction 2 to Item 601 of Regulation S-K.

 

87


Exhibit 10.1

 

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

SUPPLY AGREEMENT

 

This SUPPLY AGREEMENT (the “ Agreement ”) is made and entered into as of the 1 st  day of February 2014 (the “ Supply Agreement Effective Date ”) by and between (i)  AMAG PHARMACEUTICALS, INC. , a Delaware corporation with its principal place of business at 1100 Winter Street, MA 02451, USA (“ AMAG ”), and (ii)  TAKEDA PHARMACEUTICALS INTERNATIONAL GMBH , a company incorporated under the laws of Switzerland, with its principal place of business at Thurgauerstrasse 130,CH-8152 Glattpark-Opfikon (Zurich) (“ Takeda ”).  Takeda is an Affiliate of Takeda Pharmaceutical Company Limited, a company incorporated under the laws of Japan, with its principal place of business at 1-1, Doshomachi 4-chome, Chuo-ku, Osaka, 540-8645, Japan ( “TPC” ).  AMAG and Takeda are sometimes referred to herein individually as a “ Party ” and collectively as the “ Parties ”.

 

RECITALS

 

WHEREAS , AMAG and TPC have entered into that certain License, Development and Commercialization Agreement, dated March 31, 2010, amended June 22, 2012 (the “ License Agreement ”), pursuant to which AMAG granted TPC certain rights to develop and commercialize AMAG’s proprietary product Feraheme ®  (ferumoxytol) Injection in the Licensed Territory;

 

WHEREAS , pursuant to Article 7 of the License Agreement, AMAG and TPC agreed that TPC would purchase Product from AMAG in finished form in unlabeled vials for commercial use pursuant to a separate supply agreement and quality agreement;

 

WHEREAS , AMAG and TPC have agreed pursuant to a letter agreement dated February 01, 2014 (the “ Letter Agreement ”) that AMAG will supply Takeda with such Product (and Takeda will purchase such Product) for use in accordance with the terms and conditions of the License Agreement and this Agreement;

 

WHEREAS , TPC, Takeda Canada, Inc. (an Affiliate of TPC) and AMAG are parties to that certain Quality Agreement, dated, for supply of the Product for Canada (the “ Canada Quality Agreement ”), and Takeda Global Research & Development Centre (Europe) Ltd., Takeda Italia Farmaceutici S.p.A. (now known as Takeda Italia S.p.A.) and Takeda, each an Affiliate of TPC, and AMAG are parties to that certain quality agreement, dated August 27, 2012, for supply of the Product for the European Union and Switzerland, as amended from time to time by the parties to such agreement (as amended, the “ Technical Quality Agreement ”); and

 

Whereas, the Parties desire to replace the Canadian Quality Agreement and the Technical Quality Agreement for all future purchases and supplies of Product made and effected according to this Agreement by a restated Quality Agreement (the “ Restated Quality Agreement ”) to be negotiated between the Parties in good faith and implemented in due course. It is hereby the Parties common understanding that the Restated Quality Agreement shall

 



 

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

generally contain the same allocation of rights and obligations to each Party as it is assigned in the Canadian Quality Agreement and/or the Technical Quality Agreement respectively; and

 

WHEREAS , AMAG and TPC have previously entered into an Interim Canadian Supply Agreement, dated March 22, 2012, and AMAG and Takeda have previously entered into an Interim Supply Agreement for the EU, dated August 9, 2012 and an Interim Supply Agreement for Switzerland, dated August 9, 2012 (collectively, the “ Interim Agreements ”), which shall apply to and govern the supply of Product under each such respective agreement (it being understood and agreed that this Agreement shall apply to and govern the purchase of Product from and after the Supply Agreement Effective Date for all countries in the Licensed Territory);

 

NOW THEREFORE , in consideration of the mutual promises and covenants set forth below, Takeda and AMAG mutually agree as follows:

 

1.                                       DEFINITIONS.

 

Capitalized terms used but not defined herein shall have the meanings set forth in the License Agreement.  As used in this Agreement, the following capitalized terms shall have the following meanings:

 

1.1                                Acceptance Tests ” means those test methods as and to the extent set forth in the Restated Quality Agreement to be performed to determine that the Product supplied to Takeda conforms to the Drug Product Specifications.

 

1.2                                “Adjusted Cap” shall have the meaning set forth in Section 7.1(b).

 

1.3                                “AMAG Indemnitees” shall have the meaning set forth in Section 9.1(b).

 

1.4                                “[***]” shall have the meaning set forth in Section 7.6(a).

 

1.5                                “Baseline Materials Cost” shall have the meaning set forth in Section 7.1(b).

 

1.6                                “Business Day” means (a) any Day excluding Saturday, Sunday and all official national and local public holidays in either (i) New York City, New York, USA or (ii) Denmark and (b) solely with respect to the timing for delivery of Product hereunder, any Day excluding Saturday, Sunday and all official national and local public holidays in the respective country of the delivery location specified in the purchase order.

 

1.7                                Capital Equipment ” means any piece of equipment with an original cost in excess of [***] and a useful life of more than [***].

 

1.8                                Change Control System ” shall mean those certain processes for developing, evaluating and implementing changes to Product material and packaging specifications, packaging instructions, test methods, manufacturing and sampling instructions and manufacturing records as and to the extent set forth in the applicable Quality Agreement.

 

2



 

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

1.9                                “Claims” shall have the meaning set forth in Section 9.1(a).

 

1.10                         Commercial Supply Forecast ” shall have the meaning set forth in Section 2.2.

 

1.11                         Customized Reference Standard” means any non-compendial or not commercially available substance that has been shown by an extensive set of analytical tests to be authentic material of high purity, obtained from existing production material of high purity, or prepared by further purification of existing production material.  A list of Customized Reference Standards applicable to Acceptance Tests to be performed to determine that the Product supplied to Takeda conforms to the Drug Product Specifications is set forth in the Restated Quality Agreement.

 

1.12                         “Day” means calendar day.

 

1.13                         “Drug Product” means the Product in the form to be supplied to Takeda in accordance with this Agreement, including the Specifications.

 

1.14                         “Drug Product Intermediate” or “DPI” means ferumoxytol used in the production of Drug Product for supply to the European Union and Canada, and if applicable (that is, if a DPI is used for supply of Drug Product to the following countries), to Switzerland and other countries, in accordance with this Agreement, in each case, including the Specifications.

 

1.15                         “Drug Substance” means the Product in bulk form prior to being formulated and packaged in the form required for delivery to Takeda in accordance with this Agreement, including the Specifications.

 

1.16                         “DSS” or “Designated Second Source Supplier” means a Third Party manufacturer of the Drug Substance, Drug Product Intermediate and/or Drug Product as established in accordance with the License Agreement or pursuant to Section 6.2.

 

1.17                         EMA ” means the European Medicines Agency.

 

1.18                         “Extended Price Period” shall have the meaning set forth in Section 7.1(b).

 

1.19                         “Fully Burdened Manufacturing Cost” means the consolidated fully burdened cost incurred by AMAG in the Manufacture of Product, calculated in accordance with GAAP and with AMAG’s accounting practices applied on a normal and customary basis by AMAG consistent with its practices, which shall equal [***].

 

1.20                         GAAP ” means the generally accepted accounting principles in the United States.

 

1.21                         “Harmonization” , with a correlative meaning for “Harmonized” , means use of the manufacturing process approved by the EMA as of June 22, 2012 or at any time during the term of this Agreement to manufacture the Product for sale in the United States at the same manufacturing sites used to manufacture the Product for sale in the Licensed Territory, but

 

3



 

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

excluding analytical testing not required by the FDA for the Product approved for sale in the United States.

 

1.22                         “Harmonized Product” means any Product, manufactured according to the Harmonized manufacturing process, by AMAG, or on AMAG´s behalf by a DSS, intended for supply outside the Licensed Territory.

 

1.23                         “Indemnified Party” shall have the meaning set forth in Section 9.1(c).

 

1.24                         “Indemnifying Party” shall have the meaning set forth in Section 9.1(c).

 

1.25                         “Initial Price Period” shall have the meaning set forth in Section 7.1(a).

 

1.26                         “Insolvency Event” shall have the meaning set forth in Section 1.59 of the License Agreement.

 

1.27                         “Interim Product” shall have the meaning set forth in Section 2.8.

 

1.28                         “Insolvency Transfer Event” shall have the meaning set forth in Section 6.3(a).

 

1.29                         “License Agreement” shall have the meaning set forth in the Recitals.

 

1.30                         License Agreement Effective Date ” means March 31, 2010.

 

1.31                         “MAA” means an application to the appropriate Regulatory Authority for approval to market the Product (but excluding pricing approvals) in any particular jurisdiction.

 

1.32                         “Manufacturing Site” means the manufacturing facility of AMAG, its Affiliate or a DSS where Drug Substance, Drug Product Intermediate and/or Drug Product is Manufactured for the Licensed Territory.

 

1.33                         Manufacturing SOPs ” means, as to a Product, the specific methods, techniques, processes and standard operating procedures that are to be used by AMAG or a DSS to Manufacture Drug Product, Drug Product Intermediate and/or Drug Substance.

 

1.34                         [***] shall have the meaning set forth in Section 7.6(a).

 

1.35                         “Minimum Order Quantity” shall have the meaning set forth in Section 2.4.

 

1.36                         “MSDS” shall have the meaning set forth in Section 3.11.

 

1.37                         “New Product Configuration” shall have the meaning set forth in Section 2.7.

 

1.38                         “Non-Conformity” or “Non-Conforming” shall have the meaning set forth in Section 5(a).

 

4



 

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

1.39                         “Party” or “Parties” shall have the meaning set forth in the introductory paragraph.

 

1.40                         “Process Changes” shall have the meaning set forth in Section 3.6(a).

 

1.41                         Product means any Product (as defined in the License Agreement) then being Developed or Commercialized under the License Agreement pursuant to the terms and conditions thereof, in finished form in unlabeled vials and/or such other presentation as agreed by the Parties.

 

1.42                         Product Price shall have the meaning set forth in Section 7.1.

 

1.43                         Quality Agreements ” shall have the meaning set forth in Section 3.1.

 

1.44                         “Quality Control Procedures” shall have the meaning set forth in Section 3.3.

 

1.45                         [***] Materials Cost” shall have the meaning set forth in Section 7.1(b).

 

1.46                         “Required Sites” shall have the meaning set forth in Section 6.1.

 

1.47                         “Samples” means retained samples, reference samples and stability samples of the Product, as applicable.

 

1.48                         Specifications ” means, with respect to a particular regulatory jurisdiction in the Licensed Territory, upon MAA approval for such jurisdiction, the characteristics for Drug Substance, Drug Product Intermediate and Drug Product included in such MAA.  The Specifications as of the Supply Agreement Effective Date are set forth in the Restated Quality Agreement, and the Parties shall amend such Specifications from time to time upon any MAA approval in the Licensed Territory or amendment of any Specifications pursuant to Section 3.6.

 

1.49                         “Takeda Indemnitees” shall have the meaning set forth in Section 9.1(a).

 

2.                                       PURCHASE AND SUPPLY.

 

2.1                                Purchase and Supply Agreement.   During the term of this Agreement, Takeda agrees to buy, and AMAG agrees to sell, all of Takeda’s and its Affiliates’ and their respective sublicensees’ requirements of Product for commercial use under the License Agreement for the Licensed Territory, in accordance with the terms and conditions of this Agreement (including without limitation, the Quality Agreements, each of which shall be incorporated herein by reference whether or not attached hereto) and the License Agreement.  Takeda shall have the right to use Product ordered under this Agreement for clinical use; provided that (a) such Product shall be subject to all of the terms and conditions of this Agreement, including the Specifications applicable to commercial supply, and (b) if Takeda desires that AMAG supply Product to Takeda for clinical use that is different from the Drug Product that AMAG is then supplying for commercial use under this Agreement, the Parties will discuss in good faith and enter into, each

 

5



 

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

in its sole discretion, a different arrangement governing such supply.  All Product supplied by or on behalf of AMAG under this Agreement will be supplied in finished form in unlabeled vials, or as otherwise agreed by the Parties.  Takeda shall be solely responsible for labeling and packaging such vials in accordance with the terms of this Agreement (including without limitation the Quality Agreements) and the License Agreement.

 

2.2                                Commercial Supply Forecasts.

 

(a)                                  On or before the Supply Agreement Effective Date, Takeda shall deliver to AMAG a detailed forecast of Takeda’s requirements for Product for commercial use to be delivered in each month of the [***] period beginning with the first full calendar month following the date on which such forecast is delivered to AMAG (a “ Commercial Supply Forecast ”).  Takeda shall thereafter provide an updated Commercial Supply Forecast on a monthly basis no later than five (5) Days before the end of each calendar month, so that prior to the beginning of each calendar month, AMAG shall have been provided with an updated rolling detailed Commercial Supply Forecast for each month during the subsequent [***] period.  Each such Commercial Supply Forecast shall be reasonably consistent with Takeda’s projected commercial sales of the Product in the Licensed Territory on a monthly basis.  The first [***] of each Commercial Supply Forecast will correspond to Product ordered in accordance with Section 2.4 prior to the delivery of such Commercial Supply Forecast.  The [***] of each Commercial Supply Forecast will be binding. The quantities indicated for the remaining [***]of each Commercial Supply Forecast will be treated as a forecast only and will not create any obligations for either Party, provided that the quantities set forth in the [***] month of any Commercial Supply Forecast may not exceed or be less than the quantity set forth for such [***] in the immediately prior Commercial Supply Forecast by [***], whichever is larger.  An illustration of the foregoing forecasting/ordering process is set forth in Exhibit B .

 

(b)                                  AMAG shall promptly notify Takeda of any problems of which AMAG becomes aware that could reasonably be expected to prevent AMAG from providing timely deliveries of Product in accordance with Takeda’s forecast amounts, and the Parties shall cooperate in resolving such problems relating to the Manufacture and supply of Product under this Agreement.

 

2.3                                Supply in Excess of Forecast.  Takeda may order Product for commercial use in excess of the binding portion of any Commercial Supply Forecast, and AMAG shall supply to Takeda up to [***] of such binding portion as ordered, rounded up to an integer multiple of the applicable Minimum Order Quantity.  If Takeda orders more than such amount, AMAG shall use Commercially Reasonable Efforts to supply such additional amounts ordered, subject to Section 2.6 and to the Parties’ agreement on any Capital Equipment acquisitions necessary to enable AMAG or its DSS to supply such additional amounts.

 

2.4                                Ordering.   All Product ordered under this Agreement shall be pursuant to written purchase orders, each of which shall specify the quantity of Product ordered and the requested delivery date.  Except for orders for the Interim Product, the minimum quantity of Product

 

6



 

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

ordered in each purchase order for commercial supply shall be as set forth in Exhibit D (as applicable, the “Minimum Order Quantity” ), unless agreed otherwise in writing by the Parties.  The quantity of Product ordered in each purchase order, other than orders for Interim Product, shall be a multiple of the applicable Minimum Order Quantity.  At the request of either Party, the Parties shall meet and discuss in good faith reasonable changes to the applicable Minimum Order Quantity in response to (i) changes to the Specifications or manufacturing process for a Product for the Licensed Territory, (ii) Product characteristics that are specific to the Product supplied for a particular regulatory jurisdiction in the Licensed Territory, or (iii) Takeda’s ability to market a Product with particular characteristics in additional regulatory jurisdictions in the Licensed Territory.  Except for purchase orders for Interim Product, Takeda shall submit each such purchase order to AMAG no later than [***] prior to the delivery date indicated in such purchase order.  Any purchase orders for Product submitted by Takeda will be governed exclusively by the terms contained herein and the License Agreement.  Any term or condition in any order, confirmation or other document furnished by Takeda or AMAG that is in any way inconsistent with the terms and conditions of this Agreement or the License Agreement is hereby expressly rejected, unless expressly agreed otherwise in writing by the Parties.  Within fifteen (15) Days after receipt of a purchase order placed in accordance with this Section 2.4, AMAG shall confirm or decline in writing such purchase order; provided, however, that AMAG may decline such purchase order only with respect to any quantities of the Product that are in excess of the permissible variance under Section 2.3.  AMAG will be deemed to have accepted any purchase order not confirmed or declined within such seven (7)-Day period.  All purchase orders confirmed by AMAG are binding and may not be cancelled unless otherwise agreed in writing by AMAG.

 

2.5                                Product Allocation Upon Insufficient Supply .  In addition to Takeda’s rights under Section 6.3(a)(ii) and (iii), if AMAG is unable, for any reason beyond its reasonable control (including an unanticipated increase in demand for the Product beyond the production capacity of the Manufacturing Sites), to supply sufficient quantities of the Product to meet (i) the binding portion of Takeda’s then-current Commercial Supply Forecast for the Licensed Territory and (ii) AMAG’s previously forecasted requirements for Harmonized Product for supply outside the Licensed Territory which AMAG is unable to fulfill from manufacturing facilities other than the Manufacturing Sites, then AMAG shall promptly establish an allocation procedure with respect to the total available supply of the Product and Harmonized Product from the Manufacturing Sites for the Licensed Territory and outside the Licensed Territory, which will provide the following allocations to Takeda:

 

(a)                                  First, an amount of the Product and Harmonized Product from the Manufacturing Sites sufficient to satisfy any warranty obligation to replace Non-Conforming Product which AMAG may owe to Takeda at the time of such allocation; provided, however, that if the total available supply of Product and Harmonized Product from the Manufacturing Sites is insufficient to satisfy such obligation to Takeda plus all of AMAG’s similar warranty obligations outside the Licensed Territory for Harmonized Products, then this allocation shall be made pro rata on a unit basis among all such warranty obligations.

 

7



 

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

(b)                                  Second, an amount of the Product and Harmonized Product from the Manufacturing Sites sufficient to satisfy any backlog from Takeda’s previous binding purchase orders for Product and Harmonized Product that AMAG may owe to Takeda at the time of such allocation; provided, however, that if the total available supply of Product and Harmonized Product from the Manufacturing Sites is insufficient to satisfy such obligation to Takeda plus all of AMAG’s similar obligations outside the Licensed Territory for Harmonized Products, then this allocation shall be made pro rata on a unit basis among all such obligations.

 

(c)                                   Third, a fraction of the remaining supply of the Product and Harmonized Product from the Manufacturing Sites (if any), the numerator of which fraction shall be the aggregate quantity of the Product which Takeda has projected that it will purchase from AMAG during [***], as determined by Takeda’s latest purchase orders and Commercial Supply Forecasts submitted to AMAG for such [***], and the denominator of which fraction shall be the aggregate quantity of the Product and the Harmonized Product from the Manufacturing Sites which all parties (including AMAG and Takeda) have projected that they will purchase from AMAG during the [***] and which AMAG would be expected to supply from the Manufacturing Sites, as determined by such parties’ latest binding orders and estimates (including those of AMAG itself relating to AMAG’s internal demand forecasts) submitted to AMAG for such [***].

 

If AMAG is prevented from providing timely deliveries of Product in accordance with Takeda’s binding forecast amounts, then:

 

AMAG shall promptly -and in addition to the allocation procedure described under Sections 2.5 (a), (b) and (c)- establish an allocation procedure with respect to the total available supply of AMAG’s future manufacturing slots at the Manufacturing Sites for manufacture of (i) the Product and Harmonized Product from the Manufacturing Sites for the Licensed Territory and outside the Licensed Territory and (ii) drug product of Feraheme ®  (ferumoxytol) Injection manufactured by AMAG for sale in the U.S.A. (“ U.S.A. Drug Product ”), from the Manufacturing Sites until timely deliveries of Product to Takeda are resumed.  Such allocation shall provide the following allocations of such future manufacturing slots to be devoted to the manufacture of Product for Takeda:

 

(d)                                  First, an amount of AMAG’s future manufacturing slots at the Manufacturing Sites sufficient to satisfy any warranty obligation to replace Non-Conforming Product which AMAG may owe to Takeda at the time of such allocation; provided, however, that if the total available supply of AMAG’s future manufacturing slots at the Manufacturing Sites is insufficient to satisfy such obligation to Takeda plus all of AMAG’s similar warranty obligations outside the Licensed Territory for Harmonized Products, then this allocation shall be made pro rata on a unit basis among all such warranty obligations; and

 

(e)                                   Second, an amount of AMAG’s future manufacturing slots at the Manufacturing Sites sufficient to satisfy any backlog from Takeda’s previous binding purchase orders for Product and Harmonized Product that AMAG may owe to Takeda at the time of such

 

8



 

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

allocation; provided, however, that if the total available supply of AMAG’s future manufacturing slots at the Manufacturing Sites is insufficient to satisfy such obligation to Takeda plus all of AMAG’s similar obligations outside the Licensed Territory for Harmonized Products, then this allocation shall be made pro rata on a unit basis among all such obligations.

 

(f)                                    Third, a fraction of the remaining of AMAG’s future manufacturing slots at the Manufacturing Sites, the numerator of which fraction shall be the aggregate quantity of the Product which Takeda has projected that it will purchase from AMAG during the [***], as determined by Takeda’s latest purchase orders and Commercial Supply Forecasts submitted to AMAG for such [***] and the denominator of which fraction shall be the aggregate quantity of the Product, the Harmonized Product and U.S.A Drug Product from the Manufacturing Sites which all parties (including AMAG and Takeda) have projected that they will purchase from AMAG during the [***] and which AMAG would be expected to supply from the Manufacturing Sites, as determined by such parties’ latest binding orders and estimates (including those of AMAG itself relating to AMAG’s internal demand forecasts of U.S.A. Drug Product) submitted to AMAG for such [***].  AMAG will use Commercially Reasonable Efforts to work with DSSs to re-allocate such future manufacturing slots at the Manufacturing Sites in accordance with such allocation.

 

Each of AMAG and Takeda shall cooperate in resolving such problems relating to the Manufacture and supply of Product under this Agreement and to reduce the impact of such circumstances.

 

AMAG shall use Commercially Reasonable Efforts to avoid any circumstances that would require allocation under this Section 2.5 and to reduce the impact of such circumstances as soon as reasonably practicable if they arise.  Should such circumstances arise, AMAG shall promptly notify Takeda in writing, and the Parties shall cooperate in developing a plan to avoid, resolve or reduce the impact of such problems relating to the Manufacture and supply of Product under this Agreement.  Such plan will be designed to address the period of insufficient supply of the Product occurring in the ordered and binding portions of Takeda’s then-current Commercial Supply Forecast ([***]) for the Licensed Territory according to this Section 2.5.  AMAG will use Commercially Reasonable Efforts to work with DSSs to supply timely deliveries of Product to Takeda as soon as reasonably practicable.

 

2.6                                Capital Equipment and Manufacturing Fees.

 

(a)                                  Capital Equipment Purchases Before the Supply Agreement Effective Date . Takeda shall reimburse AMAG in accordance with Section 2.6(b) for those Capital Equipment expenditures incurred after the License Agreement Effective Date and prior to the Supply Agreement Effective Date in the amounts set forth in Exhibit  E.

 

(b)                                  Manufacturing Fees .  For any Capital Equipment to be reimbursed by Takeda in accordance with Section 2.6(a) or Section 2.6(c) or Section 2.6(d) of this Agreement, AMAG shall invoice and Takeda shall pay AMAG a fee per unlabeled vial (the “ Manufacturing Fee ”) determined in accordance with this Section 2.6(b), provided that such Manufacturing Fee

 

9



 

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

shall be payable as described in Section 7.2, subject to the true-up procedure described in Section 7.3(b), and subject to the remaining terms and conditions set forth in Article 7.  AMAG shall invoice Takeda for all Capital Equipment to be reimbursed in accordance with Section 7.2 of this Agreement during any given calendar year at Manufacturing Fee per vial.  For each calendar year, at the time of each shipment of Product hereunder, AMAG shall provide to Takeda a written invoice for Product supplied in such delivery with the Manufacturing Fee payable per vial of Product being equal to the average amount per vial of the total aggregate amount any Capital Equipment to be reimbursed by Takeda from the prior calendar year that would be payable hereunder if, during the course of such calendar year, Takeda purchased the number of vials forecast in the last Commercial Supply Forecast for such calendar year provided by Takeda to AMAG prior to commencement of such calendar year.

 

(c)                                   Capital Equipment Purchases After the Supply Agreement Effective Date .  AMAG shall notify Takeda in writing describing in detail any Capital Equipment proposed to be acquired by AMAG after the Supply Agreement Effective Date for use in supplying Product to Takeda for which Takeda would bear [***].  Takeda will be responsible to AMAG for any Capital Equipment expenditures (all without markup by AMAG) made after the Supply Agreement Effective Date to the extent attributable to AMAG’s supply of Product to Takeda for the Licensed Territory where Takeda agrees to such Capital Equipment expenditures or to the extent that such Capital Equipment purchase is reasonably necessary for the manufacture of the Product for the Licensed Territory.  Within thirty (30) Days after Takeda’s receipt of such notice, the Parties shall meet and discuss in good faith AMAG’s acquisition and use of such Capital Equipment.  For any such equipment, the Parties shall reasonably allocate between the Parties the Capital Equipment expenditures [***], in each case for the [***], and shall determine a schedule for Takeda’s payment of its portion of such Capital Equipment expenditures in accordance with Section 2.6(b) of this Agreement, provided that in any event Takeda shall pay such portion in full by no later than the end of the following fiscal year after the end of such thirty (30)-Day period.  Any dispute between the Parties over whether such Capital Equipment is reasonably necessary to the manufacture of the Product for the Licensed Territory will be resolved in accordance with Section 12.1 of this Agreement.  The Parties shall agree on a written budget for any Capital Equipment expenditure to be incurred in accordance with this Section 2.6(c).

 

(d)                                  Invoices .  AMAG shall include Takeda’s portion of such Capital Equipment expenditures in the invoices provided pursuant to Section 7.2, in accordance with the applicable payment schedule, and Takeda shall pay such invoices as provided in such section.

 

(e)                                   Risk of Loss; Insurance .  For clarity, any such Capital Equipment expenditures and Manufacturing Fees are not included in the Fully Burdened Manufacturing Cost, and all Capital Equipment will be solely owned by AMAG and/or its designee.  AMAG shall be responsible to either obtain insurance or self-insure against any losses to such Equipment.  AMAG shall be responsible for any risk of catastrophic loss (e.g., fire, flood or theft) of such Capital Equipment.  Notwithstanding the foregoing, the replacement, repair and/or servicing of any Capital Equipment due to normal wear and tear, mechanical problems or

 

10



 

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

obsolescence would be deemed Capital Equipment expenditures and reimbursement would be governed by Section 2.6(c) of this Agreement.

 

2.7                                New Product Configuration.   Except for Process Changes addressed in Section 3.6, if Takeda desires that AMAG supply a Product not within the scope of the Specifications, such as in a package size or dosage form specific to the Licensed Territory, (“ New Product Configuration ”), Takeda shall notify AMAG, and the Parties shall promptly meet and discuss in good faith such proposed New Product Configuration, a reasonable means for supplying such New Product Configuration, the terms of such supply, and a written budget for costs (all without markup by AMAG) to implement and supply such New Product Configuration with such budget to include all anticipated Third Party and AMAG internal costs.  If a budget and the terms and conditions of such supply is agreed, AMAG shall use Commercially Reasonable Efforts to satisfy Takeda’s New Product Configuration supply needs itself or through one or more DSS in accordance with such budget.  Takeda shall be solely responsible for the budgeted costs incurred by AMAG in connection with such activities; provided however, that Takeda shall not be obligated to reimburse, and AMAG shall not be obligated to conduct, any activities whose costs exceed the agreed budget.  If the implementation of the New Product Configuration results in increased profit to AMAG under this Agreement, or increased profit to AMAG on sales of the New Product Configuration outside the Licensed Territory, then the Parties will negotiate in good faith towards a reasonable allocation between the Parties of the costs borne by Takeda for the New Product Configuration and AMAG will provide a credit equal to its agreed upon allocation of such costs against amounts that become due hereunder until such credited amount is fully applied.

 

2.8                                Interim Product .  In addition to the amounts set forth in the Commercial Supply Forecast and ordered in accordance with Section 2.4, with respect to Product described in this Section 2.8 and in Exhibit A (collectively, the “ Interim Product ”) and for which (i) the quality control release by AMAG is issued no later than [***] and (ii) the variation to extend shelf life is approved by [***], the following shall apply: (a) Takeda shall be required to purchase all such Interim Product as was manufactured for use in [***] and (b) Takeda shall have the right, but not the obligation, to purchase all such Interim Product as was manufactured for use in [***], provided that Takeda provides written notice to AMAG prior to [***] of Takeda’s commitment to purchase such Interim Product as was manufactured for use in [***] (if Takeda determines not purchase such Interim Product as was manufactured for use in [***], Takeda shall provide written notice promptly to AMAG).  Takeda shall submit a purchase order for such Interim Product as was manufactured for use in [***] within [***] after the quality control release by AMAG.  For any Interim Product as was manufactured for use in [***] that Takeda purchases under this Section 2.8, Takeda shall submit purchase orders in accordance with Section 2.4, except that the delivery date for such orders shall be at least five (5) business Days after AMAG’s receipt of the purchase order.

 

11



 

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

3.                                       MANUFACTURE; REGULATORY.

 

3.1          Quality Agreements. The Canada Quality Agreement governs the quality assurance obligations and responsibilities of the Parties with respect to the Manufacture and supply of the Product for commercial use in Canada which was ordered and supplied prior to the Effective Date of this Agreement, and the Technical Quality Agreement governs the quality assurance obligations and responsibilities of the Parties with respect to the Manufacture and supply of the Product for commercial use in the European Union and Switzerland which was ordered and supplied prior to the Effective Date of this Agreement the “ Quality Agreements ”).  For the future purchases and supplies of Products based on the stipulations set forth in this Agreement  the Parties shall negotiate in good faith and enter into the Restated Quality Agreement. Such Restated Quality Agreement shall generally contain the same allocation of rights and obligations  to each Party as it is assigned in the Canadian Quality Agreement and/or the Technical Quality Agreement respectively. In the event of a discrepancy between the provisions of a Quality Agreement/Restated Quality Agreementand the provisions of this Agreement or the Manufacturing SOPs, the provisions of the Quality Agreements/Restated Quality Agreement shall control with respect to terms governing quality of the Product, and the provisions of this Agreement shall control with respect to any other conflicting terms between such agreements.

 

3.2          Product Specifications; Testing and Customized Reference Standards.  AMAG or its designee shall test each batch of Product in accordance with the Acceptance Tests prior to shipment and shall include with each shipment of Product an original certificate of analysis confirming that such batch meets the Drug Product Specifications.  Upon receipt of Product, Takeda shall conduct applicable tests of Product in accordance with the applicable Quality Agreement and to the extent required by a Regulatory Authority in the Licensed Territory.  AMAG shall transfer to Takeda all information related to the Product reasonably necessary for and requested by Takeda to perform quality testing required by applicable Laws or a Regulatory Authority in the Territory; provided that the foregoing shall not obligate AMAG to conduct technology transfer of any methods. AMAG shall provide to Takeda reasonable quantities of any Customized Reference Standard necessary to enable Takeda to perform applicable tests of Product in accordance with the Restated Quality Agreement and to the extent required by a Regulatory Authority in the Licensed Territory.  For all Customized Reference Standards delivered to Takeda, Takeda shall promptly reimburse AMAG for [***] incurred in the course of manufacturing, testing and releasing such standards. Takeda shall monitor consumption of such Customized Reference Standards and shall order further supply of Customized References Standards from AMAG. AMAG shall deliver to Takeda Customized Reference Standards within [***] from receipt of an acceptable Purchase Order from Takeda. Delivery shall be made FCA (Incoterms 2010).  Customized Reference Standards shall be stored by Takeda in accordance with AMAG’s recommended storage conditions and used within their given expiry or retest date as provided by AMAG.

 

3.3          Quality Control.  AMAG will (or will ensure that its DSS will) maintain and follow a quality assurance and quality control testing program consistent with the Specifications,

 

12



 

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

cGMP, and all other requirements of applicable Laws and consistent with the Quality Agreements (the “ Quality Control Procedures ”), which will include performing the applicable Acceptance Tests on each batch of Product supplied to Takeda pursuant to Section 3.2.  AMAG shall ensure that all Product supplied to Takeda hereunder is manufactured, processed, stored, tested, transported and otherwise handled in accordance with Section 8.3(i).

 

3.4          Regulatory Inspections.   Upon the request of any Regulatory Authority having jurisdiction over the manufacture of Product for the Licensed Territory, AMAG shall allow such Regulatory Authority access to observe and inspect AMAG’s or its DSS’ facility for manufacturing Product and procedures used for the manufacture, packaging, release and stability testing, and/or warehousing of Product and to audit such facilities for compliance with cGMP and/or other applicable Laws.  AMAG shall cooperate (and shall use Commercially Reasonable Efforts to ensure that its DSS cooperates) with any inspection by a Regulatory Authority having jurisdiction over the manufacture of Product for the Licensed Territory, whether prior to or after Regulatory Approval of a Product, and to notify Takeda of any written or oral notifications or inspection activity by any Regulatory Authority or other governmental agency or authority of competent jurisdiction that relates to the manufacture of Product supplied for the Licensed Territory to Takeda hereunder in accordance with the Quality Agreements.  The Parties agree that each Party shall have the right to have no more than three (3) representatives observe, as witnesses, any such inspection by a Regulatory Authority relating to the manufacture or testing of the Product, subject to the limitations regarding the disclosure of CMC Information set forth in this Agreement and/or the License Agreement.

 

3.5          Quality Assurance Audits.   The Parties’ rights and obligations with respect to quality assurance audits are as set forth in the Quality Agreements.

 

3.6          Change in Specifications or Manufacturing Process.

 

AMAG shall not make any material changes to the Specifications or to the materials, equipment, process or procedures used to manufacture Product for the Licensed Territory ( “Process Changes” ) without Takeda’s prior written consent, which consent shall not be unreasonably withheld or delayed.  For clarity, a material change shall be any change that must be approved by a Regulatory Authority, as described in the Restated Quality Agreement. AMAG shall manage all Process Changes in accordance with its Change Control System and the applicable Quality Agreement and shall keep Takeda informed of the progress of such changes.  Upon any change to the Specifications, the Parties shall amend the Restated Quality Agreement accordingly.

 

(a)           If, after the Supply Agreement Effective Date, a Regulatory Authority requires a Process Change as a condition for obtaining or maintaining Regulatory Approval for the Product in the Licensed Territory (“Regulatory required Process Change”), Takeda shall promptly notify AMAG, and the Parties shall meet and discuss how to implement such requirement.  AMAG shall use Commercially Reasonable Efforts to accommodate such Process Change and, if AMAG implements such Process Change, shall use Commercially Reasonable

 

13



 

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

Efforts to do so in a cost-effective manner.  If, as a result of such change, the Fully Burdened Manufacturing Cost exceeds the applicable Cap or Adjusted Cap, then [***], notwithstanding anything to the contrary in this Agreement.  With respect to any expenses incurred by AMAG in connection with such Process Change that are not included in the Fully Burdened Manufacturing Cost: (i) Capital Equipment expenditures will be shared as provided in Section 2.6 and (ii) Takeda shall [***].  In addition, Takeda shall [***].

 

(b)           If, after the Supply Agreement Effective Date, AMAG requests a Process Change that is not required to obtain or maintain Regulatory Approval for the Product in the Licensed Territory and other than Process Changes addressed in Section 3.6(d) of this Agreement, promptly, and in any event within thirty (30) Days, following AMAG’s written notice of a proposed Process Change, the Parties shall meet and discuss such proposal in good faith.  If Takeda determines that it will not grant such consent to a Process Change, Takeda shall promptly notify AMAG following such determination, provide an explanation of its concerns and use Commercially Reasonable Efforts to cooperate with AMAG on an implementation of such Process Change that would be acceptable to Takeda, not later than forty-five (45) Days after receipt of written notice from AMAG of the proposed Process Change, however Takeda shall not be deemed to have given its consent to such requested Process Change if Takeda shall fail to provide its concerns within the forty-five Days period. If the Parties agree to make such Process Change, then AMAG shall use Commercially Reasonable Efforts to implement such Process Change in a cost-effective manner. With respect to any expenses incurred by AMAG in connection with such Process Change that are not included in the Fully Burdened Manufacturing Cost, [***].

 

(c)          If, after the Supply Agreement Effective Date, Takeda requests a Process Change that is not required to obtain or maintain Regulatory Approval for the Product in the Licensed Territory, the Parties shall meet and discuss such proposal in good faith.  AMAG shall use Commercially Reasonable Efforts to accommodate such Process Change and, if AMAG implements such Process Change, shall use Commercially Reasonable Efforts to do so in a cost-effective manner.  If as a result of such change, the Fully Burdened Manufacturing Cost exceeds the applicable Cap or Adjusted Cap, [***], notwithstanding anything to the contrary in this Agreement.  With respect to any expenses incurred by AMAG in connection with such Process Change that are not included in the Fully Burdened Manufacturing Cost: (i) Capital Equipment expenditures will be shared as provided in Section 2.6 and (ii) Takeda shall [***].

 

(d)           If, after the Supply Agreement Effective Date, either Party proposes a Process Change that is not required to obtain or maintain Regulatory Approval for the Product in the Licensed Territory, but which is in the view of the proposing Party to be deemed to create any economical advantages for both Parties (including, but not limited to, reducing the Fully Burdened Manufacturing Cost, improving reliability of supply, or reducing lead time for manufacturing) , the Parties shall meet and discuss such proposal in good faith.  AMAG shall use Commercially Reasonable Efforts to accommodate such Process Change and, if AMAG implements such Process Change, shall use Commercially Reasonable Efforts to do so in a cost-

 

14



 

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

effective manner.  If as a result of such change, the Fully Burdened Manufacturing Cost exceeds the applicable Cap or Adjusted Cap, then such excess costs will [***].

 

3.7          Compliance with Laws.   AMAG shall comply, and shall use Commercially Reasonable Efforts to ensure and to require that its DSSs shall comply, with all Laws applicable to the manufacture, processing, storage, testing, transport, disposal and other handling of Product by AMAG and its DSSs under this Agreement.  AMAG will maintain, and will require its DSS to maintain, during the term of this Agreement, all government permits, including without limitation health, safety and environmental permits, necessary for AMAG to supply the Product to Takeda in accordance with this Agreement.  Takeda shall provide AMAG with written notice of any additional regulatory requirements that relate to the manufacture of Product for the Licensed Territory.  If such requirements necessitate a change to the Specifications, the Parties shall proceed in accordance with Section 3.6.

 

3.8          Documentation and Samples.   Each Party shall maintain complete, accurate and authentic accounts, notes, data and records pertaining to the methods and facilities such Party uses for the manufacture, processing, testing, packing, labeling, holding and distribution (as applicable) of the Product, in accordance with applicable Laws.  Subject to AMAG’s right to limit disclosure of CMC Information in accordance with the terms of the License Agreement, each Party shall make such records available to the other Party for inspection promptly following receipt of the other Party’s written request, and shall make available to such other Party copies of such records, provided that AMAG may redact CMC Information from such records in accordance with the terms of the License Agreement.  The Parties’ rights and obligations with respect to Samples shall be as set forth in the applicable Quality Agreement.

 

3.9          Product Complaints .  The Parties’ responsibilities with respect to complaints and reports of adverse events relating to the Product in the Field in the Licensed Territory are set forth in the Quality Agreements and the Pharmacovigilance Agreement, respectively.

 

3.10        Recalls .  The Parties’ rights and obligations with respect to recalls are as set forth in Section 7.4 of the License Agreement.  Additional procedures for and consequences of recalls may be set forth in the Quality Agreements and/or the Pharmacovigilance Agreement.

 

3.11        Waste Handling .  With respect to handling of waste related to the Product in a Party’s control or possession (including the disposal of any Product), such Party shall be responsible at its own cost (except as otherwise provided in this Agreement or the License Agreement) to dispose of all such Product and/or related waste in conformance with the applicable material safety data sheet (“ MSDS ”) maintained by AMAG from time to time and all applicable Laws.  AMAG shall provide the MSDS for Drug Substance and the MSDS for Drug Product to Takeda promptly following the Supply Agreement Effective Date and promptly upon any amendments thereto.

 

3.12        Spoilage; Product Yield .  AMAG shall use Commercially Reasonable Efforts to avoid spoilage and minimize scrap loss of materials used in the Manufacture of the Product. Except as provided below, [***], for the type of materials and processes involved in

 

15



 

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

Manufacturing the Product by AMAG or its DSS (which shall apply to Manufacture of the Product by AMAG or its DSS).

 

4.                                       DELIVERY AND ACCEPTANCE.

 

4.1          Delivery; Export Compliance.   For each purchase order submitted by Takeda and accepted by AMAG in accordance with Section 2.4, AMAG shall deliver to the common carrier specified by Takeda in the applicable purchase order the specified quantity of Product within five (5) Days after the delivery dates specified in the applicable purchase order.  Unless otherwise agreed by the Parties, time is of the essence for delivery of the Product in accordance with the delivery date(s) requested in Takeda’s purchase order.  Unless otherwise agreed by the Parties in writing, delivery shall be made FCA (Incoterms 2010) AMAG’s DSS’ facility or Third Party contractor’s storage warehouse set forth on Exhibit F .  As set forth in the Quality Agreements, AMAG may change any such facility or warehouse at which delivery may be made with six (6) months prior written notice to Takeda, and Exhibit F will be deemed amended at the end of such notice period (or such later date as AMAG may specify in its written notice).  AMAG will provide Product in accordance with the terms of this Agreement.  AMAG shall include with each shipment of Product (a) a batch certificate, (b) a certificate of cGMP compliance, (c) a MSDS and (d) a packing list.  At the time of each shipment, AMAG shall transmit to Takeda an electronic copy of the foregoing documents by fax or email, as directed by Takeda.  Takeda shall prepare, obtain, and maintain all necessary import and export licenses, permits or registrations relating to the Product and shall keep AMAG informed regarding the filing or maintenance of any such licenses, permits or registrations.  Takeda shall be responsible for (x) making necessary shipping arrangements and (y) all financial arrangements for shipping and handling of the Product, including freight charges, storage during transit, customs, duties, taxes, and insurance.  Title to any shipment of Product will pass to Takeda when risk of loss passes in accordance with this Section 4.1.

 

5.                                       DELIVERY OF NON-CONFORMING PRODUCT.

 

(a)           Takeda shall notify AMAG of any shipment of Product that does not conform to the Drug Product Specifications, the applicable Quality Agreement or applicable Laws by giving written notice to AMAG within (i) ten (10) Business Days after arrival of such shipment at Takeda’s delivery location at Cerano, Italy, or other delivery location specified in the applicable purchase order, for any nonconformity discoverable through reasonable visual inspection of the packaging of such shipment, and (ii) the earlier of (A) the completion of confirmatory testing of such shipment or (B) ninety (90) Days after delivery of such shipment, for all other nonconformities, including in such notice, in each case (i) and (ii), a description of the nature of the nonconformity ( “Non-Conformity” or “Non-Conforming” ).  Takeda shall notify AMAG in writing as promptly as reasonably practicable (but in no event later than ten (10) Business Days after completion of confirmatory testing for such shipment.  If the Non-Conformity under clause (ii) is latent and could not have been reasonably discovered by Takeda during such ninety (90)-Day period (or earlier completion of confirmatory testing) through reasonable visual inspection or the testing procedures that Takeda is required to perform under

 

16



 

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

the applicable Quality Agreement upon receipt of such shipment, Takeda shall notify AMAG of the Non-Conformity within fifteen (15) Days after discovery.

 

(b)           AMAG shall notify Takeda as promptly as reasonably practicable (but in no event later than thirty (30) Days after receiving Takeda’s notice of a Non-Conformity) whether AMAG agrees that the Product is Non-Conforming.  Irrespective of whether AMAG agrees with Takeda’s assertion of a Non-Conformity, AMAG shall use Commercially Reasonable Efforts to initiate manufacturing of replacement Product for such allegedly Non-Conforming Product as soon as reasonably practicable.

 

(c)           If AMAG agrees that the Product is Non-Conforming, then AMAG shall replace such Non-Conforming Product as soon as reasonably practicable at no additional cost to Takeda, and except for AMAG’s indemnification obligations under Article 8, such replacement of the Non-Conforming Product shall be Takeda’s sole and exclusive remedy and AMAG’s sole obligation with respect to such Non-Conforming Product.

 

(d)           If AMAG disagrees that the Product is Non-Conforming, then such Product shall be submitted to a mutually acceptable Third Party laboratory as soon as reasonably practicable.  The Third Party laboratory shall determine whether such Product is Non-Conforming, and the Parties agree that such laboratory’s determination shall be final and determinative.  The Party against whom the Third Party laboratory rules shall bear all costs of the Third Party testing and all out-of-pocket costs incurred to establish and qualify the Third Party laboratory.

 

(e)           If the Third Party laboratory determines that the Product is Non-Conforming, then as soon as reasonably practicable, AMAG shall supply to Takeda the Product that AMAG initiated manufacturing under sub-section (d) above, at no additional cost to Takeda to the extent that Takeda has already paid for such Non-Conforming Product), and except for AMAG’s indemnification obligations under Article 8, such replacement of the Non-Conforming Product shall be Takeda’s sole and exclusive remedy and AMAG’s sole obligation with respect to such Non-Conforming Product.

 

(f)            If the Third Party laboratory determines that the Product is not Non-Conforming, then Takeda shall pay AMAG for the Product manufactured under sub-section (d) above and supplied to Takeda in accordance with Article 7, as well as the Product initially supplied and identified by Takeda as Non-Conforming.

 

(g)           Takeda shall, at AMAG’s expense, including shipping and handling, freight charges, storage during transit, customs, duties, taxes, Third Party charges for retesting for importation into Europe and insurance, return or destroy, as directed by AMAG, any Product determined to be Non-Conforming as provided in this Article 5.  Takeda shall perform any destruction of Non-Conforming Product in accordance with applicable Law, and shall, upon AMAG’s request, provide AMAG with a customary certificate of destruction attesting to the complete destruction of the subject material and providing reasonably sufficient information

 

17



 

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

detailing and identifying the material destroyed.  Takeda may retain a reasonable quantity of Non-Conforming Product for its own archival purposes.

 

6.                                       SUPPLY SECURITY

 

6.1          Primary Supply Chain and Second Source .  The Parties’ obligations with respect to the Primary Supply Chain and the establishment, regulatory approval and maintenance of a DSS (other than the Primary Supply Chain) for each of Drug Substance, Drug Product Intermediate and Drug Product (the “ Required Sites ”) are set forth in the License Agreement.

 

6.2          Additional Designated Second Source Suppliers or Qualification Activities .

 

(a)           In addition to the Primary Supply Chain and Required Sites, at any time, AMAG may propose to Takeda (i) to qualify, initiate and maintain an additional Designated Second Source Supplier or (ii) additional qualification, initiation or maintenance activities for an existing Designated Second Source Supplier, in each case (i) or (ii) as reasonably required to supply Product for the Licensed Territory or to meet increased demand for Product in the Licensed Territory.  The Parties shall promptly meet and discuss in good faith such proposal, and shall use good faith efforts to agree on whether to conduct the proposed activities and, if so, a detailed plan for implementing the proposal, including the applicable activities and timelines and expenses therefor.  The costs for implementing such proposal shall be allocated to the Parties [***], based on Takeda’s most recent forecast volumes and AMAG’s then-current estimate of Product volumes for [***].

 

(b)           Upon Takeda’s reasonable written request, AMAG shall use Commercially Reasonable Efforts to qualify, initiate and maintain additional DSS manufacturing facilities for Drug Substance, Drug Product Intermediate and/or Drug Product, in addition to the Required Sites.  If Takeda requests any such new DSS, Takeda shall reimburse AMAG for all costs incurred by AMAG (whether internal costs or out-of-pocket costs, all without mark up by AMAG) to qualify, initiate and maintain such additional DSS manufacturing facilities, provided that Capital Equipment expenditures shall be allocated between the Parties.  If the use of such DSS increases the Fully Burdened Manufacturing Cost to a value that exceeds the applicable Cap, Takeda shall [***] reasonably allocated pursuant to Section 2.6.

 

(c)           AMAG shall have the right to source Product from any DSS for supply to Takeda at any time and for any reason, subject to Takeda’s acceptance, not to be unreasonably withheld or delayed, and in accordance with the terms of this Agreement.  If AMAG’s use of any such DSS (other than the Primary Supply Chain and Required Sites) results in an increase in the Fully Burdened Manufacturing Cost of Product, such increase will be allocated to [***], based on Takeda’s most recent forecast volumes and AMAG’s then-current estimate of [***].  For clarity, the Product Price for any Product obtained by AMAG from a DSS and supplied to Takeda shall be subject to the pricing terms set forth in Section 7.1.

 

18



 

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

6.3          Transfer Event .

 

(a)           Right to Obtain Product .  Takeda shall have the right to obtain Product for use in the Licensed Territory directly from a DSS by placing a purchase order through a contract to which AMAG is a party upon an Insolvency Event of AMAG (an “ Insolvency Transfer Event ”).  Upon the occurrence of a Insolvency Transfer Event, Takeda shall notify AMAG in writing of its intent to source from the DSS and shall have the right to place a purchase order with the DSS for that amount of Product that AMAG failed to supply based upon Takeda’s binding purchase orders, plus any additional amount that takes into consideration Takeda’s customer’s orders for the applicable calendar quarter and minimum batch sizes or other minimum supply requirements imposed by a DSS.  For clarity, Takeda’s rights under this Section 6.3(a) are limited solely to obtaining Product from a DSS during the duration of the Insolvency Event, and Takeda shall have no right to receive (or provide to any Third Party) any AMAG Know-How related to Manufacturing of the Product except as otherwise expressly provided in the License Agreement or to the extent that disclosure of AMAG Know-How is reasonably required for Takeda to Finish the Product.  [***].

 

(b)           Cost Sharing .  If Takeda purchases Product from a DSS following an Insolvency Transfer Event as provided in Section 6.3(a), the Parties shall [***].  Takeda shall invoice AMAG [***] on a quarterly basis, providing reasonable documentation therefor, and AMAG shall pay each such invoice within thirty (30) Days after receipt thereof.

 

(c)           Purchase Resumption .  Promptly following the resolution of the deficiency(ies) causing the Insolvency Transfer Event, Takeda shall use Commercially Reasonable Efforts to [***]) within a reasonable time period after AMAG: (i) reasonably demonstrates that it is able to supply Product in accordance with the terms of this Agreement and Takeda’s most recent Commercial Supply Forecast provided under Section 2.2 and (ii) [***] of Drug Product exclusive to Takeda, taking into account any residual Product purchase and other obligations of Takeda to the DSS.

 

(d)           Exclusive Remedy .  So long as AMAG (i) uses Commercially Reasonable Efforts to meet Takeda’s forecasted demand for Product as set forth in Takeda’s forecasts provided under Section 2.2 and (ii) uses Commercially Reasonable Efforts to work with DSSs to supply Product to Takeda (including using Commercially Reasonable Efforts to manage demand and supply of the Product, taking into account the demand for Product for the Licensed Territory and outside the Licensed Territory), Takeda’s right to place purchase orders for Product with a DSS under Section 6.3(a) and the cost sharing provided under Section 6.3(b) shall be Takeda’s sole and exclusive remedy, and AMAG’s sole liability, for AMAG’s failure to supply as set forth in Sections 6.3(a); provided, however, that the foregoing remedy shall not be the sole and exclusive remedy if such failure to supply is caused by AMAG’s or its DSS’s (x) failure to comply with applicable Laws relating to the Manufacture of the Product or (y) gross negligence or willful misconduct.

 

19



 

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

(e)           Termination of Exclusive Supply .  If [***] following an Insolvency Transfer Event, AMAG is unable to meet Takeda’s demand for Product as set forth in Takeda’s most recent Commercial Supply Forecast provided under Section 2.2, then Takeda shall have the right [***].  In such event, AMAG shall no longer be obligated to supply Product to Takeda (and Takeda shall no longer be obligated to purchase Product from AMAG), and Takeda will have the right to purchase all of its requirements of the Product directly from a DSS.  AMAG shall reasonably cooperate with Takeda in the transition to the DSS.  In addition, at Takeda’s written request, AMAG shall undertake promptly, using Commercially Reasonable Efforts, to identify, qualify and maintain one or more new DSSs reasonably acceptable to the Parties to supply Product and Drug Substance for Product.  All costs and expenses for such identification, qualification and maintenance shall be allocated to Takeda and AMAG, respectively, [***], based on Takeda’s most recent forecasts provided under Section 2.2 and AMAG’s then-current estimate of [***].  The Parties shall use good faith efforts to agree on a reasonable allocation of such costs and expenses.

 

7.                                       PRICES AND PAYMENT.

 

7.1          Price.  For all Product delivered to Takeda pursuant to this Agreement, Takeda shall pay to AMAG a price per unlabeled vial determined in accordance with this Section 7.1 (the “ Product Price ”), provided that such amount shall be payable as described in Section 7.2, subject to the true-up procedure described in Section 7.3, and subject to the remaining terms and conditions set forth in this Article 7:

 

(a)           Initial Price Period .  For all Product ordered by Takeda [***] period following the License Agreement Effective Date (the “ Initial Price Period ”):

 

(i)            if the Fully Burdened Manufacturing Cost of Product ordered by Takeda is [***], as set forth in Exhibit C ( as applicable [***], the “ Cap ”) then the Product Price for such Product shall equal the [***]; and

 

(ii)           if the Fully Burdened Manufacturing Cost of Product ordered by Takeda is [***], except as provided in Section 3.6.

 

(b)           Extended Price Period .  For all Product ordered by Takeda during the [***] period following the Initial Price Period (such [***] period, the “ Extended Price Period ”), the Product Price shall be calculated as described above for the Initial Price Period, but subject to the adjustment described in this Section 7.1(b).

 

(i)            At the end of the Initial Price Period, AMAG shall determine the [***] used to calculate the Fully Burdened Manufacturing Cost for Product at the beginning of each [***] after the License Agreement Effective Date ([***] , the “ Baseline Materials Cost ”) .   At the beginning of each [***] in the Extended Price Period, AMAG shall determine the [***] used to calculate the Fully Burdened Manufacturing Cost for Product ordered in such [***] (the “ [***] Materials Cost ”).  If, in any such [***] , the difference between the [***] and the [***] , then (A) AMAG shall determine the “ Adjusted Cap ” for such [***] , and (B) the

 

20



 

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

Product Price for such [***] shall be as described in Section 7.1(a), with the Adjusted Cap substituted for the Cap.  AMAG shall notify Takeda in writing of the Baseline Materials Cost, [***] Materials Cost and any Adjusted Cap promptly after calculation thereof. AMAG will use the Adjusted Cap in the true-up calculation as described in Section 7.3

 

(ii)           Notwithstanding Section 7.1(b)(i), if AMAG first supplies Product to Takeda from a particular DSS during the [***] after the License Agreement Effective Date (such DSS, the “ New DSS ”), then (A) a different Adjusted Cap shall apply to Product supplied by the New DSS and Product supplied by AMAG or any other DSS during the Extended Price Period, (B) the Baseline Materials Cost and Adjusted Cap will be determined on a supplier-by-supplier basis, (C) the Baseline Materials Cost for the New DSS will equal the [***] at the beginning of [***] (the “ Baseline Period ”), and (D) the Cap will apply to the New DSS during the Baseline Period, and the Adjusted Cap for the New DSS will be calculated at the beginning of [***] after the Baseline Period and each [***] thereafter during the Extended Price Period.

 

(c)           After Extended Price Period .  The Product Price for all Product ordered by Takeda after the Extended Price Period shall equal [***].  Following the Extended Price Period, AMAG shall use Commercially Reasonable Efforts to reduce [***] .

 

(d)           Clarifications .  To the extent reasonably practicable, the Product Price for all Product ordered by Takeda shall be consistent with [***] .  Notwithstanding the foregoing in Sections 7.1(a) and (b), in the event of force majeure under Section 12.10 during the Initial Price Period or Extended Price Period, the Product Price for Product ordered during such force majeure event shall equal [***] .

 

7.2          Method of Payment.   AMAG shall invoice Takeda for all Product delivered hereunder during any given calendar year at a single price per vial as described in this Section 7.2 (and a per vial Manufacturing Fee in accordance with Section 2.6 of this Agreement).  For each calendar year, at the time of each shipment of Product hereunder, AMAG shall provide to Takeda a written invoice for Product supplied in such delivery with (i) a Manufacturing Fee per vial of Product in accordance with Section 2.6 of this Agreement and (ii) the amount payable per vial of Product being equal to the average amount per vial that would be payable hereunder if, during the course of such calendar year, Takeda purchased the number of vials forecast in the last Commercial Supply Forecast for such calendar year provided by Takeda to AMAG prior to commencement of such calendar year and the applicable price for such vials determined in accordance with Section 7.1.  All payments due hereunder by one Party to the other Party shall be paid in United States dollars not later than [***] following the receipt of the applicable invoice.  Payment shall be made by wire transfer of immediately available funds into a deposit account designated by a Party from time to time.  If a Party does not receive payment of any sum due to it on or before the due date, simple interest shall thereafter accrue on the sum due until the date of payment at the per annum rate of [***] over the then-current [***] or the maximum rate allowable by applicable Laws, whichever is lower.

 

21



 

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

7.3                                Annual True-Up .

 

(a)                                  Purchase Price True-Up .  Within sixty (60) Days after the end of each calendar year, AMAG shall provide to Takeda a report detailing (i) the total number of vials of Product delivered by AMAG in such calendar year, (ii) a calculation of the aggregate Purchase Price for such Product as calculated under Section 7.1, and (iii) the actual aggregate amount invoiced by AMAG and paid by Takeda for Product delivered in such calendar year.  If the total amount invoiced and paid (i.e., the total amount described in the foregoing clause (iii)) is [***] (ii)), then AMAG shall invoice and Takeda shall pay [***] to AMAG in accordance with Section 7.2. If the total amount invoiced and paid (i.e., the total amount described in the foregoing clause (iii)) [***] (ii)), then AMAG shall credit [***] to the next invoice(s) issued to Takeda under Section 7.2 for Product delivered during the next calendar year until [***] is fully applied.  By way of an illustrative example, [***].  Notwithstanding any other section of this Agreement, AMAG shall have the right to off-set any credits owed by AMAG to Takeda under this Section 7.3(a) in connection with [***] against (i) any amounts owed by Takeda to AMAG in connection with [***] and (ii) any amounts then owed by Takeda to AMAG against [***].

 

(b)                                  Manufacturing Fees True-Up .  Within sixty (60) Days after the end of each calendar year, AMAG shall provide to Takeda a report detailing (i) the [***] for Product delivered in such calendar year, and (ii) the total amount of [***] in such calendar year in accordance with [***].  If the total amount invoiced and paid (i.e., the total amount described in the foregoing clause (i)) [***] to be reimbursed by Takeda in such calendar year (i.e., the total amount described in the foregoing clause (ii)), then AMAG shall credit [***] to the next invoice(s) issued to Takeda under Section 7.2 for Product delivered during the next calendar year until [***] is fully applied.  If the total amount invoiced and paid (i.e., the total amount described in the foregoing clause (i)) [***] to be reimbursed by Takeda in such calendar year (i.e., the total amount described in the foregoing clause (ii)), then AMAG shall invoice and Takeda shall pay [***] to AMAG in accordance with Section 7.2.  Notwithstanding any other section of this Agreement, AMAG shall have the right to off-set any credits owed by AMAG to Takeda under this Section 7.3(b) in connection with the [***] against (i) any amounts owed by Takeda to AMAG in connection with the [***] and (ii) any amounts then owed by Takeda to AMAG against the aggregate of Capital Equipment expenditures to be reimbursed by Takeda that were incurred by AMAG in that particular calendar year or the prior calendar year.

 

7.4                                Taxes.  The Parties will cooperate and use commercially reasonable efforts to minimize the imposition of value added, sales, excise, and other taxes and government charges on the sale and delivery of Product purchased by Takeda.  Takeda will be responsible for payment of any and all taxes (other than taxes based upon the income of AMAG) (including applicable value added, sales, use or similar consumption taxes imposed, and for any customs or import duties, tariffs or taxes imposed as a result of the purchase, sale, use, importation or delivery destination of Product as specified by Takeda.  In the event that any payment made under this Agreement is subject to a deduction and withholding of any tax, [***].  Takeda shall timely pay over to the appropriate tax authority for the account of AMAG, the amount of tax deducted and withheld from the payment made to AMAG. Takeda will promptly provide AMAG

 

22



 

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

with an original receipt or other documentation satisfactory to AMAG evidencing payment of the tax to the tax authority.  Takeda and AMAG will reasonably cooperate in completing and filing documents required under the provisions of any applicable tax treaty or under any other applicable Laws, in order to enable Takeda to reduce or eliminate the amount of any tax that must be deducted and withheld from any payment made to AMAG under this Agreement.  In the event AMAG recovers any tax amounts previously deducted or withheld, all such tax amounts that are recovered by AMAG (net of any out-of-pocket expenses paid by AMAG to recover such tax amounts) shall be promptly paid by AMAG to Takeda.

 

7.5                                Records; Audits .  AMAG shall maintain complete and accurate records in sufficient detail to permit Takeda to confirm the accuracy of the Fully Burdened Manufacturing Costs, Baseline Materials Cost and [***] Materials Cost under this Agreement and to verify AMAG’s compliance with Sections 2.1, 3.12 and 7.1(d), and Takeda shall maintain complete and accurate records in sufficient detail to permit AMAG to confirm the accuracy of any amounts paid to Takeda under Section 6.3(b) and to confirm Takeda’s compliance with its obligations under Section 2.2 to provide a Commercial Supply Forecast that is reasonably consistent with its projected commercial sales of the Product on a quarterly basis.  Upon reasonable prior notice, such records shall be available during regular business hours for a period of three (3) years from the creation of individual records for examination, not more often than once each Fiscal Year, by an independent certified public accountant selected by the other Party and reasonably acceptable to the audited Party, for the sole purpose of verifying the accuracy of such amounts invoiced, AMAG’s compliance with Sections 2.1, 3.12 and 7.1(d), and Takeda’s compliance with Section 2.2.  Any such auditor shall not disclose the audited Party’s Confidential Information, except to the extent such disclosure is necessary to verify the accuracy of the invoices issued by such Party or the amount of payments due by a Party under this Agreement, confirm AMAG’s compliance with Sections 2.1, 3.12 and 7.1(d) or confirm Takeda’s compliance with Section 2.2. Any amounts shown to be owed but unpaid (and not otherwise the subject of a good faith dispute by a Party) shall be paid within [***] from the accountant’s report, plus interest (as set forth in Section 7.2) from the original due date.  Any amounts showed to have been overpaid (and not otherwise the subject of a good faith dispute by a Party) will be refunded within [***] from the accountant’s report.  The auditing Party shall bear the full cost of such audit involving payments of amounts owed hereunder unless such audit discloses an overpayment by the auditing Party or underpayment by the audited Party during the applicable Fiscal Year of more than [***] of the amount due, in which case the audited Party shall bear the full cost of such audit.

 

7.6                                Harmonization .

 

(a)                                  [***]

 

(b)                                  [***]

 

(c)                                   [***]

 

23



 

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

(d)                                  [***]

 

8.                                       REPRESENTATIONS AND WARRANTIES

 

8.1                                Mutual Representations and Warranties.   Each Party hereby represents and warrants to the other Party as of the Supply Agreement Effective Date as follows:

 

(a)                                  Such Party (i) is duly organized, validly existing and in good standing under the laws of the state in which it is organized; (ii) has the power and authority and the legal right to own and operate its property and assets, to lease the property and assets it operates under lease, and to carry on its business as it is now being conducted; and (iii) is in compliance with all requirements of applicable law, except to the extent that any noncompliance would not materially adversely affect such Party’s ability to perform its obligations under this Agreement.

 

(b)                                  Such Party (i) has the power and authority and the legal right to enter into this Agreement and to perform its obligations hereunder and (ii) has taken all necessary action on its part to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder.  This Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid, binding obligation, enforceable against such Party in accordance with its terms, except as such enforcement may be affected by bankruptcy, reorganization, insolvency, moratorium or similar laws affecting creditor’s rights generally and except for general principles of equity.

 

(c)                                   All necessary consents, approvals and authorizations of all governmental authorities and other persons required to be obtained by such Party in connection with this Agreement have been obtained, except for those that cannot be obtained prior to the filing or approval of a Marketing Authorization Application for the Product.

 

(d)                                  The execution and delivery of this Agreement and the performance of such Party’s obligations hereunder (i) do not conflict with or violate any requirement of applicable Laws or any material contractual obligation of such Party and (ii) do not materially conflict with, or constitute a material default or require any consent under, any material contractual obligation of such Party.

 

8.2                                No Debarment.   In the course of Manufacturing the Product, each Party shall not use, during the term of this Agreement any employee, contractor or consultant who has been debarred by any Regulatory Authority, or, to such Party’s Best Knowledge, is the subject of debarment proceedings by a Regulatory Authority. Each Party shall notify the other Party promptly upon becoming aware of any employee, contractor or consultant who has been debarred or is the subject of debarment proceedings by any Regulatory Authority.

 

8.3                                Limited Warranty.   AMAG warrants that Product at the time of delivery to Takeda will: (i) be manufactured, tested and released in accordance with the Specification as set forth in the applicable Quality Agreement, cGMP, applicable Laws and the applicable Quality Agreement, (ii) not be adulterated or misbranded within the meaning of the FD&C Act or other

 

24



 

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

applicable Laws, (iii) conforms to the applicable Drug Product Specifications, and (iv) be delivered not later than six (6) months from the date of manufacture of such Product; provided that (A) Interim Product are known to have a manufacturing date of as set forth on Exhibit A (and Section 8.3(iv) shall not apply to such Interim Product), and (B) in the event of a quality investigation of any Product, such Product will be delivered not later than eight (8) months from the date of manufacture of such Product unless otherwise agreed to by the Parties in writing.

 

8.4                                Warranty Disclaimer .  EXCEPT AS EXPRESSLY PROVIDED IN THE LICENSE AGREEMENT AND THIS AGREEMENT, NO REPRESENTATIONS OR WARRANTIES WHATSOEVER, WHETHER EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, OR NON-MISAPPROPRIATION OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS, ARE MADE OR GIVEN BY OR ON BEHALF OF A PARTY.

 

9.                                       INDEMNIFICATION; LIMITATION OF LIABILITY.

 

9.1                                Indemnity.   In addition to the Parties’ indemnification rights and obligations under Article 11 of the License Agreement for activities other than the Manufacture of Product, the Parties’ shall have the following rights and obligations:

 

(a)                                  Indemnification by AMAG .  AMAG shall defend, indemnify, and hold Takeda and its Affiliates and their respective officers, directors, employees, and agents (the “Takeda Indemnitees” ) harmless from and against any and all Third Party claims, suits, proceedings, damages, expenses (including court costs and reasonable attorneys’ fees and expenses), and recoveries (collectively, “Claims” ) to the extent that such Claims arise out of, are based on, or result from: (i) AMAG’s or its Affiliates’ or DSS’ willful misconduct or gross negligence with respect to the Manufacture of Product; or (ii) AMAG’s breach of its obligations, warranties, representations or covenants under this Agreement.  The foregoing indemnity obligation shall not apply to the extent (x) that the Takeda Indemnitees fail to comply with the indemnification procedures set forth in Section 9.1(c) and AMAG’s defense of the relevant Claims is materially prejudiced by such failure, or (y) of any Claim for which Takeda is required to indemnify any AMAG Indemnitee under this Agreement or the License Agreement.

 

(b)                                  Indemnification by Takeda .  Takeda shall defend, indemnify, and hold AMAG and its Affiliates and its DSS and their respective officers, directors, employees, and agents (the “ AMAG Indemnitees ”) from and against any and all Claims to the extent that such Claims arise out of, are based on, or result from: (i) Takeda’s or its Affiliates’ or contract manufacturers’ Manufacture of Product; or (ii) Takeda’s breach of its obligations, warranties, representations or covenants under this Agreement.  The foregoing indemnity obligation shall not apply to the extent (x) that the AMAG Indemnitees fail to comply with the indemnification procedures set forth in Section 9.1(c) and Takeda’s defense of the relevant Claims is materially prejudiced by such failure, or (y) of any Claim for which AMAG is required to indemnify any Takeda Indemnitee under this Agreement or the License Agreement.

 

25



 

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

(c)                                   Indemnification Procedures.  The Party claiming indemnity under this Section 9.1 (the “ Indemnified Party ”) shall give written notice to the Party from whom indemnity is being sought (the “ Indemnifying Party ”) in a reasonably timely manner after learning of such Claim.  The Indemnified Party shall provide the Indemnifying Party with reasonable assistance, at the Indemnifying Party’s expense, in connection with the defense of the Claim for which indemnity is being sought.  The Indemnified Party may participate in and monitor such defense with counsel of its own choosing at its sole expense; provided, however, the Indemnifying Party shall have the right to assume and conduct the defense of the Claim with counsel of its choice.  The Indemnifying Party shall not settle any Claim without the prior written consent of the Indemnified Party, not to be unreasonably withheld or delayed, unless the settlement involves only the payment of money.  The Indemnified Party shall not settle any such Claim without the prior written consent of the Indemnifying Party.  If the Indemnifying Party does not assume and conduct the defense of the Claim as provided above, (i) the Indemnified Party may defend against, and consent to the entry of any judgment or enter into any settlement with respect to, the Claim in any manner the Indemnified Party may deem reasonably appropriate (and the Indemnified Party need not consult with, or obtain any consent from, the Indemnifying Party in connection therewith), and (ii) the Indemnifying Party will remain responsible to indemnify the Indemnified Party as provided in this Section 9.1.

 

9.2                                Limitation of Liability.   NEITHER PARTY WILL BE LIABLE TO THE OTHER PARTY FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, PUNITIVE, OR INDIRECT DAMAGES ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES.  NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION 9.2 IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF THE PARTIES UNDER THIS ARTICLE 9 OR UNDER ARTICLE 11 OF THE LICENSE AGREEMENT, OR DAMAGES AVAILABLE FOR A PARTY’S BREACH OF CONFIDENTIALITY OBLIGATIONS IN ARTICLE 10 OR UNDER ARTICLE 12 OF THE LICENSE AGREEMENT.

 

10.                                CONFIDENTIALITY.

 

10.1                         Confidentiality.   The Parties agree that any Confidential Information (as defined in the License Agreement) of a Party disclosed by such Party to the other Party under this Agreement shall be deemed to have been disclosed under the License Agreement and shall be subject to all the rights and obligations of the Parties under the provisions of Article 12 and, if applicable, Section 5.1(b), of the License Agreement.  For clarity, Takeda agrees and acknowledges that the Specifications and the Acceptance Tests are the Confidential Information of AMAG.

 

11.                                TERM AND TERMINATION.

 

11.1                         Term.   This Agreement shall commence on the Supply Agreement Effective Date and shall continue in effect until the expiration or termination of the License Agreement.

 

26



 

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

11.2                         Surviving Obligations.   Termination or expiration of this Agreement shall not (a) affect any other rights of either Party that may have accrued up to the date of such termination or expiration or (b) relieve Takeda of its obligation to pay to AMAG sums due in respect of firm orders of Product submitted prior to termination or expiration of this Agreement.  The provisions of ARTICLES 5, 9, 10 and 12 and Sections 3.8, 7.5, 8.4 and 11.2 shall survive the termination or expiration of this Agreement.

 

12.                                GENERAL TERMS.

 

12.1                         Dispute Resolution.  Except as expressly provided in Section 5(c) of this Agreement and subject to Sections 14.5 and 14.6 of the License Agreement, any dispute between the Parties arising out or relating to this Agreement or any Quality Agreement that the Parties are unable to resolve within [***] after such dispute is first identified by either Party in writing to the other, shall be referred by the Parties to the Designated Executive for each Party for attempted resolution by good faith negotiations within [***] after such notice is received.  If any such dispute is not resolved by such Designated Executives within such period, either Party may at any time thereafter invoke the ADR provisions set forth in Exhibit E to the License Agreement.

 

12.2                         Independent Contractors.   Each Party shall act solely as an independent contractor, and nothing in this Agreement shall be construed to give either Party the power or authority to act for, bind, or commit the other Party in any way.  Nothing herein shall be construed to create the relationship of partners, principal and agent, or joint-venture partners between the Parties.

 

12.3                         English Language; Governing Law .  This Agreement was prepared in the English language, which language shall govern the interpretation of, and any dispute regarding, the terms of this Agreement.  This Agreement and all disputes arising out of or related to this Agreement or any breach hereof shall be governed by and construed under the laws of the State of New York, United States of America, without giving effect to any choice of law principles that would require the application of the laws of a different state.  The UN Convention on Contracts for the International Sale of Goods is expressly disclaimed.

 

12.4                         Notice .  Any notice required or permitted to be given under this Agreement shall be in writing, shall specifically refer to this Agreement, and shall be addressed to the appropriate Party at the address specified below or such other address as may be specified by such Party in writing in accordance with this Section 12.4, and shall be deemed to have been given for all purposes (a) when received, if hand-delivered or sent by a reputable courier service, or (b) five (5) business Days after mailing, if mailed by first class certified or registered air mail, postage prepaid, return receipt requested.

 

If to AMAG:

 

AMAG Pharmaceuticals, Inc.

 

 

1100 Winter Street

 

 

Waltham, MA 02451

 

27



 

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

 

USA

 

 

Attn: General Counsel

 

 

 

 

 

AMAG Pharmaceuticals, Inc.

 

 

1100 Winter Street

 

 

Waltham, MA 02451

 

 

USA

 

 

Attn: Chief Business Officer

 

 

 

With a copy to:

 

Goodwin Procter LLP

 

 

Exchange Place

 

 

53 State Street

 

 

Boston, MA 02109

 

 

USA

 

 

Attn: Stuart Cable, Esq.

 

 

 

If to Takeda:

 

Takeda Pharmaceuticals International GmbH

 

 

Thurgauerstrasse 130

 

 

CH-8152 Glattpark-Opfikon (Zurich)

 

 

 

 

 

Takeda Pharma A/S

 

 

Langebjerg 1

 

 

4000 Roskilde

 

 

Denmark

 

 

Attn: Operations External Supply

 

 

 

 

 

Takeda Pharmaceuticals International GmbH

 

 

Corporate Legal

 

 

Thurgauerstrasse 130

 

 

CH-8152 Glattpark-Opfikon

 

 

Switzerland

 

 

Attn: General Counsel

 

12.5                         Severability.   If any one or more of the provisions of this Agreement is held to be invalid or unenforceable by any court of competent jurisdiction from which no appeal can be or is taken, the provision shall be considered severed from this Agreement and shall not serve to invalidate any remaining provisions hereof.  The Parties shall make a good faith effort to replace any invalid or unenforceable provision with a valid and enforceable one such that the objectives contemplated by the Parties when entering this Agreement may be realized.

 

12.6                         No Waiver.   Any delay in enforcing a Party’s rights under this Agreement or any waiver as to a particular default or other matter shall not constitute a waiver of such Party’s

 

28



 

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

rights to the future enforcement of its rights under this Agreement, except with respect to an express written and signed waiver relating to a particular matter for a particular period of time.

 

12.7                         Entire Agreement.   This Agreement and the exhibits attached hereto, along with the License Agreement and the Letter Agreement, constitute the entire, final, complete and exclusive agreement between the Parties and supersede all previous agreements or representations, written or oral, with respect to the subject matter of this Agreement, including the Interim Agreements, which are hereby terminated in accordance with their terms.  This Agreement may not be modified or amended except in a writing signed by a duly authorized representative of each Party.

 

12.8                         Nonassignability; Binding on Successors.   Neither Party may assign or transfer this Agreement or any rights or obligations hereunder without the prior written consent of the other, except that a Party may make such an assignment without the other Party’s consent to its Affiliates or to a Third Party successor to substantially all of the business of such Party in connection with a Change of Control of such Party under which the License Agreement is assigned or transferred to such Third Party.  Any successor or assignee of rights and/or obligations permitted hereunder shall, in writing to the other Party, expressly assume performance of such rights and/or obligations.  Any permitted assignment shall be binding on the successors of the assigning Party.  Any assignment or attempted assignment by either Party in violation of the terms of this Section 12.8 shall be null, void and of no legal effect.

 

12.9                         Performance by Affiliates .  Each Party may discharge any obligations and exercise any right hereunder through any of its Affiliates, including, in the case of TPC, Takeda.  Each Party hereby guarantees the performance by its Affiliates of such Party’s obligations under this Agreement, and shall cause its Affiliates to comply with the provisions of this Agreement in connection with such performance.  Any breach by a Party’s Affiliate of any of such Party’s obligations under this Agreement shall be deemed a breach by such Party, and the other Party may proceed directly against such Party without any obligation to first proceed against such Party’s Affiliate. The Parties agree and acknowledge the confirmation of TPC with respect to such obligation in the Letter Agreement.

 

12.10                  Force Majeure.   Both Parties shall be excused from the performance of their obligations under this Agreement to the extent that such performance is prevented by force majeure and the nonperforming Party promptly provides notice of the prevention to the other Party.  Such excuse shall be continued so long as the condition constituting force majeure continues and the nonperforming Party takes reasonable efforts to remove the condition.  For purposes of this Agreement, force majeure shall include conditions beyond the control of the Parties, including an act of God, war, civil commotion, terrorist act, labor strike or lock-out, epidemic, failure or default of public utilities or common carriers, destruction of production facilities or materials by fire, earthquake, storm or like catastrophe, and failure of plant or machinery (provided that such failure could not have been prevented by the exercise of skill, diligence, and prudence that would be reasonably and ordinarily expected from a skilled and experienced person engaged in the same type of undertaking under the same or similar

 

29



 

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

circumstances). If a force majeure persists for more than [***], then the Parties will discuss in good faith the modification of the Parties’ obligations under this Agreement in order to mitigate the delays caused by such force majeure .

 

12.11                  Counterparts.   This Agreement may be executed in one (1) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

 

[Signature page follows]

 

30



 

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

SIGNATURE PAGE TO SUPPLY AGREEMENT

 

IN WITNESS WHEREOF, each Party has caused this Supply Agreement to be signed and delivered by its duly authorized officer or representative as of the Supply Agreement Effective Date.

 

 

AMAG PHARMACEUTICALS, INC.

 

 

 

 

 

By:

/s/ William K. Heiden

 

 

 

 

Name: William K. Heiden

 

 

 

Title: President and Chief Executive Officer

 

 

 

Date:  2/7/14

 

 

 

TAKEDA PHARMACEUTICALS INTERNATIONAL GMBH

 

 

 

 

By:

/s/ Dr. Barthold Piening

 

 

 

Name: Dr. Barthold Piening

 

 

 

Title: Executive Vice President Operations

 

 

 

 

 

By:

/s/ Alexander Maechler

 

 

 

Name: Alexander Maechler

 

 

 

Title: Senior Director Corp. Legal

 

 



 

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

EXHIBIT A

INTERIM PRODUCT BATCHES

 

Region

 

Lot #

 

Lot Size

 

Mfg date
Mon/YR

 

AMAG Release
Status

 

Vials with Takeda

[***]

 

[***]

 

[***]

 

[***]

 

[***]

 

[***]

 

 

 

 

 

 

 

 

 

 

 

[***]

 

[***]

 

[***]

 

[***]

 

[***]

 

[***]

[***]

 

[***]

 

[***]

 

[***]

 

[***]

 

[***]

[***]

 

[***]

 

[***]

 

[***]

 

[***]

 

[***]

[***]

 

[***]

 

[***]

 

[***]

 

[***]

 

[***]

[***]

 

[***]

 

[***]

 

[***]

 

[***]

 

[***]

[***]

 

[***]

 

[***]

 

[***]

 

[***]

 

[***]

[***]

 

[***]

 

[***]

 

[***]

 

[***]

 

[***]

[***]

 

[***]

 

[***]

 

[***]

 

[***]

 

[***]

 



 

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

EXHIBIT B

COMMERCIAL SUPPLY FORECASTING

 

[***]

 

C-1



 

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

EXHIBIT C

PRODUCT PRICE DURING INITIAL PRICE PERIOD

 

[***]

 

[***]

[***]

 

[***]

[***]

 

[***]

[***]

 

[***]

[***]

 

[***]

 

D-1



 

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

EXHIBIT D

 

MINIMUM ORDER QUANTITY

 

Regulatory Jurisdiction

 

Minimum Order Quantity

 

Canada

 

Switzerland

 

European Union

 

 

[***]

All other countries and
regions of the Licensed
Territory

 

[***] , unless agreed otherwise

by the Parties in writing

 

E-1



 

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

EXHIBIT E

 

CAPITAL EQUIPMENT EXPENDITURES

 

[***]

 

F-1



 

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.  ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

EXHIBIT F

 

LOCATIONS OF DSS AND THIRD PARTY CONTRACTOR WAREHOUSE

 

DSS and Third Party Contractor
Warehouse

 

Locations

Drug Substance & Drug Product Intermediate

 

SAFC

3300 South Second St.

Saint Louis, MO 63118

USA

 

 

 

Drug Product

 

DSM

5900 Martin Luther King Jr. Hwy

Greenville, NC 27834

USA

 

 

 

Third Party Warehouse

 

PACKAGING COORDINATOR’S INC.

(successor in interest to Catalent Pharma Solutions)

3001 Red Lion Road

Philadelphia, PA 19114

USA

 

PACKAGING COORDINATOR’S INC.

(successor in interest to Catalent Pharma Solutions)

2200 Lake Shore Drive

Woodstock, IL, 60098

USA

 

G-1


Exhibit 10.2

 

[AMENDED AND RESTATED] EMPLOYMENT AGREEMENT

 

This [Amended and Restated] Employment Agreement (the “ Agreement ”) is entered into as of [Date] (the “ Effective Date ”) by and between AMAG Pharmaceuticals, Inc., a Delaware corporation with offices at 1100 Winter Street, Waltham, MA 02451 (together with its subsidiaries and affiliates, the “ Company ”), and [ Executive Name ] of [ Address ] (“ you ”).

 

[WHEREAS, you and the Company previously entered into that certain Employment Agreement, dated [ Date ], which was amended by the Amendment to Employment Agreement, dated [ Date ], the “ Prior Agreement ”);

 

WHEREAS, you and the Company desire to amend and restate the Prior Agreement on the terms and conditions set forth herein.]

 

NOW THEREFORE, in consideration of the premises and mutual agreements hereinafter set forth, and intending to be legally bound hereby, the parties hereto agree as follows:

 

1.                                       Position; Duties .

 

(a)                                  Position .  You shall continue to serve as [ Title ] of the Company.

 

(b)                                  Duties .  You shall perform for the Company the duties customarily associated with the office of [ Title ] and such other duties as may be assigned to you from time to time by the Company’s [ Title ] or the Company’s Board of Directors (the “ Board ”) that are consistent with the duties normally performed by those performing the role of the most senior executives of similar entities.  You shall devote substantially your full business time and best efforts to the performance of your duties hereunder and the business and affairs of the Company and will not undertake or engage in any other employment, occupation or business enterprise; provided , however , that you may participate as a member of the board of directors or advisory board of other entities and in professional organizations and civic and charitable organizations; provided further , that any such positions are disclosed to the Chief Executive Officer and/or the Board or the Audit Committee thereof and do not materially interfere with your duties and responsibilities to the Company.  You shall be based in the Company’s principal offices, which currently are in Waltham, Massachusetts.

 

2.                                       Term .  The term of this Agreement shall be for a three (3) year period commencing on the Effective Date unless terminated earlier pursuant to Section 4 below (the “ Initial Term ”).  The term of this Agreement shall automatically renew for additional three-year terms (each, a “ Renewal Term ”) following the Initial Term and any Renewal Term unless either party provides written notice to the other party at least sixty (60) days before the end of the Initial Term or any Renewal Term, as applicable, that it does not desire to renew this Agreement, in which case this Agreement shall expire at the end of the Initial Term or any Renewal Term, as applicable.  The Initial Term and any Renewal Term are referred to herein collectively as the “ Term .”

 



 

3.                                       Compensation and Benefits .  The Company shall pay you the following compensation and benefits for all services rendered by you under this Agreement (subject to any tax withholdings required by law):

 

(a)                                  Base Salary .  The Company will pay you a base salary at the rate currently in effect and, effective February 17, 2014, at the annualized rate of [$XXX,XXX ] (“ Base Salary ”), minus withholdings as required by law and other deductions authorized by you, which amount shall be paid in equal installments at the Company’s regular payroll intervals, but not less often than monthly.  Your base salary may be increased annually by the Board or the Compensation Committee in their sole discretion.

 

(b)                                  Bonus .  You will be eligible to receive an annual performance bonus (the “ Annual Bonus ”) of up to [ XX% ] of Base Salary for each fiscal year during the Term of this Agreement based on the extent to which, in the discretion of the Board or the Compensation Committee in consultation with the Chief Executive Officer and/or your supervisor you achieve or exceed specific and measurable individual and Company performance objectives established by the Board or the Compensation Committee in consultation with the Chief Executive Officer and/or your supervisor and communicated to you in advance.  The exact amount of the bonus for any year during the Term shall be determined by the Board or the Compensation Committee in its sole discretion and may be more than the target bonus in the event you achieve all of your personal and Company performance objectives or less than the target bonus if you do not achieve all of your personal and Company performance objectives.  The Company shall pay the Annual Bonus no later than two and a half months after the end of the fiscal year to which the applicable bonus relates.  Unless otherwise provided herein, no bonus shall be deemed to have been earned by you for any year in which you are not actively employed by the Company on the last day of the fiscal year to which the bonus relates.

 

(c)                                   Equity Compensation .  You shall be eligible to receive stock options or other equity compensation under the Company’s equity incentive plans as determined by the Board or the Compensation Committee from time to time.

 

(d)                                  Vacation .  You will receive four (4) weeks of paid vacation per calendar year which shall accrue ratably on a monthly basis.

 

(e)                                   Benefits .  You will be eligible to participate in all group health, dental, 401(k) and other insurance and/or benefit plans that the Company may offer to similarly situated executives of the Company from time to time on the same terms as offered to such other executives.

 

(f)                                    Business Expenses .  The Company will reimburse you for all reasonable and usual business expenses incurred by you in the performance of your duties hereunder in accordance with the Company’s expense reimbursement policy.

 

4.                                       Termination .  Your employment with the Company may be terminated prior to the expiration of the Term as follows:

 

(a)                                  Death .  This Agreement shall terminate automatically upon your death.

 

2



 

(b)                                  Disability .  The Company may terminate your employment in accordance with applicable laws in the event that you shall be prevented, by illness, accident, disability or any other physical or mental condition (to be determined by means of a written opinion of a competent medical doctor chosen by mutual agreement of the Company and you or your personal representative(s)) from substantially performing your duties and responsibilities hereunder for one or more periods totaling one hundred and twenty (120) days in any twelve (12) month period.

 

(c)                                   By the Company for Cause .  The Company may terminate your employment for “Cause” upon written notice to you.  For purposes of this Agreement, “ Cause ” shall mean any of:  (i) fraud, embezzlement or theft against the Company or any of its affiliates; (ii) you are convicted of, or plead guilty or no contest to, a felony; (iii) willful nonperformance by you (other than by reason of illness) of your material duties hereunder and failure to remedy such nonperformance within ten (10) business days following written notice from the Chief Executive Officer, the Board and/or your supervisor identifying the nonperformance and the actions required to cure it; or (iv) you commit an act of gross negligence, engage in willful misconduct or otherwise act with willful disregard for the Company’s best interests, and you fail to remedy such conduct within ten (10) business days following written notice from the Chief Executive Officer, the Board and/or your supervisor identifying the gross negligence, willful misconduct or willful, disregard and the actions required to cure it (if such conduct can be cured).

 

(d)                                  By the Company Other Than For Death, Disability or Cause .  The Company may terminate your employment other than for Cause, disability or death upon thirty (30) days prior written notice to you.

 

(e)                                   By You For Good Reason or Any Reason .  You may terminate your employment at any time without Good Reason upon thirty (30) days prior written notice to the Company and with Good Reason as described in this Section 4(e).  For purposes of this Agreement, “ Good Reason ” shall mean that any of the following occurs without your prior written consent:  (i) a material adverse change in your title, position, duties or responsibilities; (ii) a material reduction by the Company in your Base Salary or your target Annual Bonus opportunity in the total annual amount that you are then eligible to receive, unless such reduction is in connection with a proportionate reduction of compensation applicable to all other executive officers; (iii) any relocation of your principal place of business to a location more than 50 miles from the Company’s current executive offices in Waltham, MA; provided, however, that this clause (iii) will not apply to the extent that any new office location is less than 50 miles from your residence; or (iv) a material breach by the Company of any of the terms or provisions of this Agreement.  Before you may resign for Good Reason, (i) you must provide written notice to the Company describing the event, condition or conduct giving rise to Good Reason within 30 days of the initial occurrence of the event, condition or conduct; (ii) the Company must fail to remedy or cure the alleged Good Reason within the 30 day period after receipt of such notice; and (iii) you must resign effective not later than 30 days after the end of the cure period.

 

5.                                       Payment Upon Termination .  In the event that your employment with the Company terminates, you will be paid the following (subject to any tax withholdings required by law):

 

3



 

(a)                                  Termination for Any Reason .  In the event that your employment terminates for any reason, the Company shall pay you for the following items that were earned and accrued but unpaid as of the date of your termination:  (i) your Base Salary; (ii) a cash payment for all accrued, unused vacation calculated at your then Base Salary rate; (iii) reimbursement for any unpaid business expenses; and (iv) such other benefits and payments to which you may be entitled by law or pursuant to the benefit plans of the Company then in effect.  In addition, if your employment terminates due to your death, the Board or the Compensation Committee, in consultation with the Chief Executive Officer and/or your supervisor, shall determine the extent to which any of the individual performance objectives established pursuant to Section 3(b)  above were met as of the time of your death.  If, based on that determination, the Board or the Compensation Committee determines that a bonus is due, the Company shall pay your estate an amount equal to such bonus, pro-rated for the portion of the fiscal year elapsed as of the time of your death,

 

(b)                                  Termination Without Cause or for Good Reason .  In addition to the payments provided for in Section 5(a) , in the event that (i) the Company terminates your employment other than for death, disability or Cause pursuant to Section 4(d)  or you terminate your employment for Good Reason pursuant to Section 4(e) ; (ii) you comply fully with all of your obligations under all agreements between the Company and you; and (iii) you execute, deliver to the Company, within 60 days of the termination of your employment, and do not revoke a general release (in a form acceptable to the Company) releasing and waiving any and all claims that you have or may have against the Company, its directors, officers, employees, agents, successors and assigns with respect to your employment (other than any obligation of the Company set forth herein which specifically survives the termination of your employment), then (i) the Company will provide you with 12 months of severance pay based on your then current Base Salary and (ii) all time-based stock options and other time-based equity awards you hold in which you would have vested if you had been employed for an additional 12 months following the date of the termination of your employment shall vest and become exercisable or nonforfeitable on the date that the release referred to above may no longer be revoked.  The foregoing severance shall be paid in equal installments over the severance period in accordance with the Company’s usual payroll schedule, commencing on the date that the release referred to above may no longer be revoked.  This Section 5(b)  shall not apply during the one year period following a Change of Control (as defined below) in which case Section 5(c)  shall apply.  Notwithstanding anything to the contrary herein, if any of the payments and benefits provided for in this Section 5(b)  constitute non-qualified deferred compensation subject to Section 409A (as defined below) and, the sixty (60) day period in which you must execute the release begins in one calendar year and ends in another, the payments and benefits provided for in this Section 5(b)  shall commence, be made or become effective in the later calendar year.

 

(c)                                   Change of Control .  In the event that (i) within one year from the date a Change of Control (as defined below) of the Company occurs, the Company (for purposes of this Section, such term to include its successor) terminates your employment other than for Cause pursuant to Section 4(c) , death or disability or you terminate your employment with Good Reason; (ii) you comply fully with all of your obligations under all agreements between the Company and you; and (iii) within 60 days of termination of your employment you execute and deliver to the Company and do not revoke a general release (in a form acceptable to the Company) releasing and waiving any and all claims that you have or may have against the

 

4



 

Company and its directors, officers, employees, agents, successors and assigns with respect to your employment (other than any obligation of the Company set forth herein which specifically survives the termination of your employment), then:

 

·                   the Company will pay you 12 months of severance pay based on your then current Base Salary, with such severance to be paid in equal installments over the severance period in accordance with the Company’s usual payroll schedule, commencing on the date that the release referred to above may no longer be revoked;

 

·                   the Company will pay you, on the first payroll date after the revocation period of the release set forth above expires, in a lump sum, one times your target annual bonus amount for the year in which the Change of Control occurs;

 

·                   the Company will pay or reimburse you for the premiums for continued coverage for you and your eligible dependents in the same amounts and for the same coverage in effect immediately prior to your termination from employment, under the Company’s group health and dental plans until the earlier of:  (i) 24 months from the date of termination of your employment; or (ii) the date you are provided with health and dental coverage by another employer’s health and dental plan (and, for purposes of clarity, if the Company is unable to extend coverage to you under its group health and dental plans due to your termination from active employment status, then, to receive this benefit, you must elect continuation coverage under COBRA and/or purchase an individual insurance policy, and the Company shall have no obligation to pay or reimburse insurance premiums or otherwise provide coverage if you fail to elect COBRA or obtain an individual policy); and

 

·                   all time-based, unvested outstanding stock options, restricted stock units and other equity incentives that were granted to you before the Change of Control occurred shall, without further action, become vested in full on the date that the release referred to above may no longer be revoked.

 

For purposes of this Agreement, “ Change of Control ” shall mean the first to occur of any of the following: (a) any “person” or “group” (as defined in the Securities Exchange Act of 1934, as amended) becomes the beneficial owner of a majority of the combined voting power of the then outstanding voting securities with respect to the election of the Board; (b) any merger, consolidation or similar transaction involving the Company, other than a transaction in which the stockholders of the Company immediately prior to the transaction hold immediately thereafter in the same proportion as immediately prior to the transaction not less than 50% of the combined voting power of the then, voting securities with respect to the election of the Board of Directors of the resulting entity; (c) any sale of all or substantially all of the assets of the Company; or (d) any other acquisition by a third party of all or substantially all of the business or assets of the Company, as determined by the Board, in its sole discretion.  The payments, benefits and acceleration of vesting of stock options, restricted stock units and other equity incentives provided in this Section 5(c)  shall override and replace with respect to you any Company wide policy with respect to payments, benefits and/or acceleration of vesting upon a Change of Control.  After the one year period following a Change of Control, this Section 5(c)  shall no longer apply, and Section 5(b)  shall continue to apply.  In the event that upon a Change of

 

5



 

Control, the Company or the successor to or acquiror of the Company’s business (whether by sale of outstanding stock, merger, sale of substantially all the assets or otherwise) elects not to assume all the then unvested outstanding stock options, restricted stock units and other equity incentives that were granted to you before the Change of Control occurred, such securities shall immediately without further action become vested in full effective no later than the effective date of the Change of Control and you shall receive the value of such stock options, restricted stock units and other equity incentives as provided in the applicable acquisition agreement (or if no such provision is made, in the applicable equity incentive plan).

 

Notwithstanding anything to the contrary herein, if any of the payments and benefits provided for in this Section 5(c)  constitute non-qualified deferred compensation subject to Section 409A and the sixty (60) day period in which you must execute the release begins in one calendar year and ends in another, the payments and benefits provided for in this Section 5(c)  shall commence, be made or become effective in the later calendar year.

 

(d)                                  Death/Disability .  In addition to the payments provided for in Section 5(a) , in the event of your death or the termination of your employment, due to your disability in accordance with Section 4(b)  above, all unvested outstanding stock options, restricted stock units and other equity incentives that were held by you at the time of your death or termination of employment due to disability shall immediately become fully vested, and exercisable by you or your personal representatives, heirs or legatees, as the case may be, at any time prior to the expiration of one (1) year from the date of your death or disability, but in no event after the expiration of the term of the applicable equity award agreement.

 

6.                                       Nonsolicitation Covenant; Non-Competition; Injunctive Relief .  In order to protect the Company’s confidential information and good will, and in exchange for the additional equity rights granted you under Sections 5(b), your employment or continued employment, and other good and valuable consideration contained in this Agreement, during your employment and for a period of twelve (12) months following the termination of your employment for any reason (the “ Restricted Period ”), you will not directly or indirectly, whether as owner, partner, shareholder, director, manager, consultant, agent, employee, co-venturer or otherwise, engage, participate or invest in any business activity anywhere in the world that (i) develops, manufactures or markets (A) an intravenous iron replacement therapeutic, (B) a mucoadhesive oral wound rinse or other device that is indicated for the management of oral mucositis/stomatitis, or (C) other therapeutic products acquired, developed or researched by the Company during the Term, or (ii) develops, manufactures or markets any products, or performs any services, that are otherwise competitive with or similar to the products or services of the Company, or products or services that the Company has under development or that are the subject of active planning at any time during your employment; provided that this shall not prohibit any possible investment in publicly traded stock of a company representing less than one percent of the stock of such company.  In addition, during the Restricted Period, you will not, directly or indirectly, in any manner, other than for the benefit of the Company, (a) call upon, solicit, divert, take away, accept or conduct any business from or with any of the customers or prospective customers of the Company or any of its suppliers, and/or (b) solicit, entice, attempt to persuade any other employee or consultant of the Company to leave the Company for any reason or otherwise participate in or facilitate the hire, directly or through another entity, of any person who is employed or engaged by the Company or who was employed or engaged by the

 

6



 

Company within six (6) months of any attempt to hire such person.  You acknowledge and agree that if you violate any of the provisions of this Section, the running of the Restricted Period will be extended by the time during which you engage in such violation(s).  You understand that the restrictions contained in this Agreement are necessary for the protection of the business and goodwill of the Company and you consider them to be reasonable for such purpose.  Any breach of this Agreement is likely to cause the Company substantial and irrevocable damage and therefore, in the event of such breach, the Company, in addition to such other remedies which may be available, will be entitled to specific performance and other injunctive relief, without the posting of a bond.  If you violate this Agreement, in addition to all other remedies available to the Company at law, in equity, and under contract, you agree that you are obligated to pay all the Company’s costs of enforcement of this Agreement, including attorneys’ fees and expenses.  This Section 6 shall supplement, and shall not limit or be limited by, any other restrictive covenant agreement to which you and the Company are parties or any other restrictive covenant obligations you have to the Company.

 

7.                                       Assignment .  This Agreement and the rights and obligations of the parties hereto shall bind and inure to the benefit of any successor of the Company by reorganization, merger or consolidation and any assignee of all or substantially all of its business and properties.  Neither this Agreement nor any rights or benefits hereunder may be assigned by you, except that, upon your death, your earned and unpaid economic benefits will be paid to your heirs or beneficiaries.

 

8.                                       Interpretation and Severability .  It is the express intent of the parties that (a) in case any one or more of the provisions contained in this Agreement shall for any reason be held to be excessively broad as to duration, geographical scope, activity or subject, such provision shall be construed by limiting and reducing it as determined by a court of competent jurisdiction, so as to be enforceable to the fullest extent compatible with applicable law; and (b) in case any one or more of the provisions contained in this Agreement cannot be so limited and reduced and for any reason is held to be invalid, illegal or unenforceable, such invalidity, illegality or unenforceability shall not affect the other provisions of this Agreement, and this Agreement shall be construed as if such invalid, illegal or unenforceable provision had never been contained herein.

 

9.                                       Notices .  Any notice that you or the Company are required to give the other under this Agreement shall be given by personal delivery, recognized overnight, courier service, or registered or certified mail, return receipt requested, addressed in your case to you at your last address of record with the Company, or at such other place as you may from time to time designate in writing, and, in the case of the Company, to the Company at its principal office to the attention of the President and Chief Executive Officer, or at such other office as the Company may from time to time designate in writing.  The date of actual delivery of any notice under this Section 9 shall be deemed to be the date of receipt thereof.

 

10.                                Waiver .  No consent to or waiver of any breach or default in the performance of any obligation hereunder shall be deemed or construed to be a consent to or waiver of any other breach or default in the performance of any of the same or any other obligations hereunder.  No waiver hereunder shall be effective unless it is in writing and signed by the waiving party.

 

7



 

11.                                Complete Agreement; Modification .  This Agreement sets forth the entire agreement of the parties with respect to the subject matter hereof, and supersedes any previous oral or written communications, negotiations, representations, understandings, or agreements between them, including the Prior Agreement.  Any modification of this Agreement shall be effective only if set forth in a written document signed by you and a duly authorized officer of the Company.

 

12.                                Headings .  The headings of the Sections hereof are inserted for convenience only and shall not be deemed to constitute a part, or affect the meaning, of this Agreement.

 

13.                                Counterparts .  This Agreement may be signed in two (2) counterparts, each of which shall be deemed an original and both of which shall together constitute one agreement.

 

14.                                Choice of Law; Jurisdiction .  This Agreement shall be deemed to have been made in the Commonwealth of Massachusetts, and the validity, interpretation and performance of this Agreement shall be governed by, and construed in accordance with, the laws of Massachusetts, without regard to conflict of law principles.  You hereby consent and submit without limitation to the jurisdiction of courts in Massachusetts in connection with any action arising out of this Agreement, and waive any right to object to any such forum as inconvenient or to object to venue in Massachusetts.  You agree that, in any action arising out of this Agreement, you will accept service of process by registered mail or the equivalent directed to your last known address or by such other means permitted by such court.

 

15.                                Advice of Counsel; No Representations .  You acknowledge that you have been advised to review this Agreement with your own legal counsel, that prior to entering into this Agreement, you have had the opportunity to review this Agreement with your attorney, and that the Company has not made any representations, warranties, promises or inducements to you concerning the terms, enforceability or implications of this Agreement other than as are contained in this Agreement.

 

16.                                I.R.C. § 409A .  Notwithstanding anything to the contrary set forth herein, any payments and benefits provided under this Agreement that constitute “deferred compensation” within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended (the “ Code ”) and the regulations and other guidance thereunder and any state law of similar effect (collectively, the “ Section 409A ”) shall not commence in connection with your termination of employment unless and until you have also incurred a “separation from service” (as such term is defined in Treasury Regulation Section 1.409A-1(h) (the “ Separation From Service ”), unless the Company reasonably determines that such amounts may be provided to you without causing you to incur the additional 20% tax under Section 409A.

 

It is intended that each installment of severance pay provided for in this Agreement is a separate “payment” for purposes of Treasury Regulation Section 1.409A-2(b)(2)(i).  For the avoidance of doubt, it is intended that severance payments set forth in this Agreement satisfy, to the greatest extent possible, the exceptions from the application of Section 409A provided under Treasury Regulation Sections 1.409A-1(b)(4), 1.409A- 1(b)(5), and 1.409A-1(b)(9).

 

8



 

If the Company (or, if applicable, the successor entity thereto) determines that any payments or benefits constitute “deferred compensation” under Section 409A and you are, on the termination of service, a “specified employee” of the Company or any successor entity thereto, as such term is defined in Section 409A(a)(2)(B)(i) of the Code, then, solely to the extent necessary to avoid the incurrence of the adverse personal tax consequences under Section 409A, the timing of the payments and benefits shall be delayed until the earlier to occur of:  (a) the date that is six months and one day after your Separation From Service, or (b) the date of your death (such applicable date, the “ Specified Employee Initial Payment Date ”).  On the Specified Employee Initial Payment Date, the Company (or the successor entity thereto, as applicable) shall (i) pay to you a lump sum amount equal to the sum of the payments and benefits that you would otherwise have received through the Specified Employee Initial Payment Date if the commencement of the payment of such amounts had not been so delayed pursuant to this Section and (ii) commence paying the balance of the payments and benefits in accordance with the applicable payment schedules set forth in this Agreement.

 

17.                                Survival .  Provisions of this Agreement which by their terms must survive the termination of this Agreement in order to effectuate the intent of the parties will survive any such termination, whether by expiration of the Term, termination of your employment, or otherwise, for such period as may be appropriate under the circumstances.  Such provisions include, without limitation, Sections 5 (to the extent severance payments are due under such Section) and 6 of this Agreement.

 

18.                                Excise Tax-Related Provisions .  If any payment or benefit you would receive pursuant to this Agreement or any other agreement (“ Payment ”) would (a) constitute a “parachute payment” within the meaning of Section 280G of the Code, and (b) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the “ Excise Tax ”), then such Payment shall be adjusted so that it would equal the Reduced Amount.  The “Reduced Amount” shall be either (i) the largest portion of the Payment that would result in no portion of the Payment being subject to the Excise Tax or (ii) the total Payment, whichever amount of (i) or (ii), after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in your receipt, on an after-tax basis, of the greater amount of the Payment notwithstanding that all or some portion of the Payment may be subject to the Excise Tax.  If a reduction in payments or benefits constituting “parachute payments” is necessary so that the Payment equals the Reduced Amount, any such reduction will occur in a manner necessary to provide you with the greatest post-reduction economic benefit.  If more than one manner of reduction of Payments necessary to arrive at the Reduced Amount yields the greatest economic benefit to you, the Payments will be reduced pro rata (the “ Pro Rata Reduction Method ”).  Notwithstanding the foregoing, if the Pro Rata Reduction Method would result in any portion of the Payment being subject to taxes pursuant to Section 409A, then the Pro Rata Reduction Method shall be modified so as to avoid the imposition of taxes pursuant to Section 409A as follows: (A) as a first priority, the modification shall preserve to the greatest extent possible, the greatest economic benefit for you as determined on an after-tax basis; (B) as a second priority, Payments that are contingent on future events ( e.g., being terminated without Cause), shall be eliminated before Payments that are not contingent on future events; and (C) as a third priority, Payments that are “deferred compensation” within the meaning of Section 409A shall be reduced before Payments that are not “deferred compensation” within the meaning of Section 409A.

 

9



 

[Remainder of this page is intentionally left blank]

 

10



 

SIGNATURE PAGE TO

AMENDED AND RESTATED EMPLOYMENT AGREEMENT

 

IN WITNESS WHEREOF , the Company and you have executed this Agreement as of the day and year first set forth above.

 

 

 

AMAG Pharmaceuticals, Inc.

 

 

 

 

 

By:

/s/ William K. Heiden

 

 

Name: William K. Heiden

 

 

Title: President and CEO

 

 

 

 

 

 

 

[Executive Name]

 

Schedule of material terms of this Form Agreement for each of the Company’s named executive officers (other than the Chief Executive Officer):*

 

Name

 

Section 1(b)
Title**

 

Section 3(a)
Base Salary**

 

Section 3(b)
Target Bonus
(Percentage of Base Salary)

 

Frank E. Thomas

 

Executive Vice President and Chief Operating Officer

 

$

437,800

 

50

%

Christopher White

 

Senior Vice President and Chief Business Officer

 

$

338,300

 

40

%

Scott Holmes

 

Vice President Finance and Investor Relations, Chief Accounting Officer, Principal Financial Officer and Treasurer

 

$

265,000

 

35

%

 


* The Company enters into this Form Agreement with each of its executive officers; however, except for such agreements with our named executive officers (which are deemed material), such agreements with our other executive officers are immaterial in amount or significance and therefore details for such agreements have been omitted in reliance on Item 601(b)(10)(iii)(A) of Regulation S-K. The Company is party to an employment agreement with its Chief Executive Officer, which is filed separately from this Form Agreement.

 

** Reflects terms under the Form Agreements as currently in effect.

 


Exhibit 10.3

 

AMENDED AND RESTATED EMPLOYMENT AGREEMENT

 

This Amended and Restated Employment Agreement (the “ Agreement ”) is entered into as of February 7, 2014 (the “ Effective Date ”) by and between AMAG Pharmaceuticals, Inc., a Delaware corporation with offices at 1100 Winter Street, Waltham, MA 02451 (together with its subsidiaries and affiliates, the “ Company ”), and William K. Heiden of [ Address ] (“ you ”).

 

WHEREAS, you and the Company previously entered into that certain Employment Agreement, dated May 6, 2012 (the “ Prior Agreement ”);

 

WHEREAS, you and the Company desire to amend and restate the Prior Agreement on the terms and conditions set forth herein.

 

Now therefore, in consideration of the premises and mutual agreements hereinafter set forth, and intending to be legally bound hereby, the parties hereto agree as follows:

 

1.             Position; Duties .

 

a)            Position .  You shall continue to serve as President and Chief Executive Officer of the Company.

 

b)            Duties .  You shall perform for the Company the duties customarily associated with the office of President and Chief Executive Officer and such other duties as may be assigned to you from time to time by the Company’s Board of Directors (the “ Board ”) that are consistent with the duties normally performed by those performing the role of the most senior executives of similar entities.  You shall devote substantially your full business time and best efforts to the performance of your duties hereunder and the business and affairs of the Company and will not undertake or engage in any other employment, occupation or business enterprise; provided, however, that you may participate as a member of the board of directors or advisory board of other entities and in professional organizations and civic and charitable organizations; provided further, that any such positions are disclosed to the Board or the Audit Committee thereof and do not materially interfere with your duties and responsibilities as President and Chief Executive Officer.  You shall be based in the Company’s principal offices, which currently are in Waltham, Massachusetts

 

2.             Term .  The term of this Agreement shall be for a three (3) year period commencing on the Effective Date unless terminated earlier pursuant to Section 4 below (the “ Initial Term ”).  The term of this Agreement shall automatically renew for additional three-year terms (each, a “ Renewal Term ”) following the Initial Term and any Renewal Term unless either party provides written notice to the other party at least sixty (60) days before the end of the Initial Term or any Renewal Term, as applicable, that it does not desire to renew this Agreement, in which case this Agreement shall expire at the end of the Initial Term or any Renewal Term, as

 



 

applicable.  The Initial Term and any Renewal Term are referred to herein collectively as the “ Term .”

 

3.             Compensation and Benefits .  The Company shall pay you the following compensation and benefits for all services rendered by you under this Agreement (subject to any tax withholdings required by law):

 

a)            Base Salary .  The Company will pay you a base salary at the rate currently in effect and, effective February 17, 2014, at the annualized rate of at least $538,175 (“ Base Salary ”), minus withholdings as required by law and other deductions authorized by you, which amount shall be paid in equal installments at the Company’s regular payroll intervals, but not less often than monthly.  Your base salary may be increased annually by the Board or the Compensation Committee in their sole discretion.

 

b)            Bonus .  You will be eligible to receive an annual performance bonus (the “ Annual Bonus ”) of up to 75% of Base Salary for each fiscal year during the Term of this Agreement based on the extent to which, in the discretion of the Board or the Compensation Committee in consultation with you, you achieve or exceed specific and measurable individual and Company performance objectives established by the Board or the Compensation Committee in consultation with you and communicated to you in advance.  The exact amount of the bonus for any year during the Term shall be determined by the Board or the Compensation Committee in its sole discretion and may be more than the target bonus in the event you achieve all of your personal and Company performance objectives or less than the target bonus if you do not achieve all of your personal and Company performance objectives.  The Company shall pay the Annual Bonus no later than two and a half months after the end of the fiscal year to which the applicable bonus relates.  Unless otherwise provided herein, no bonus shall be deemed to have been earned by you for any year in which you are not actively employed by the Company on the last day of the fiscal year to which the bonus relates.

 

c)             Equity Compensation .  You shall be eligible to receive stock options or other equity compensation under the Company’s equity incentive plans as determined by the Board or the Compensation Committee from time to time.

 

d)            Vacation .  You will receive four (4) weeks of paid vacation per calendar year which shall accrue ratably on a monthly basis.

 

e)             Benefits .  You will be eligible to participate in all group health, dental, 401(k), and other insurance and/or benefit plans that the Company may offer to similarly situated executives of the Company from time to time on the same terms as offered to such other executives.

 

f)             Business Expenses .  The Company will reimburse you for all reasonable and usual business expenses incurred by you in the performance of your duties hereunder in accordance with the Company’s expense reimbursement policy.

 

2



 

4.             Termination .  Your employment with the Company may be terminated prior to the expiration of the Term as follows:

 

a)            Death .  This Agreement shall terminate automatically upon your death.

 

b)            Disability .  The Company may terminate your employment in accordance with applicable laws in the event that you shall be prevented, by illness, accident, disability or any other physical or mental condition (to be determined by means of a written opinion of a competent medical doctor chosen by mutual agreement of the Company and you or your personal representative(s)) from substantially performing your duties and responsibilities hereunder for one or more periods totaling one hundred and twenty (120) days in any twelve (12) month period.

 

c)             By the Company for Cause .  The Company may terminate your employment for “Cause” upon written notice to you.  For purposes of this Agreement, “ Cause ” shall mean any of: (i) fraud, embezzlement or theft against the Company or any of its affiliates; (ii) you are convicted of, or plead guilty or no contest to, a felony; (iii) willful nonperformance by you (other than by reason of illness) of your material duties hereunder and failure to remedy such nonperformance within thirty (30) business days following written notice from the Board identifying the nonperformance and the actions required to cure it; or (iv) you commit an act of gross negligence, engage in willful misconduct or otherwise act with willful disregard for the Company’s best interests, and you fail to remedy such conduct within thirty (30) business days following written notice from the Board identifying the gross negligence, willful misconduct or willful disregard and the actions required to cure it (if such conduct can be cured).

 

d)            By the Company Other Than For Death, Disability or Cause .  The Company may terminate your employment other than for Cause, disability or death upon thirty (30) days prior written notice to you.

 

e)             By You For Good Reason or Any Reason .  You may terminate your employment at any time without Good Reason upon thirty (30) days prior written notice to the Company and with Good Reason as described in this Section 4(e).  For purposes of this Agreement, “ Good Reason ” shall mean that any of the following occurs without your prior written consent: (i) a material adverse change in your title, position, duties or responsibilities; (ii) a material reduction by the Company in your Base Salary or your target Annual Bonus opportunity in the total annual amount that you are then eligible to receive, unless such reduction is in connection with a proportionate reduction of compensation applicable to all other executive officers; (iii) any relocation of your principal place of business to a location more than 50 miles from the Company’s current executive offices in Waltham, MA; provided, however , that this clause (iii) will not apply to the extent that any new office location is less than 50 miles from your residence; or (iv) a material breach by the Company of any of the terms or provisions of this Agreement. Before you may resign for Good Reason, (i) you must provide written notice to the Company describing the event, condition or conduct giving rise to Good Reason within 30 days of the initial occurrence of the event, condition or conduct; (ii) the Company must fail to remedy

 

3



 

or cure the alleged Good Reason within the 30 day period after receipt of such notice; and (iii) you must resign effective not later than 30 days after the end of the cure period.

 

5.             Payment Upon Termination .  In the event that your employment with the Company terminates, you will be paid the following (subject to any tax withholdings required by law):

 

a)            Termination for Any Reason.   In the event that your employment terminates for any reason, the Company shall pay you for the following items that were earned and accrued but unpaid as of the date of your termination: (i) your Base Salary; (ii) a cash payment for all accrued, unused vacation calculated at your then Base Salary rate; (iii) reimbursement for any unpaid business expenses; and (iv) such other benefits and payments to which you may be entitled by law or pursuant to the benefit plans of the Company then in effect.  In addition, if your employment terminates due to your death, the Board or the Compensation Committee shall determine the extent to which any of the individual performance objectives established pursuant to Section 3(b) above were met as of the time of your death.  If, based on that determination, the Board or the Compensation Committee determines that a bonus is due, the Company shall pay your estate an amount equal to such bonus, pro-rated for the portion of the fiscal year elapsed as of the time of your death.

 

b)            Termination Without Cause or for Good Reason .  In addition to the payments provided for in Section 5(a), in the event that (i) the Company terminates your employment other than for death, disability or Cause pursuant to Section 4(d) or you terminate your employment for Good Reason pursuant to Section 4(e); (ii) you comply fully with all of your obligations under all agreements between the Company and you; and (iii) you execute, deliver to the Company, within sixty (60) days of the termination of your employment, and do not revoke a general release (in a form acceptable to the Company) releasing and waiving any and all claims that you have or may have against the Company, its directors, officers, employees, agents, successors and assigns with respect to your employment (other than any obligation of the Company set forth herein which specifically survives the termination of your employment), then (i) the Company will provide you with twenty-four (24) months of severance pay based on your then current Base Salary and (ii) all time-based stock options and other time-based equity awards you hold in which you would have vested if you had been employed for an additional twenty-four (24) months following the date of the termination of your employment shall vest and become exercisable or nonforfeitable on the date that the release referred to above may no longer be revoked. The foregoing severance shall be paid in equal installments over the severance period in accordance with the Company’s usual payroll schedule, commencing on the date that the release referred to above may no longer be revoked.  This Section 5(b) shall not apply during the one year period following a Change of Control (as defined below), in which case Section 5(c) shall apply.  Notwithstanding anything to the contrary herein, if any of the payments and benefits provided for in this Section 5(b) constitute non-qualified deferred compensation subject to Section 409A (as defined below) and the sixty (60) day period in which you must execute the release begins in one calendar year and ends in another, the payments and benefits provided for in this Section 5(b) shall commence, be made or become effective in the later calendar year.

 

4



 

c)             Change of Control . In the event that (i) within one (1) year from the date a Change of Control (as defined below) of the Company occurs, the Company (for purposes of this section, such term to include its successor) terminates your employment other than for Cause pursuant to Section 4(c), death or disability or you terminate your employment with Good Reason; (ii) you comply fully with all of your obligations under all agreements between the Company and you; and (iii) within sixty (60) days of termination of your employment you execute and deliver to the Company and do not revoke a general release (in a form acceptable to the Company) releasing and waiving any and all claims that you have or may have against the Company and its directors, officers, employees, agents, successors and assigns with respect to your employment (other than any obligation of the Company set forth herein which specifically survives the termination of your employment), then:

 

·                   the Company will pay you twenty-four (24) months of severance pay based on your then current Base Salary, with such severance to be paid in equal installments over the severance period in accordance with the Company’s usual payroll schedule, commencing on the date that the release referred to above may no longer be revoked;

 

·                   the Company will pay you, on the first payroll date after the revocation period of the release set forth above expires, in a lump sum, two times (2X) your target annual bonus amount for the year in which the Change of Control occurs;

 

·                   the Company will pay or reimburse you for the premiums for continued coverage for you and your eligible dependents in the same amounts and for the same coverage in effect immediately prior to your termination from employment, under the Company’s group health and dental plans until the earlier of: (i) twelve (12) months from the date of termination of your employment; or (ii) the date you are provided with health and dental coverage by another employer’s health and dental plan (and, for purposes of clarity, if the Company is unable to extend coverage to you under its group health and dental plans due to your termination from active employment status, then, to receive this benefit, you must elect continuation coverage under COBRA and/or purchase an individual insurance policy, and the Company shall have no obligation to pay or reimburse insurance premiums or otherwise provide coverage if you fail to elect COBRA or obtain an individual policy); and

 

·                   all time-based, unvested outstanding stock options, restricted stock units and other equity incentives that were granted to you before the Change of Control occurred shall, without further action, become vested in full on the date that the release referred to above may no longer be revoked.

 

For purposes of this Agreement, “ Change of Control ” shall mean the first to occur of any of the following: (a) any “person” or “group” (as defined in the Securities Exchange Act of 1934, as amended) becomes the beneficial owner of a majority of the combined voting power of the then outstanding voting securities with respect to the election of the Board; (b) any merger, consolidation or similar transaction involving the Company; other than a transaction in which the

 

5



 

stockholders of the Company immediately prior to the transaction hold immediately thereafter in the same proportion as immediately prior to the transaction not less than 50% of the combined voting power of the then voting securities with respect to the election of the Board of Directors of the resulting entity; (c) any sale of all or substantially all of the assets of the Company; or (d) any other acquisition by a third party of all or substantially all of the business or assets of the Company, as determined by the Board, in its sole discretion.  The payments, benefits and acceleration of vesting of stock options, restricted stock units and other equity incentives provided in this Section 5(c) shall override and replace with respect to you any Company wide policy with respect to payments, benefits and/or acceleration of vesting upon a Change of Control.  After the one year period following a Change of Control, this Section 5(c) shall no longer apply, and Section 5(b) shall continue to apply.  In the event that upon a Change of Control, the Company or the successor to or acquiror of the Company’s business (whether by sale of outstanding stock, merger, sale of substantially all the assets or otherwise) elects not to assume all the then unvested outstanding stock options, restricted stock units and other equity incentives that were granted to you before the Change of Control occurred, such securities shall immediately without further action become vested in full effective no later than the effective date of the Change of Control and you shall receive the value of such stock options, restricted stock units and other equity incentives as provided in the applicable acquisition agreement (or if no such provision is made, in the applicable equity incentive plan).

 

Notwithstanding anything to the contrary herein, if any of the payments and benefits provided for in this Section 5(c) constitute non-qualified deferred compensation subject to Section 409A and the sixty (60) day period in which you must execute the release begins in one calendar year and ends in another, the payments and benefits provided for in this Section 5(c) shall commence, be made or become effective in the later calendar year.

 

d)            Death/Disability .  In addition to the payments provided for in Section 5(a), in the event of your death or the termination of your employment due to your disability in accordance with Section 4(b) above, all unvested outstanding stock options, restricted stock units and other equity incentives that were held by you at the time of your death or termination of employment due to disability shall immediately become fully vested and, with respect to stock options, exercisable by you or your personal representatives, heirs or legatees, as the case may be, at any time prior to the expiration of one (1) year from the date of your death or disability, but in no event after the expiration of the term of the applicable equity award agreement.

 

6.             Nonsolicitation Covenant; Non-Competition; Injunctive Relief .  In order to protect the Company’s confidential information and good will, and in exchange for the additional equity rights granted you under Sections 5(b), your employment or continued employment, and other good and valuable consideration contained in this Agreement, during your employment and for a period of twelve (12) months following the termination of your employment for any reason (the “ Restricted Period ”), you will not directly or indirectly, whether as owner, partner, shareholder, director, manager, consultant, agent, employee, co-venturer or otherwise, engage, participate or invest in any business activity anywhere in the world that (i) develops, manufactures or markets (A) an intravenous iron replacement therapeutic, (B) a mucoadhesive oral wound rinse or other device that is indicated for the management of oral

 

6



 

mucositis/stomatitis, or (C) other therapeutic products acquired, developed or researched by the Company during the Term, or (ii) develops, manufactures or markets any products, or performs any services, that are otherwise competitive with or similar to the products or services of the Company, or products or services that the Company has under development or that are the subject of active planning at any time during your employment; provided that this shall not prohibit any possible investment in publicly traded stock of a company representing less than one percent of the stock of such company.  In addition, during the Restricted Period, you will not, directly or indirectly, in any manner, other than for the benefit of the Company, (a) call upon, solicit, divert, take away, accept or conduct any business from or with any of the customers or prospective customers of the Company or any of its suppliers, and/or (b) solicit, entice, attempt to persuade any other employee or consultant of the Company to leave the Company for any reason or otherwise participate in or facilitate the hire, directly or through another entity, of any person who is employed or engaged by the Company or who was employed or engaged by the Company within six (6) months of any attempt to hire such person.  You acknowledge and agree that if you violate any of the provisions of this Section, the running of the Restricted Period will be extended by the time during which you engage in such violation(s).  You understand that the restrictions contained in this Agreement are necessary for the protection of the business and goodwill of the Company and you consider them to be reasonable for such purpose.  Any breach of this Agreement is likely to cause the Company substantial and irrevocable damage and therefore, in the event of such breach, the Company, in addition to such other remedies which may be available, will be entitled to specific performance and other injunctive relief, without the posting of a bond.  If you violate this Agreement, in addition to all other remedies available to the Company at law, in equity, and under contract, you agree that you are obligated to pay all the Company’s costs of enforcement of this Agreement, including attorneys’ fees and expenses.  This Section 6 shall supplement, and shall not limit or be limited by, any other restrictive covenant agreement to which you and the Company are parties or any other restrictive covenant obligations you have to the Company.

 

7.             Assignment .  This Agreement and the rights and obligations of the parties hereto shall bind and inure to the benefit of any successor of the Company by reorganization, merger or consolidation and any assignee of all or substantially all of its business and properties.  Neither this Agreement nor any rights or benefits hereunder may be assigned by you, except that, upon your death, your earned and unpaid economic benefits will be paid to your heirs or beneficiaries.

 

8.             Interpretation and Severability .  It is the express intent of the parties that (a) in case any one or more of the provisions contained in this Agreement shall for any reason be held to be excessively broad as to duration, geographical scope, activity or subject, such provision shall be construed by limiting and reducing it as determined by a court of competent jurisdiction, so as to be enforceable to the fullest extent compatible with applicable law; and (b) in case any one or more of the provisions contained in this Agreement cannot be so limited and reduced and for any reason is held to be invalid, illegal or unenforceable, such invalidity, illegality or unenforceability shall not affect the other provisions of this Agreement, and this Agreement shall be construed as if such invalid, illegal or unenforceable provision had never been contained herein .

 

7



 

9.             Notices .  Any notice that you or the Company are required to give the other under this Agreement shall be given by personal delivery, recognized overnight courier service, or registered or certified mail, return receipt requested, addressed in your case to you at your last address of record with the Company, or at such other place as you may from time to time designate in writing, and, in the case of the Company, to the Company at its principal office, or at such other office as the Company may from time to time designate in writing.  The date of actual delivery of any notice under this Section 9 shall be deemed to be the date of receipt thereof.

 

10.          Waiver .  No consent to or waiver of any breach or default in the performance of any obligation hereunder shall be deemed or construed to be a consent to or waiver of any other breach or default in the performance of any of the same or any other obligations hereunder.  No waiver hereunder shall be effective unless it is in writing and signed by the waiving party.

 

11.          Complete Agreement; Modification .  This Agreement sets forth the entire agreement of the parties with respect to the subject matter hereof, and supersedes any previous oral or written communications, negotiations, representations, understandings, or agreements between them, including the Prior Agreement.  Any modification of this Agreement shall be effective only if set forth in a written document signed by you and a duly authorized officer of the Company.

 

12.          Headings .  The headings of the Sections hereof are inserted for convenience only and shall not be deemed to constitute a part, or affect the meaning, of this Agreement.

 

13.          Counterparts .  This Agreement may be signed in two (2) counterparts, each of which shall be deemed an original and both of which shall together constitute one agreement.

 

14.          Choice of Law; Jurisdiction .  This Agreement shall be deemed to have been made in the Commonwealth of Massachusetts, and the validity, interpretation and performance of this Agreement shall be governed by, and construed in accordance with, the laws of Massachusetts, without regard to conflict of law principles.  You hereby consent and submit without limitation to the jurisdiction of courts in Massachusetts in connection with any action arising out of this Agreement, and waive any right to object to any such forum as inconvenient or to object to venue in Massachusetts.  You agree that, in any action arising out of this Agreement, you will accept service of process by registered mail or the equivalent directed to your last known address or by such other means permitted by such court.

 

15.          Advice of Counsel; No Representations .  You acknowledge that you have been advised to review this Agreement with your own legal counsel, that prior to entering into this Agreement, you have had the opportunity to review this Agreement with your attorney, and that the Company has not made any representations, warranties, promises or inducements to you concerning the terms, enforceability or implications of this Agreement other than as are contained in this Agreement.

 

16.          I.R.C. § 409A .  Notwithstanding anything to the contrary set forth herein, any payments and benefits provided under this Agreement that constitute “deferred compensation”

 

8



 

within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended (the “ Code ”) and the regulations and other guidance thereunder and any state law of similar effect (collectively, the “ Section 409A ”) shall not commence in connection with your termination of employment unless and until you have also incurred a “separation from service” (as such term is defined in Treasury Regulation Section 1.409A-1(h) (the “ Separation From Service ”), unless the Company reasonably determines that such amounts may be provided to you without causing you to incur the additional 20% tax under Section 409A.

 

It is intended that each installment of severance pay provided for in this Agreement is a separate “payment” for purposes of Treasury Regulation Section 1.409A-2(b)(2)(i).  For the avoidance of doubt, it is intended that severance payments set forth in this Agreement satisfy, to the greatest extent possible, the exceptions from the application of Section 409A provided under Treasury Regulation Sections 1.409A-1(b)(4), 1.409A-1(b)(5), and 1.409A-1(b)(9).

 

If the Company (or, if applicable, the successor entity thereto) determines that any payments or benefits constitute “deferred compensation” under Section 409A and you are, on the termination of service, a “specified employee” of the Company or any successor entity thereto, as such term is defined in Section 409A(a)(2)(B)(i) of the Code, then, solely to the extent necessary to avoid the incurrence of the adverse personal tax consequences under Section 409A, the timing of the payments and benefits shall be delayed until the earlier to occur of: (a) the date that is six months and one day after your  Separation From Service, or (b) the date of your death (such applicable date, the “ Specified Employee Initial Payment Date ”).  On the Specified Employee Initial Payment Date, the Company (or the successor entity thereto, as applicable) shall (i) pay to you a lump sum amount equal to the sum of the payments and benefits that you would otherwise have received through the Specified Employee Initial Payment Date if the commencement of the payment of such amounts had not been so delayed pursuant to this Section and (ii) commence paying the balance of the payments and benefits in accordance with the applicable payment schedules set forth in this Agreement.

 

17.          Survival .  Provisions of this Agreement which by their terms must survive the termination of this Agreement in order to effectuate the intent of the parties will survive any such termination, whether by expiration of the Term, termination of your employment, or otherwise, for such period as may be appropriate under the circumstances. Such provisions include, without limitation, Sections 5 and 6 of this Agreement.

 

18.          Excise Tax-Related Provisions .  If any payment or benefit you would receive pursuant to this Agreement or any other agreement (“ Payment ”) would (a) constitute a “parachute payment” within the meaning of Section 280G of the Code, and (b) be subject to the excise tax imposed by Section 4999 of the Code (the “ Excise Tax ”), then such Payment shall be adjusted so that it would equal the Reduced Amount.  The “Reduced Amount” shall be the largest portion of the Payment that would result in no portion of the Payment being subject to the Excise Tax.  If a reduction in payments or benefits constituting “parachute payments” is necessary so that the Payment equals the Reduced Amount, any such reduction will occur in a manner necessary to provide you with the greatest post-reduction economic benefit after taking into account all applicable federal, state and local employment taxes, income taxes and the Excise Tax (all computed at the highest applicable marginal rate).  If more than one manner of

 

9



 

reduction of Payments necessary to arrive at the Reduced Amount yields the greatest economic benefit to you, the Payments will be reduced pro rata (the “ Pro Rata Reduction Method ”). Notwithstanding the foregoing, if the Pro Rata Reduction Method would result in any portion of the Payment being subject to taxes pursuant to Section 409A, then the Pro Rata Reduction Method shall be modified so as to avoid the imposition of taxes pursuant to Section 409A as follows: (A) as a first priority, the modification shall preserve to the greatest extent possible, the greatest economic benefit for you as determined on an after-tax basis; (B) as a second priority, Payments that are contingent on future events (e.g., being terminated without Cause), shall be eliminated before Payments that are not contingent on future events; and (C) as a third priority, Payments that are “deferred compensation” within the meaning of Section 409A shall be reduced before Payments that are not “deferred compensation” within the meaning of Section 409A.

 

[Remainder of this page is intentionally left blank]

 

10



 

SIGNATURE PAGE TO

AMENDED AND RESTATED EMPLOYMENT AGREEMENT

 

 

IN WITNESS WHEREOF , the Company and you have executed this Agreement as of the day and year first set forth above.

 

 

AMAG Pharmaceuticals, Inc.

 

 

 

 

 

 

 

By:

/s/ Frank E. Thomas

 

Name:

Frank E. Thomas

 

Title:

Chief Operating Officer

 

 

 

 

 

 

 

/s/ William K. Heiden

 

William K. Heiden

 

 


Exhibit 31.1

 

CERTIFICATIONS

 

I, William K. Heiden, certify that:

 

1.                 I have reviewed this Quarterly Report on Form 10-Q of AMAG Pharmaceuticals, Inc.;

 

2.                 Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.                 Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.                 The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a)                Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)                Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)                 Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d)                Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.                 The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a)                All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b)                Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date:  May 5, 2014

 

 

/s/ William K. Heiden

 

William K. Heiden

 

President and Chief Executive Officer (Principal Executive Officer)

 

1


 

Exhibit 31.2

 

CERTIFICATIONS

 

I, Scott A. Holmes, certify that:

 

1.                 I have reviewed this Quarterly Report on Form 10-Q of AMAG Pharmaceuticals, Inc.;

 

2.                 Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.                 Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.                 The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a)                Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)                Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)                 Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d)                Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.                 The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a)                All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b)                Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: May 5, 2014

 

 

/s/ Scott A. Holmes

 

Scott A. Holmes

 

Chief Accounting Officer, Vice President of Finance and Investor Relations and Treasurer

 

(Principal Financial Officer)

 

1


 

Exhibit 32.1

 

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of AMAG Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2014 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, William K. Heiden, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

 

(1)            The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)            The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

/s/ William K. Heiden

 

William K. Heiden

 

President and Chief Executive Officer

 

(principal executive officer)

 

May 5, 2014

 

1


 

Exhibit 32.2

 

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of AMAG Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2014 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Scott A. Holmes, Chief Accounting Officer, Vice President of Finance and Treasurer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

 

(1)            The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)            The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

/s/ Scott A. Holmes

 

Scott A. Holmes

 

Chief Accounting Officer, Vice President of Finance and Investor Relations and Treasurer

 

(principal financial officer)

May 5, 2014

 

1